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SUMMARY
Drug-resistant tuberculosis poses a threat to global tuberculosis control by the
WHO DOTS strategy. Studies in the United States and Europe have shown (i) that
drug-resistant tuberculosis is present in every country; (ii) that, by contrast to previous
dogma, drug-resistant bacilli are virulent and can be transmitted, especially in
institutional settings and to immunocompromised patients; and (iii) that the majority
of cases arise by acquisition of drug resistance due to errors in the management of TB
cases. (iv) Furthermore, it has been shown that the extremely high case fatality rates
of the 1980s and early 1990s can be reduced by individualized, but costly treatment.
However, the majority of drug-resistant TB cases reside in the developing world.
Data on disease epidemics in less developed parts of the world are scarce. The aim of
this thesis was to study the disease dynamics of drug-resistant TB in a developing
country where TB is endemic.
All cases of drug-resistant TB during a 5-year period in two communities with
poor socioeconomic living conditions were included for this observational study.
Three different methods were used: restriction fragment length polymorphism
(RFLP), mutation detection analysis by dot-blot hybridisation technique and a
Geographic Information System. Results of RFLP analysis and mutation detection
analysis showed that community outbreaks of drug-resistant Mycobacterium
tuberculosis strains occur, even without the involvement of immunocomprimised
patients. Infection with a drug-resistant strain occurred in new patients (primary drug
resistance) as well as in patients treated before (exogenous reinfection). Exogenous
reinfection was also shown to be an important mechanism of recurrence after previous
cure for drug-sensitive TB. Transmission of drug-resistant strains occurred more
frequent in areas with lower socioeconomic living conditions. The relative
contribution of transmission differed substantially between the group of multi drug-
resistant (two thirds of cases) and single-drug-resistant (no cases) cases, which
probably reflects the prolonged infectiousness of multi drug-resistant cases. To stop
the growing epidemic of multi drug-resistant TB, prevention of acquisition as well as
transmission of drug-resistant tuberculosis will be required. This will only be possible
in areas where a DOTS strategy is well functioning and with a modification of central
elements of the standard DOTS mechanism: a "DOTS-plus" strategy. Early and
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accurate diagnosis of drug resistance is essential for effective management. Diagnosis
based on two direct smear tests might have to be replaced by routine drug-
susceptibility tests at diagnosis. Because the routine performance of phenotypic drug-
susceptibility tests was inferior to the performance of genotypic tests, the
development of an affordable commercial kit testing a limited number of mutations
conferring resistance could be of great value in the global fight against multidrug-
resistant TB. Because of the importance of early diagnosis, selective active contact
tracing for multidrug-resistant cases, additional to the routine passive contact tracing,
could prove to be cost-effective. Individualized treatment regimens are effective in
reducing the failure rate, mortality and probably transmission of multidrug-resistant
TB.
Multidrug-resistant tuberculosis is a problem confronting the efforts for global
tuberculosis control. Efficient strategies to turn the tide exist, but international
political commitment and financial support will be essential.
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OPSOMMING
Middel weerstandige tuberkulose hou 'n bedreiging in vir globale tuberkulose
kontrole deur die WGO DOTS strategie. Studies in die Verenigde State en Europa het
getoon (i) dat middel weerstandige tuberkulose in alle lande voorkom; (ii) dat, in
teenstelling met vorige dogma, middel weerstandige bakterieë virulent is en oorgedra
kan word, veral in inrigtings en aan immuun-onderdrukte pasiënte; en (iii) dat die
meeste gevalle ontstaan deur die verwerwing van middel weerstandigheid a.g.v. die
foutiewe hantering van tuberkulose gevalle. (iv) Bykomend is getoon dat die
ontsettende hoë mortaliteit syfers van die 1980s verlaag kan word deur ge-
individualiseerde, maar duur behandeling.
Die meeste middel weerstandige tuberkulose gevalle woon egter in die
ontwikkelende wêreld. Data oor siekte epidemies in minder ontwikkelde dele van die
wêreld is skaars. Die doel van hierdie tesis was om die siekte dinamiek van middel
weerstandige tuberkulose te bestudeer in 'n ontwikkelende land waar tuberkulose
endemies is.
Alle gevalle van middel weerstandige tuberkulose gedurende 'n 5-jaar periode in
twee lae sosio-ekonomiese gemeenskappe, is in hierdie studie ingesluit. Drie
verskillende metodes is gebruik: restriksie fragment lengte polimorfistne (RFLP),
mutasie analise deur dot-blot hibridisasie en 'n Geografiese Inligting Stelsel.
Resultate van die RFLP analise het getoon dat uitbrake van middel weerstandige
Mycobacterium tuberculosis stamme in die gemeenskap voorkom, selfs sonder die
aantasting van immuun-onderdrukte pasiënte. Infeksie met middel weerstandige
stamme het voorgekom in nuwe pasiënte (primêre middel weerstandigheid) en ook in
pasiënte wat reeds voorheen behandel is (eksogene herinfeksie ). Daar is ook gevind
dat eksogene herinfeksie 'n belangrike meganisme was van herhaalde tuberkulose na
vorige genesing van middel sensitiewe tuberkulose. Die oordrag van middel
weerstandige stamme het meer dikwels voorgekom in areas met laer sosio-
ekonomiese omstandighede. Die relatiewe bydrae van oordrag het merkwaardig
verskil tussen multi-middel weerstandigheid (twee derdes van gevalle) en enkel-
middel weerstandigheid (geen gevalle). Dit weerspieël waarskynlik die verlengde
periode van infektiwiteit van die multi-middel weerstandige gevalle. Die bekamping
van die groeiende epidemie van multi-middel weerstandige tuberkulose, vereis die
voorkoming van verworwe sowel as oorgedraagde middel weerstandige tuberkulose.
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Dit sal slegs moontlik wees in areas waar 'n DOTS strategie reeds goed funksioneer
en met 'n aanpassing van die sentrale elemente van die roetine DOTS meganisme: 'n
"DOTS-plus" strategie. Vroeë en akkurate diagnose van middel weerstandigheid is
essensieël vir effektiewe hantering. Diagnose gebaseer op twee direkte sputum smeer
toetse mag moontlik vervang moet word deur roetine middel sensitiwiteit bepalings
by diagnose. Die roetine fenotipiese middel sensitiwiteit bepaling is gevind om
minderwaardig te wees in vergelyking met die genotipiese toetse. Die ontwikkeling
van 'n bekostigbare toetsstelsel wat die mees algemene mutasies vir middel
weerstandigheid salopspoor, kan van groot waarde wees in die stryd teen muti-
middel weerstandige tuberkulose. Aangesien vroeë diagnose so belangrik is, kan
aktiewe kontak opsponng koste-effektief wees. Ge-individualiseerde
behandelingskedules is effektief om die sukses van behandeling en oorlewing te
verbeter, en moontlik ook om die oordrag van multi-middel weerstandige tuberkulose
te verminder.
Multi-middel weerstandige tuberkulose is 'n probleem vir die globale kontrole van
tuberkulose. Effektiewe strategieë om die vloed te stuit, bestaan, maar politieke
verbintenis en geldelike ondersteuning sal essensieël wees.
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1CHAPTER1
General Introduction
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General Introduction
A. A history of the concept of contagiousness of tuberculosis and the efforts for its
control.
The concept of contagiousness of tuberculosis (TB) waxed and waned over the past
three millennia. This reflected the chronic nature of TB and the absence of acute
dramatic epidemics, as seen with plague, smallpox and cholera. Moreover, the
acceptance of the notion contagion was not based on objectivity but reflected the
Zeitgeist - the spirit of the time'. Greek and Roman scholars viewed TB as contagious.
Aristotle (384 to 322 B.C.) wrote " ... the breath is bad and heavy, ... one takes the
disease because there is in the air something disease producing'", Galenus (129 to 200
B.C.) stated that phthisis (TB) could easily be caught from a tuberculous patient,
especially if they breathed out putrid air. By the end of the 161h century, most physicians
and scientists in Southern Europe advocated the contagious theory while empiricism in
Northern Europe opposed the notion of contagion in the absence of experimental proof
and accepted non-specific factors such as inheritance and environmental factors as the
cause of TB '. In the 191h century, the established medical profession was influenced by
the French Revolution. The year 1865 demarcates the modern era, when experimental
medicine began to unravel the nature ofTB. Jean-Antoine Villemin reported his success
in transmitting TB from man to rabbit by inoculation'. Villemin's theory was rejected
but stimulated and advanced TB research in Europe. The contagion debate was finally
resolved by the discovery of the tubercle bacillus by Robert Koch in 18824•
The belief in TB as a disease of a contagious or non-specific nature determined the
historic evolution in the combat against TB. In the 151h century, Fracastoro ' advised that
"When you begin your treatment in the initial stage, pay attention to the germs only, for
if these could be destroyed ...no more effective remedy could be employed." The
contagious nature ofTB led to the concept of close contact in the transmission ofTB. In
1720, Benjamin Marten" wrote: "It may, therefore. be very likely that by habitual lying
in the same bed with a consumptive patient. consistently eating and drinking with him
or by frequently conversing so nearly as to draw in part of the breath he emits from the
lung. consumption may be caught by a sound person ... .1 imagine that slightly
2
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3conversing with consumptive patients is seldom or never sufficient to catch the disease. "
To prevent transmission, cities such as Naples built a TB hospital and passed stringent
laws in 1782 stipulating both precautions during illness (notification of disease by the
physician and admission at the hospital) and measures to be taken after death (such as
destruction of household goods susceptible to contamination, replastering the house
. from cellar to garret, burn wooden doors and windows, ... ) I
Hippocrates was the first to recommend environmental measures, such as a change
10 climate, in the treatment of phthisis," From the mid 17th century, physicians
recommended sea voyages or travel to healthy climates for the dreaded phthisis. The
Sanatorium Movement, which peaked between mid 1800s and mid 1900s, was an
expression of the popular concept of fresh air, diet, rest and exercise as a means of
keeping away the miasma'.
Koch's discovery of the microbial cause of TB did not slow the momentum of the
Sanatorium Movement but led to the desire to reinforce natural resistance by a regulated
healthy regimen and to prevent spread by isolation and education until a specific cure
could be found. It would still be another 60 years after Koch's discovery before the
long-hoped-for chemotherapeutic era became reality with the discovery of streptomycin
as a potentially reliable cure for TB8. The discovery of additional antibiotics such as
para-aminosalicycic-acid and isoniazid gave impetus to treatment in general hospitals
and outpatient treatment in the community'. However, it was only after several
controlled studies that the primacy of drug therapy was undeniably established. As
stated by Mitchison": "We must conclude that many accepted measures in the treatment
ofTB are becoming increasingly irrelevant in an age when potent chemotherapy can be
given. In particular, treatment by surgery, prolonged rest in bed, and by dietary
supplements is usually unnecessary and serves only to prolong the patient's incapacity
and to increase the cost of his treatment."
TB is now a disease that can be effectively cured in the vast majority (>90%) of
patients. Clinical trials by the British Medical Council and co-workers have elucidated
the optimal regimen now incorporated in the World Health Organisation (WHO)
directly observed treatment, short-course (DOTS) strategy. The current WHO DOTS
strategy includes 5 points: (1) national government commitment, (2) directly observed
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standardised treatment, (3) diagnosis by sputum smear microscopy, (4) reliable supply
of first-line drugs and (5) standardised recording and reporting system 10.
The close historical relationship between TB and social living conditions stresses
the need for attempts to control TB to look beyond medical interventions. Government
commitment should thus not only be limited to ensuring a high quality program but also
consider efforts to improve the living conditions of the poorest.
B. Tuberculosis in South Africa: history, burden and disease control strategies
Knowledge concerning the prevalence of TB in South Africa prior to the zo"
century is limited. It appears that the initial spread was closely related to the degree of
contact of native people with European cotonizers". In the 191h century, the pool of
infection was boosted by the large number of consumptive immigrants seeking the
benefits of the South African climate: "... the Cape which cures consumption; the Cape
which is of Good Hope to all weak chests; the Cape which offers life and health ... "".
Rapid urbanisation, political policies maintaining unequal living conditions and unequal
access to health care have contributed to the extent and racial differences of the South
African TB epidemic in the zo" century'f (Figure I).
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5It has been estimated that 6 to 10million South Africans are infected resulting in
. more than 80000 notified cases per year. The highest TB notification rate occurs among
persons of the Coloured population 13. .
Although TB was a recognised health problem in South Africa, little effort was
made to control the disease prior to 1900. In 1919, a commission made numerous
recommendations for the implementation of various control measures: improvement in
housing and sanitation, provision of diagnosis facilities, TB dispensaries and hospitals.
However, few of these recommendations were acted uponl2. The failure of early efforts
to control the spread ofTB is dramatically highlighted in the 1940s. Armed for the first
time with a 'silver bullet', in the form of streptomycin and isoniazid, South African
medical authorities launched mass chest x-ray surveys and educational campaigns
during the 1950s. Because of lack of hospital accommodation, cases were treated on an
outpatient basis. In the absence of adequate staff to supervise therapy, this often resulted
in patients failing to complete their therapy'<. By the end of the 1980s, shorter regimens
and full supervision could improve the situation. In 1996, the government committed
itself to the implementation of the WHO DOTS program'".
c. Drug-resistant tuberculosis
Pioneering studies recognised the problem of drug resistance in TB almost
immediately after the introduction of streptomycin. In 1946, Youmans observed that a
large number of patients treated with streptomycin relapsed after a period of clinical
improvement. The bacilli isolated from these patients were resistant to streptomycin 15.
A study in 1947 showed that during treatment, the proportion of bacilli resistant to
streptomycin increased progressively'". Addition of para-aminosalicyclic acid reduced
the prevalence of streptomycin resistance significantly'" and introduced the principle of
multi drug regimens, central in modem TB treatment. Another landmark in the study of
drug resistance in TB was the concept of spontaneous mutants, defined as those bacilli
resistant to antituberculous drugs present in large bacterial populations prior to any
contact with antituberculous drugs'". These resistant mutants occur at a low, but fixed
rate for each drug: 1 in 106 for isoniazid and streptomycin and 1 in 108 for rifampin 18-20.
Drug-resistant M tuberculosis mutants have a selective advantage over susceptible
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bacilli under circumstances of inadequate treatment management, such as erratic drug
supply, prescription of monotherapy and patient non-compliance. Clinical drug
resistance occurs once these mutants comprise a substantial proportion of the bacterial
population. This type of drug resistance is classified as acquired drug resistance and
defined by the WHO as TB caused by bacilli resistant to one or more drugs in a patient
previously treated for I month or longer '. Early data from animal models suggested
that drug-resistant strains were less infective and less pathogenic22•23. Primary drug
resistance, reflecting the transmission of a drug-resistant strain, and defined by the
WHO as TB caused by bacilli resistant to one or more drugs in a patient never treated
before'", was therefore assumed to be rare. The rare occurrence of outbreaks of drug-
resistant TB before 1990 supported this dogma.
As Canetti noted 30 years ago: "The basic aspects oj this (drug-resistant TB) was
gained within the first 15 years after the introduction oj chemotherapy Jar TB
treatment .... And then the research impetus fell away ...Any disease-linked phenomenon
loses much oj its attraction Jar research once the ways Jar its prevention have been
found. ... The general Jeeling tends to prevail that resistance has slipped into history ....
To make a long story short. plenty oj work is waiting Jar microbial genetieists in the
field oj TB ... Drug resistance is a field oj admirable diversity. The field has something
to offer to almost everybody: the clinician, the pathologist, the pharmacologist. the
biochemist, the epidemiologist, and the geneticist.r"
When there was a resurgence of TB in the developed world in the mid-1980s after
decades of steady decline, and outbreaks of drug-resistant TB occurred, it was clear that
drug-resistant TB had not slipped into history. Research into drug-resistant TB revived.
A global survey on anti-tuberculosis drug resistance determined that drug resistance is
ubiquitous, with several hotspots of multidrug-resistant TB around the world'".
Microbial geneticists elucidated the genetic basis of resistance. Point mutations in
specific genes are known to confer resistance to the 5 first-line drugs. The most
important genes are the rpoB gene26 (rifampin resistance), katG gene27 (isoniazid
resistance), rpsL gene28 (streptomycin resistance), embB gene29 (ethambutol resistance)
and pncA genc30 (pyrazinamide resistance). This knowledge opened possibilities for the
development of rapid diagnostic tests. Traditional epidemiological and molecular
6
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7epidemiological research clearly showed that drug-resistant strains are transmissible and
pathogenic'l". Clinical research has shown that the outcome of patients with drug-
resistant TB is poor, especially among HIV positive patients, but can be improved with
rapid initiation of appropriate treatment.
During the last decade, our knowledge about drug-resistant TB has broadened, but
the management of these patients has changed little. Routine clinical diagnosis is still
based on 'slow' culture-based drug-susceptibility techniques, requiring 6 to 8 weeks. The
optimal treatment for multidrug-resistant TB cases is not known because regimens have
not been investigated in large clinical trials. Furthermore, TB control programmes are
directed towards the prevention of the acquisition of drug resistance and, especially in
developing countries, ignore the occurrence of transmission of drug-resistant strains.
D. Molecular epidemiology of drug-sensitive and drug-resistant tuberculosis
Understanding the disease dynamics of TB is complicated because only a small
proportion (approximately 10 %) of persons infected with M tuberculosis ever develop
clinical TB, and this only after an incubation period ranging from days to decades.
Furthermore, in areas with a high incidence of TB, multiple transmission events can
occur as people are often in contact with more than one TB case. This makes it
extremely difficult to identify the source of infection and site of transmission by
conventional epidemiological research using case history, contact investigation and the
tuberculin skin test.
Laboratory-based tests were investigated to improve data gathering. Since 1971,
phage typing was used to differentiate between different M. tuberculosis strains.
However, the possible application of phage typing was limited: the method was labor-
intensive, the interlaboratory reproducibility of the method poor and the discriminatory
ability of the scheme limited, as only three types could be distinguished reliably'". The
first application of modem molecular biology to identify strains of M tuberculosis was
reported in 198436. The finding that two isolates with the same phage type possessed
different restriction-fragment-Iength polymorphism (RFLP) patterns when the
mycobacterial DNA was hybridised with the entire M tuberculosis chromosome gave
an indication of the potential of the RFLP technique", The complexity of the observed
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banding patterns obtained by this method resulted in poor differentiation between
strains. The discovery that repetitive DNA elements are located at different
chromosomal sites of M. tuberculosis has revolutionised the DNA fingerprinting or
RFLP technique of M. tuberculosis38-43. The repetitive DNA elements investigated are
insertion sequences (lS6110, IS986 and IS1081) and short repetitive DNA sequences
(direct repeat, major polymorphic tandem repeat, and polymorphic GC-rich repetitive
sequencesr". Southern blotting of genomic DNA with IS6110 as a probe has become
the most widely used and internationally standardised technique for strain typing of M.
tuberculosis", Multiple studies have demonstrated that the degree of polymorphism
generated by this technique appears well suited for epidemiological investigations in
areas with a high as well as areas with a low incidence of TB45-48. There is sufficient
data indicating that epidemiological independent isolates of M. tuberculosis can have a
high degree of RFLP polymorphism while epidemiological related isolates show
identical banding pattems32.45.49-51.
Since 1990, RFLP analysis has been applied to multiple aspects of the epidemiology
of TB. RFLP analysis has been used to investigate outbreaks in communities", find
unexpected chains of transmission 53, track nosocomial transmission of strains",
differentiate between disease originating from reactivation of latent infection or recent
infection 47.54,document exogenous reinfection and relapse in individual patients'",
prove laboratory contamination " and document characteristics of TB in specific
populations, such as HIV positive patients ". RFLP analysis has also been used in the
study of drug-resistant TB. Many studies have investigated outbreaks of drug-resistant
TB and were able to demonstrate the occurrence of transmission of drug-resistant strains
from an infectious case to another person31.32,46.57-63.Studies on individual patients have
documented that the RFLP pattern does not change with the development of drug
resistance64. Exogenous reinfection with a drug-resistant strain has been proven to occur
in an HIV positive patienr". Population-based studies in low incidence areas have
demonstrated that the proportion of drug-resistant TB due to transmission of drug-
resistant strains is low, since the overwhelming majority of drug-resistant stains
retrieved from patients residing within a specific geographic area had distinct RFLP
pattcrns'",
8
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9Even though the application of DNA fingerprinting has increased insight into the
epidemiology of TB, some key assumptions have not been rigorously evaluated, thereby
leading to possible misinterpretation of data.
The first assumption is that IS6110 RFLP analysis accurately identifies clones of M
tuberculosis. The use of insertion elements may seem paradoxical, as they are
genetically unstable. The pace at which changes occur determines the number of
different strains involved in a group of isolates with a common ancestor. To be useful
for epidemiologic studies, a certain rate of genetic alteration is necessary. If genetic
rearrangements occur considerably faster than the epidemiological event studied,
epidemiological related strains will appear unrelated. If, however, genetic events occur
slower than the epidemiological event, unrelated strains will appear related'". Animal
models and in vitro studies have suggested that IS6110 patterns are stable, for example,
there was no observable change in IS6110 patterns after 2 months of passage through
guinea pigs", after 4 weeks passage in monolayers of in vitro cultivated macrophages or
after 6 months passage in liquid medium culture66. However, minor changes in RFLP
patterns (addition or loss of one band) have been documented in serial isolates from one
patient and in isolates from patients with clear epidemiological links45,67-69. For
population-based studies, the interpretation of strains with minor differences remains
controversial. The best DNA fingerprinting technique will therefore be the one that is
based on repetitive DNA elements with a rate of genetic rearrangement that occurs in
synchrony with the time frame of the epidemiologic situation studied".
The molecular clock of an insertion element is not the only determinant for validity
of the assumption that identical fingerprints indicate clonal dissemination. The degree of
M. tuberculosis heterogeneity in the population studied is another crucial component in
limiting the possibility that identical RFLP fingerprints might occur by chance among
unrelated individuals. Clonality is therefore only convincingly demonstrated when
considerable background diversity exists in the population, such that isolates with
identical patterns imply infection by a common source'". Furthermore, the accuracy of
strain classification has been shown to be dependent on the number and location of
IS6110 insertions because of the existence of preferential sites or hotspots for
integration ofIS61 JO, such as the direct repeat locus7o. It is now generally accepted that
aiVERSITEJT STElLENBOSCH
BIBUOTEEK
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additional genetic markers are necessary for the unambiguous confinnation of identity
of strains with a low (less or equal to 5) number oflS6110 copies':". No consensus has
been reached whether additional RFLP analysis is valuable for strains with ~ 6 IS6110
insertion elements 73.
The second key assumption that might interfere with correct interpretation of RFLP
analysis is that isolates with identical patterns indicate recent transmission from an
infectious patient to another person. It is possible that interpretation of clustering may
vary in different communities, depending on the TB incidence in the community'". In
areas with a high TB incidence, clusters may not always represent a single chain of
recent transmission but may be formed by repeated generations of recent transmission".
In contrast, clusters of M. tuberculosis isolates occurring in areas with a low TB
incidence may result from transmission that occurred in the distant past and reactivation
at the same time in different persons53,75.
In conclusion, the value of molecular epidemiology will depend on the integration
of a multi-probe RFLP technique with conventional epidemiological approaches and
requires knowledge about the demographic characteristics of the population studied.
Only then will molecular epidemiology improve our understanding of disease dynamics
ofTB and subsequently permit the design of more efficient TB control strategies.
E. Aim, setting and structure of this study
Drug-resistant TB is recognised as a threat for global TB control. Data on the
epidemiology of drug-resistant TB in the developed world is available from surveillance
studies, nosocomial outbreaks and a few studies on community outbreaks of drug-
resistant TB. The most important results of these studies are fourfold. First, data from
the recent WHO-I UATLD survey on drug resistance in TB suggest that drug-resistant
TB is a global problem with several hotspot locations of multidrug-resistant TB25.
Second, data from outbreak studies indicate that, in contrast to the prior dogma, drug-
resistant M. tuberculosis strains are virulent, pathogenic and can be transmitted from
one patient to another ':". Third, the majority of cases of drug-resistant TB are acquired
due to treatment errors and not through transmission of a drug-resistant strain'". Fourth,
10
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outcome-based research has shown that morbidity and mortality of drug-resistant TB is
much higher compared to morbidity and mortality of drug-sensitive TB31,32.
Even though the majority of drug-resistant TB cases occur in the developing world,
our knowledge concerning the epidemiology of drug-resistant TB in the developing
world is extremely limited, except for some data gained from surveillance studies. The
aim of this study was therefore to primarily evaluate the disease dynamics of drug-
resistant TB in a developing country where TB is endemic.
The work for this thesis was performed in a well-defined geographic area consisting
of two communities within the Cape Town Metropolitan area, South Africa. This area
was selected in 1992 as the principal research site for the TB research team of the
University of Stellenbosch and the Glaxo Wellcome Action TB Programme ". The area
shows many characteristics of an urban area in a developing country (a detailed
demographic and socio-economic description is included chapter 7). The area is further
characterised by an extremely high incidence of TB: a notification rate of more then
1000/100000/year in 199147 and an incidence rate of bacteriological positive cases of
225/1 OOOOO/yearduring the period 1996-199877• The discrepancy between these two
rates can be explained by 3 factors: (1) the relatively important contribution of smear
and culture negative childhood cases (39% of all notified cases); (2) the high rate of
retreatment cases (approximately 30 %) and (3) the fact that only 70% of notified adults
are bacteriological positive.
Since 1992, the epidemiology of TB in this area has been studied prospectively by
collecting clinical data and cultures positive for M tuberculosis from all patients
notified as TB cases. The research team has not interfered with patient treatment, which
is prescribed and provided by the primary health care clinics according to the guidelines
of the National Tuberculosis control Program. Treatment facilities and treatment
guidelines are outlined in chapter 2. Diagnostic procedures were extended for research
purposes to ensure that all patients were interviewed by a study nurse and investigated
by chest radiography, that all sputa obtained were cultured. and all cultures positive for
M. tuberculosis were analysed by RFLP method. A computerised database has been
created. This database consists of clinical data on all (more than 900) patients included
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and results of RFLP analysis of more than 2000 M. tuberculosis cultures. Furthermore,
all M. tuberculosis cultures are stored at minus 20 degrees Celsius for further analysis.
My Ph.D. study was nssted in this large prospective epidemiologic study on TB. All
70 residents identified as cases of drug-resistant TB during a 5 year period (1 April
1992 until 31 March 1997) were included. Three different methods were used to study
the disease dynamics of drug-resistant TB in the selected study site: RFLP analysis, also
known as DNA fingerprinting, mutation detection analysis by dot-blot hybridisation
method and spatiotemporal analysis by the use of a geographic information system
(GIS). The molecular epidemiologic method of RFLP analysis is described in detail in
chapter 2. Chapter 2 also includes a description of the methods used for microscopy and
culture of M. tuberculosis. The dot-blot hybridisation method used for mutation
detection analysis is described in detail in the chapter 3. The Geographic Information
System is described in detail in chapter 8. All analysis by RFLP method and dot-blot
hybridization method of M. tuberculosis drug-resistant isolates has been performed by
myself. The GIS analysis was performed in collaboration with M. Kunneke, under
supervision of Prof. L. Zietsman.
Each chapter describes a clinical application of molecular biology andlor GIS and
includes the literature review relevant to the specific topic. In chapter 2, I have
investigated the possibilities and limits of the RFLP method for the epidemiologic study
of drug-resistant TB. In chapter 4, the classification of patients into different categories
by clinical and molecular epidemiologic methods is compared. In chapter 6, mutation
detection analysis is applied to study the frequency distribution of the different
mutations within the area and to evaluate the clinical use of mutation detection analysis.
In chapter 7, an outbreak of drug-resistant TB is described by the combined use of
RFLP and mutation detection analysis. In chapter 8, a GIS is applied to characterise the
socio-economic risk factors for the occurrence of drug-resistant TB and the transmission
thereof. Chapter 9 reports on the outcome analysis of patients treated for drug-resistant
TB. All patients included in these studies form part of the 70 cases of drug-resistant TB
identi fied in the area during the 5-year study period.
An additional study on a selected population of cases of drug-sensitive TB was
included to support one of the major findings of this Ph.D. study, namely that most
12
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cases of drug-resistant TB were caused by exogenous (re)infection with a drug-resistant
strain. The study on the relative importance of exogenous reinfection after curative
treatment for drug-sensitive TB is reported in chapter 5.
REFERENCES
1. Haas F, Haas SS. The origins of Mycobacterium tuberculosis and the notion of its contagiousness. In
Rom WN, Garay S. (Eds) Tuberculosis. Boston: Little, Brown and Company, 1996: Pp. 3-19.
2. Aristotle. In Problems, The complete works of Aristotle. Volume2. The Revised Oxford Translation.
1. Barnes (Ed.). Oxford: Princeton/Bollinen Series LXXI.2, 1984.
3. Villemin JA. Etudes sur la tuberculose: preuves rationelIes et expérimentales de le specificité et de
son inoculabilité. Paris: Baillieres, 1868.
4. Koch R, Pinner M. (Trans) The aetiology of tuberculosis. New York: National Tuberculosis
Association: 1932. P 24.
5. Fracastorii H, Wright WC (Trans-annot), De eontagione et contagiosis morbis et eorum curatione.
New York: GP Putnam's Sons, 1930.
6. Marten B. A new theory of consumption, more especially of Phthisis or consumption of the lungs.
London, 1720.
7. Davis AL. History of the Sanatorium Movement. In Rom WN, Garay S. (Eds) Tuberculosis. Boston:
Little, Brown and Company, 1996: Pp.35-54.
8. Schatz A, Bugie E, Waksman SA. Streptomycin: a substance exhibiting activity against gram
positive and gram negative bacteria. Proe Soc Exp Bioi Med 1944; 55:66-69.
9. Mitchison DA. Chemotherapy of tuberculosis: a bacteriologist's viewpoint. Br Med J 1965; 1:1331-
1338.
10. World Health Organisation. WHO Tuberculosis Program. Framework for effective tuberculosis
control. 1994. WHO/TB/94.179. WHO, Geneva.
Il. Metcalf C. A history of tuberculosis. In: Coovadia HM, Benetar SR, Eds. A century of tuberculosis.
South African perspectives. Cape Town: Oxford University Press, 1991: 20-25.
12. Packard RM. Holding back the tide: TB control efforts in South Africa. In: Coovadia HM, Benetar
SR, Eds. A century of tuberculosis. South African perspectives. Cape Town: Oxford University
Press, 1991: 43-55.
13. Strebel PM, Seager JR. Epidemiology of tuberculosis in South Africa. In: Coovadia HM, Benetar SR,
Eds. A century of tuberculosis. South African perspectives. Cape Town: Oxford University Press,
1991: 58.
14. The South African Tuberculosis Control Programme. Practical guidelines. Pretoria: Department of
Health, February 1996.
15. Youmans GP, Williston EH, Feldman WH. Increase in resistance of tubercle bacilli to streptomycin.
A preliminary report. Proe Mayo Clin 1946; 21:126-127.
Stellenbosch University http://scholar.sun.ac.za
16. Pyle MM. Relative numbers of resistant tubercle bacilli in sputum of patients before and during
treatment with streptomycin. Proe Mayo Clin 1947; 22:465-473.
17. Temple CW, Hughs EJ, Mardis RE, Towbin MN, Dey WE. Combined intermittent regimens
employing streptomycin and para-aminosalicyclic acid in the treatment of pulmonary tuberculosis.
Am Rev Tuberc 1951; 63:295-311.
18. Canetti G, Grosset 1. Teneur des souches sauvages de Mycobacterium tuberculosis en variants
resistants a I'isoniazide et en variants resistants a la streptomycine sur Ie milieu de Loewenstein-
Jensen. Ann Inst Pasteur 1961; 101:28-46
19. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1955;
1:435-445.
20. David HL. Probability distribution of drug-resistant mutants in unselected populations of
Mycobacterium tuberculosis. Appl Microbiol1970; 20:810-814.
21. WHOIIUATLD Global Working Group on Antituberculosis Drug Resistance Surveillance.
Guidelines for surveillance of drug resistance in tuberculosis. WHO Geneva / TVATLD Paris. Int J
Tuberc Lung Dis 1998; 2:72-89.
22. Mitchison DA. Tubercle bacilli resistant to isoniazid. Br Med J 1954; 1:128-130.
23. Cohn ML, David CL. Infectivity and pathogenicity of drug-resistant strains of tubercle bacilli studied
by aerogenic infection of guinea pigs. Am Rev Respir Dis 1970; 102:97 -104
24. Canetti G. The 1. Burs Amberson Lecture. Present aspects of bacterial resistance in tuberculosis. Am
Rev Resp Dis 1965; 92:687-703.
25. Pablos-Mendez A, Laszlo A, Bustreo F, Binkin N, Cohn D, Lambregts-Van Weezenbeek CSD, Kim
SJ, Chaulet P, Nunn P, Raciclione Me. Antituberculosis drug resistance in the world. The
WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. 1997
WHOITB/97.229
26. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T.
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341 :647-
650.
27. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance
of Mycobacterium tuberculosis. Nature 1992;358:591-593
28. Nair J, Rouse DA, Bai G, Morris SLo The rspL gene and streptomycin resistance in single and
multiple drug-resistant strains of Mycobacterium tuberculosis. Mol Microbiol 1993; 10:521-527.
29. Telenti A, Phillip WJ, Sreevatsan S, Bernasconi C, Stockbrauer KE, Wieier B, Musser JM, Jacobs
WR. TIle Emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to
ethambutol. Nat Med 1997; 3:567-570.
30. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinarnidase, cause
resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2:662-667.
31. Coronado VG. Beck Sague CM, Hulton MD, Davis BJ, Nicholas P, Villareal C, Woodley Cl,
Kilburn JO. Crawford JT, Frieden TR. Sinkowitz RL, Jarvis WR. Transmission of multidrug-
resistant Mycobacterium tuberculosis among persons with Human Immunodeficiency Virus infection
14
Stellenbosch University http://scholar.sun.ac.za
15
in an urban hospital: epidemiologic and Restriction Fragment Length Polymorphism analysis. J
Infect Dis 1993; 168:1052-1055.
32. Edlin BR, Tokars Jl, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among
hospitalised patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326: 1514-
21.
33. Kritski AL, Ozario Marques MJ, Rabahi MF, et al. Transmission of tuberculosis to close contacts of
patients with multi drug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153 :331-5.
34. Snider DE, Kelly GO, Cauthen GM, Thompson NJ, Kilburn JO. Infection among contacts of
tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985;
132: 125-32.
35. Saunders N A. State of the art: typing Mycobacterium tuberculosis. J Hosp Infect. 1995; 29:169-176.
36. Collins OM, de Lisle GW. DNA restriction endonuclease analysis of Mycobacterium tuberculosis
and Mycobacterium bovis BCG. J Gen Microbiol1984; 130:1019-1021.
37. Shoemaker SA, Fisher JH, Jones WD, Scoggin CHo Restriction fragment analysis of chromosomal
DNA defined different strains of Mycobacterium tuberculosis. Am Rev Resp Dis 1986; 134:210-213.
38. Van Soolingen 0, Hermans PWM. Epidemiology of tuberculosis by DNA fingerprinting. Eur Resp J
1995; 8 S20:649s-656s.
39. Eisenach KO, Crawford JT, Bates JH. Repetitive DNA sequences as probes for Mycobacterium
tuberculosis, J Clin Micro 1988; 26:2240-2245.
40. Zainuddin ZF, Dale JW. Polymorphic DNA sequences in Mycobacterium tuberculosis detected with
a gene probe from Mycobacterium fortuitum plasmid. J Gen Microbiol1989; 135:2447-2455.
41. Mc Adam RA, Hermans PWM, Van Soolingen 0, Zainuddin ZF, Catty 0, Van Embden IDA, Dale
JW. Characterization of a Mycobacterium tuberculosis insertion sequence belonging to the IS3
family. Molec Microbiol1990; 4:1607-1613.
42. Thierry 0, Cave MD, Eisenach KO et al. IS611 0, an IS-like element of Mycobacterium tuberculosis
complex. Nucleic Acid Res 1990; 18:188.
43. Hermans PMW, Van Soolingen 0, Dale JW, Schuitema ARJ, Mc Adams RA, Catty 0, Van Embden
IDA. Insertion element IS986 form Mycobacterium tuberculosis: a useful tool for diagnosis and
epidemiology of tuberculosis. J Clin Microbiol 1990; 28: 1252-1254.
44. Van Embden IDA, Cave MD, Crawford JT, Dale JW, Eisenach KO, Ciquel B, Hermans P, Martin C,
McAdam R, Shinnick TM, Small PM. Strain identification of Mycobacterium tuberculosis by DNA
fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993; 31 :406-
409.
45. Mazurek GH, Cave MD, Eisenach KO, Wallace RJ, Bates JH, Crawford JT. Chromosomal DNA
fingerprint patterns produced with IS6110 as strain specific markers for epidemiologic study of
tuberculosis. J Clin Microbiol 1991; 29:2030-2033.
46. Godfrey-Faussett P, Stoker NG. Aspects of tuberculosis in Africa. 3. Genetic 'fingerprinting' for
clues to the pathogenesis of tuberculosis. Trans Royal Soc Trop Med Hyg 1992; 86:472-475.
Stellenbosch University http://scholar.sun.ac.za
47. Warren R, Hauman J, Beyers N, Richardson M, Schaaf HS, Donald P, van Helden P. Unexpectedly
high strain diversity of Mycobacterium tuberculosis in a high-incidence community. S Afr Med J
1996; 86:45-49.
48. Chcvril-Dellagi D, Abderrahman A, Haltiti R, Koubaji H, Ciquel B, Dellagi K. Large-scale DNA
fingerprinting of Mycobacterium tuberculosis strains as a tool for epidemiological studies of
tuberculosis. J Clin Microbiol 1993; 31 :2446-2450.
49. Small PM, van Embden IDA. Molecular epidemiology of tuberculosis. In: Bloom BR ed.
Tuberculosis: pathogenesis, protection and control. Washington, DC, American Society for
Microbiology,1994.
50. Hermans PWM, van Soolingen D, Dale JW, Schuitema ARl, McAdam RA, Catty D, van Embden
JDA. Insertion element IS986 from Mycobacterium tuberculosis: a useful tool for diagnosis and
epidemiology of tuberculosis. J Clin Microbiol1990; 28:2051-2058.
51. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, Hopewell PC. An
outbreak of tuberculosis with accelerated progression among persons infected with the human
immunodeficiency virus. An analysis using Restriction-Fragment-Length Polymorphism. New Engl J
Med 1992; 326:231-235.
52. Tabet SR, Goldbaum GM, Hooten TM, Eisenach KO, Cave MD, Nolan CM. Restriction fragment
length polymorphism analysis detecting a community-based tuberculosis outbreak among persons
infected with human immunodeficiency virus. J Infect Dis 1994: 169: 189-192.
53. Barnes Pt, Yang Z, Preston-Martin S, Pogoda JM, Jones BE, Otaya M, Eisenach KD, Knowles L,
Harvey S, Cave MD. Patterns of tuberculosis transmission in central Los Angeles. ]AMA 1997;
278:1159-1163.
54. Alland 0, Kalkut GE, Moss AR, McAdam RA, Hahn IS, Bosworth W, Drucker E, Bloom BR.
Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and
conventional epidemiologic methods. New Engl J Med 1994; 330: 1710-1716.
55. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK.
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with
advanced HIV infection. New Engl J Med 1993; 328:1137-1144.
56. Braden CR, Templeton GL, Stead WW et al. Retrospective detection of laboratory cross-
contamination of Mycobacterium tuberculosis culture with the use of DNA tingerprint analysis. Clin
Infect Dis 1997;24:35-40
57. Beck-Sague C, Dooley SW, Hutton MD, Otten J, Breeden A, Crawford JT, Pitchenek AE, Woodley
C, Cauthen G, Jarvis WR. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis
infections. Factors in transmission to staff and HIV -infected patients. lAMA 1992; 268: 1280-1286.
58. Fishl MA, Uttamchandani RJ. Daikos GL, Pobletc RB, Moreno IN, Reyes RR, Boota AM,
Thompson LM. Cleary Tl, Lai S. An outbreak of tuberculosis caused by multiple-drug-resistant
tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117: 177-183.
16
Stellenbosch University http://scholar.sun.ac.za
17
59. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford IT, Nivin B, Sharp V, Hewlett 0,
Brudney K, Alland 0, Kreiswirth BN. A multi-institutional outbreak of highly drug-resistant
tuberculosis. Epidemiology and clinical outcomes. JAMA 1996; 276: 1229-1235.
60. Friedman R, Stoeckle MY, Kreiswirth BN, Johnson WD, Manoach LM, Berger J, Sathianathan K,
Hafner A, Riley LW. Transmission of multidrug-resistant tuberculosis in a large urban setting. Am J
Respir Crit Care Med 1995; 152:355-359.
61. Moss AR, Alland 0, Telzak E, Hewlett 0, Sharp V, Chiliade P, LaBombardi V, Kabus 0, Hanna B,
Palumbo L, Brudney K, Weltman A, Staockle K, Chirgwin K, SinberkoffM, Moghazeh S, Eisner W,
Lutfey M, Kreiswirth B. A city-wide outbreak of a multiple-drug resistant of Mycobacterium
tuberculosis in New York. Int J Tuberc Lung Dis 1997; 1:115-121.
62. Ritacco V, Di Lonardo M, Reniero A, Ambroggi M, Barrera L, Dambrosi A, Lopez B, Isola N, de
Kantor IN. Nosocomial spread of Human Immunodeficiency Virus-related multidrug-resistant
tuberculosis in Buenos Aires. J Infect Dis 1997; 176:637-642.
63. Valway SE, Greifinger RB, Papania M, Kilburn JO, Woodley C, DiFernando GT, Dooley SW.
Multidrug-resistant tuberculosis in the New York State prison system 1990-1991. J Infect Dis 1994;
170:151-160.
64. Godfrey-Fausset P, Stoker NG, Scott JAG, Pasvol G, Kelly P, Clancy L. DNA fingerprints of
Mycobacterium tuberculosis do not change during the development of rifampin resistance. Tubercle
Lung Dis 1993; 74:240-243.
65. Fang Z, Doig C, Rayner A, Kenna OT, Watt B, Forbes KJ. Molecular evidence for heterogeneity of
multiple-drug-resistant Mycobacterium tuberculosis population in Scotland (1990-1997). J Clin
Microbiol1999; 37:998-1003.
66. Van Soolingen 0, Hermans PWM, de Haas PEW, Soli DR, van Embden IDA. Occurrence and
stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an
insertion sequence -dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J
Clin Microbiol1991; 29:2578-2586.
67. Cave MD, Eisenach KO, Templeton G, Salfinger M, Mazurek G, Bates JH, Crawford IT. Stability of
DNA fingerprint pattern produced with IS6110 in strains of Mycobacterium tuberculosis. J C1in
Microbiol 1994; 32:262-266.
68. De Boer AS, Borgdorff MW, de Haas PEW, Nagelkerke ID, van Embden IDA, van Soolingen D.
Analysis of rate of change of IS6110 RFLP patterns of Mycobacterium tuberculosis based on serial
patient isolates. J Infect Dis 1999; 180: 1238-1244.
69. Yeh RW, Ponce de Leon A, Agasino CB, Hahn JA, Daley CL, Hopewell PC, Small PM. Stability of
Mycobacterium tuberculosis DNA genotypes. J Infect Dis 1998; 177: 1107-1111.
70. Fomukong N, Beggs M, El Hajj H, Templeton G, Eisenach K, Cave MD. Differences in the
prevalence of IS611 0 insertion sites in Mycobacterium tuberculosis strains: low and high copy
number ofIS6110. Tubercle Lung Dis 1998; 78:109-116.
Stellenbosch University http://scholar.sun.ac.za
71. Chaves F, Yang Z, EI Hajj HE, Alonso M, Burman WJ, Eisenach KO, Dronda F, Bates JH, Cave
MD. Usefulness of the secondary probe pTBNI2 in DNA fingerprinting of Mycobacterium
tuberculosis. I Clin Microbiel 1996; 34:1118-1123.
72. Van Soolingen 0, de Haas PEW, Hermans PWM, Groenen PMA, van Embden IDA. Comparison of
various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of
Mycobacterium tuberculosis. J Clin Microbiel 1993; 31: 1987-1995.
73. Warren R, Richardson M, Sampson S, Hauman JH, Beyers N, Donald PR, van Helden PD.
Generyping of Mycobacterium tuberculosis with additional markers enhances accuracy in
epidemiological studies. J Clio Microbiol 1996; 34:2219-2224.
74. Godfrey-Fausset P. Interpretation of cluster studies of tuberculosis. Lancet 1999; 353:427-428.
75. Braden CR, Templeton GL, Cave MO, Valway S, Onorato 1M, Castro KG, Moers 0, Yang Z, Stead
WW, Bates JH. Interpretation of Restriction Fragment Length Polymorphism analysis of
Mycobacterium tuberculosis isolates from a state with a large rural population. J Infect Dis 18997;
175: 1446-1452.
76. Warren R, Richardson M, van der Spuy G, Victor T, Sampson S, Beyers N, van Helden P. DNA
fingerprinting and molecular epidemiology of tuberculosis: use and interpretation in an endemic
setting. Electrophoresis 1999; 20: 1807-1812.
77. Van Rie A, Warren R, Richardson M, Victor T, Gie R.P, Enarson DA, Beyers N, and Van Helden PD.
Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl I Med
1999; 341:1174-1179.
18
Stellenbosch University http://scholar.sun.ac.za
19
CHAPTER2
Use of DNA fingerprinting in evaluating
the epidemiology of drug-resistant
tuberculosis in a high incidence area
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Use of DNA fingerprinting in evaluating the epidemiology
of drug-resistant tuberculosis in a high incidence area.
Background: Restrietion Fragment Length Polymorphism (RFLP)
analysis has been validated as a useful tool for the epidemiological study
of tuberculosis (TB). Reports on drug-resistant TB outbreaks have
shown the importance of nosocomial transmission. Population-based
studies in low incidence areas have shown a high diversity of drug-
resistant Mycobacterium tuberculosis strains. The aim of this study was
to evaluate the use of RFLP in the epidemiologic study of drug-resistant
TB in an area endemic for TB. Method: All patients residing in two
Cape Town communities and diagnosed with culture-positive drug-
resistant TB during a 5year period were included. Patients were
interviewed in a search for epidemiologieal connections. RFLP analysis
was performed by an internationally accepted method (IS6110-3') and
by additional genetic markers (IS6110-5', ORr, MTB484(1». Cluster
analysis was performed to identify strains with identical RFLP
patterns, but retrieved from patients not diagnosed as drug-resistant
TB cases. Results: RFLP analysis showed a high degree of strain
diversity among single drug resistant TB cases but a low degree of
strain diversity among multidrug-resistant TB (MDR- TB) cases. An
epidemiologic link could be identified in 68% of clustered patients
(IS6J 10-3' method) and in 74% by the use of multiple genetic markers.
Cluster analysis could identify drug -resistant strains in patients not
diagnosed as drug-resistant TB cases. Conclusion: RFLP analysis
improved the understanding of the epidemiology of drug-resistant TB
in an endemic area. Strain diversification among MDR- TB cases was
unexpectedly low, indicating substantial community transmission.
RFLP analysis could identify transmission among patients without
conventional epidemiological links. RFLP analysis could also show that
drug-resistant TB case finding by the National Tuberculosis Control
Program was incomplete.
____ 20J
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INTRODUCTION
Drug-resistant tuberculosis can result from acquisition of resistance in a patient's
original M tuberculosis strain due to treatment errors or from transmission of a drug-
resistant strain from an infectious case to another person I. Based on the current general
belief that drug-resistant TB is predominantly acquired through treatment errors, TB
control programmes are primarily directed at the prevention of acquisition of drug-
resistance. This strategy, or a failure to apply this strategy correctly, failed to contain the
problem of drug resistance. This suggests the need for a re-evaluation of the problem.
Understanding the disease dynamics of TB is complicated, because infection is
followed by disease in only a minority of infected persons (approximately 10 %) and
this after an incubation period ranging from days to decades. Furthermore, in areas with
a high TB incidence, multiple transmission events can occur as people are often in
contact with more than one TB case. Without accurate strain typing, it is difficult to
distinguish the origin of different isolates', Modem molecular epidemiology is based on
the integration of molecular biology techniques with conventional epidemiologic
approaches to track the spread of specific Mycobacterium tuberculosis strains and
understand the distribution of disease in a population. DNA fingerprinting or Restriction
Fragment Length Polymorphism (RFLP) can detect a high degree of genetic
polymorphism among M. tuberculosis and has been validated as a useful tool in the
epidemiologic study of TB3-8• Studies have shown that an identical RFLP pattern may
imply infection by a common source and therefore an epidemiologic connection while
epidemiologic unrelated strains have different RFLP patterns't':',
Many studies have investigated outbreaks of drug-resistant TB by the use of RFLP
analysis to and showed the occurrence of clonal dissemination of drug-resistant
strainsI4-21• Population-based studies can determine the relative proportion of drug-
resistant TB due to transmission. Demonstrating a high degree of RFLP polymorphism
would imply that drug-resistant TB is predominantly emerging from treatment errors. In
contrast, limited RFLP diversity would suggest a high degree of transmission with
clonal dissemination of drug-resistant strains. Population-based studies in low incidence
areas have shown that the majority of drug resistant stains have distinct RFLP patterns
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implying acquisition of drug resistance/ê. There is no data on the degree of RFLP
polymorphism among drug-resistant stains in an area where TB is endemic.
The aim of this study was to evaluate the use of RFLP analysis In the
epidemiological study of drug-resistant TB in two communities with a high TB
. incidence. The improved insight in the nature of transmission of drug-resistant TB in the
community may subsequently permit more precise targeting of disease-control
strategies.
MATERIAL AND METHODS
Setting
The area studied consists of two neighbouring Cape Town communities
(Ravensmead and Uitsig) with a total residential surface area of 2.42 km2 and a
population of 34294 (1991 census data). Two primary health care clinics and a tertiary
hospital (Tygerberg Hospital, University of Stellenbosch) serve the area. All treatment
received from the clinics is free of charge. TB patients and malnourished children
receive a daily basic meal from the nutrition kitchen in part supported by the
Department of Health. Despite the easy access to health care, many problems remain.
The infant mortality rate was still very high in 1991 (38 per 1000 life births) but has
dropped to 29 per 1000 life births in )996. The HIV prevalence in the Western Cape
Province, estimated by a survey on pregnant women conducted by the Department of
Health and Population Development, has been rising steadily from 0.37% in 1991 to
3.1% in 1996 (data from the National HIV surveys on women attending antenatal
clinics, conducted by the Department of Health and Population Development, South
Africa).
TB is one of the top 3 health problems of South Africa. The Cape Town
Metropolitan area, with a TB notification rate of 560/100 ODD/year has the dubious
distinction of possibly being the world's TB capital. Within the province, the Coloured
ethnic group is the population most affected by TB. The TB notification rate in the
communities studied has been estimated to be more than 1000/100 ODD/yearin 199123•
22
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The notification rate of all (new and retreatment) bacteriologic positive cases IS
363/100.000/year during the period 1996-98. The incidence of new bacteriologic
positive TB cases in the communities is 225/100 OOO/year (period 1996-1998)24. A
survey of drug resistant TB in the Western Cape Province conducted in 1992-93 found a
rate of 8.6% acquired and 3.2 % initial resistance in the West Cape region".
The National Tuberculosis Control Programme (NTP) guidelines for TB
management have changed with time. Before 1996, diagnosis was based on direct smear
stain for acid-fast bacilli, culture for M tuberculosis and chest radiography. Drug
sensitivity testing was requested for clinical indications such as retreatment cases and
patients who failed to respond to treatment. All patients were treated under direct
supervision for 6 months with a combination tablet consisting of isoniazid, rifampin and
pyrazinamide. Ethambutol was added for retreatment cases. In 1996, the Directly
Observed Treatment, Short-course (DOTS) strategy of the World Health Organisation
(WHO) was implemented. Since then, diagnosis of new patients is based on two direct
smear stains for acid fast bacilli. Chest radiography and M tuberculosis culture is
reserved for retreatment cases and new patients with symptoms compatible with TB but
negative acid fast smears. Drug sensitivity testing is performed in retreatment cases and
patients who fail to respond to treatment. The intensive treatment phase for new patients
consists of 4 drugs (isoniazid, rifampin, pyrazinamide and ethambutol) for 2 months;
supplemented by streptomycin for retreatment cases. The continuation phase consists of
isoniazid and rifampin for 4 months for new patients. For retreatment cases, the
intensive phase consists of isoniazid, rifampin, ethambutol and pyrazinamide for 1
month followed by 3 drugs isoniazid, rifampin and ethambutol for 5 months.
Official NTP guidelines for treatment of multi drug-resistant TB (MDR-TB), defined
as resistant against at least isoniazid and rifampin, were not available during the study
period. In the Western Cape Province, however, special treatment units for MDR-TB
patients have been developed. Patients had the option to be treated at the primary health
care clinic or at a specialised MOR-TB treatment unit which provides inpatient
treatment as well as outpatient treatment advice and outpatient follow-up.
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Data collection
In 1992, the Tuberculosis Research Group of the University of Stellenbosch started
a prospective study for which positive M. tuberculosis cultures from all patients notified
with TB were collected from the routine laboratory (South African Institute for Medical
Research, SAIMR) for RFLP analysis. The retrieval rate from this study has been
approximately 80%24. From the clinical and RFLP database created by this study, all
patients with a positive culture for M. tuberculosis resistant to at least one
antituberculosis drug between I April 1992 and 31 March 1997 were identified.
Medical files and compliance charts were reviewed and detailed information on medical
history, HIV status, history of prior TB treatment, results of microscopy, culture and
drug susceptibility testing for M. tuberculosis and details of treatment for drug-resistant
TB was collected. Furthermore, patients were interviewed by a medical anthropologist
to determine epidemiological links.
Laboratory methods
1. Microscopy and culture for M. tuberculosis
Sputum samples are sent directly from the clinics to the state SAIMR laboratory.
Samples arc mucolyzed and decontaminated by the addition of I % Nvacetyl-Lccysteine,
3 % tri-Sodium-Citrate and 4 % Sodium Hydroxide. A phosphate buffer is added to IS
ml of specimen to reach a pH of 6.7. Samples are centrifuged at 3000 g for 20 minutes.
The sediment obtained is used for acid fast smear and culture. The staining technique
used for the acid-fast smear test is the auramine 0 fluorochrome dye.
M. tuberculosis is cultured in the BACTEC system. If the sputum sample was
positive for acid fast bacilli, the growth index is checked on alternate days for 4 weeks.
Cultures from smear negative samples are checked weekly for 4 weeks. When growth is
obtained, confirmation of acid fast bacilli is performed by a Ziehl-Neelsen stain. A
blood agar procedure is used to check for contamination. Mycobacterial, non-
contaminated BACTEC growths are transferred to a Middeibrook 7H 10 broth to allow
growth for 3 weeks. The confirmation of M. tuberculosis is then performed by the
24
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ruacm production test USIng commercially available strips containing cyanogen
bromide.
Drug susceptibility testing is performed by the economic variation of the indirect
proportion method". This entails incorporation of the required drug concentration into
Lëwenstein-Jensen medium before slants are inoculated with a standardised inoculum
retrieved from the initial BACTEC growth. Drugs were tested at the critical
concentrations of 0.2 ug/ml isoniazid, 30 ug/rnl rifampin, 2 ug/ml ethambutol, Sug/ml
streptomycin and 20Ilg/ml ethionamide. Kanamycin and thiacetazone are tested on
Middlebrook 7H10 agar containing critical concentrations of respectively 5 and 2
ug/ml, Resistance was defined as 1% or more bacterial growth in comparison with a
control using international criteria. Initially, cultures are tested for resistance to
isoniazid and rifampin. If resistance to these drugs was detected, cultures were
subsequently tested for resistance to the other antituberculous drugs. Resistance to
pyrazinamide was not tested. Laboratory proficiency testing is performed internally (a
susceptible HR37v strain and a Mycobacterium avium strain resistant to all drugs is
added to each batch) as well as externally every 6 months.
2. RFLP analysis
Cultures received from SAIMR are subcultured on Lëwenstein-Jensen medium by
scraping of the slant in order to prevent selection of dominant colonies. Once sufficient
growth is achieved, one subculture together with the original culture (from SAIMR) is
stored at minus 20° Celsius. The other subculture is heated at 80° Celsius for 1 hour to
kill all mycobacteria. All colonies are scraped of the slant after addition of extraction
buffer (50 mM Tris-HCI, 25 mM EDTA, 5% Mono-sodium Glutamate). Samples are
vortexed with glass balls to disrupt all colonies and 450 III of lysozyme, 10 III of RNA-
se and 150 III Proteinase K (plus buffer) are added successively leaving enough
incubation time for each enzyme. The DNA is extracted by treating the sample
successively with Phenol:Chloroform:lsoamylalcohol (25:24:1, pH 7.6),
Chloroform:Isoamylalcohol (24:1), 3M Sodium Acetate (pH 5.2) and ice-cold
Isopropanol. DNA is precipitated by eentrifusion in ethanol and dissolved in TE buffer.
To determine the concentration of DNA and the purity of each sample, optical density is
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read at a wavelength of 260 nm (DNA) and 280 nm (protein). Six ug of mycobacterial
DNA is digested with PvuII; the rest of the extracted mycobacterial genomic DNA is
stored at - 20°C. Digestion is confirmed by electrophoresis on a agarose gel. Digested
DNA is precipitated with I0 ul tRNA, 10 JlI Sodium Acetate 3M, and ethanol after
which the DNA pellet is redissolved in TE buffer. DNA fragments are separated by
electrophoresis on a 0.8% agarose gel in TBE buffer. After denaturation of the DNA
fragments with 0.4 M Sodium Hydroxide, the DNA fragments are transferred to a
Hybond membrane (Amersham, United Kingdom) in SSPE buffer by Southern transfer
method. The membrane is washed in 2 x SSC for 10 min and baked at 80° Celsius for 2
hours. The IS6110 probe is prepared by denaturing 2.5 ~I of IS6110 probe (IO ng/ul),
adding labelling reagent to visualise the probe during ECL procedure and
gluteraldehyde to fix the labelling agent firmly to the probe. The DNA on the
membranes is hybridised with the labelled IS6110 probe at 42° Celsius. The membrane
is washed twice with primary wash to remove all excess probe and twice with 2 x SSC
to eliminate the urea. The RFLP patterns are visualised by ECL procedure and
autoradiography.
Since late 1992, as part of a prospective study, positive cultures for M. tuberculosis
from patients residing in the 2 communities studied have been genotyped by RFLP
analysis (IS6110) and analysed using Gel Compar 4.0 software (Applied Maths BVBA,
Kortrijk, Belgium). The Dice coefficient and UPGMA clustering formula was applied to
identify possible clusters of transmission.
For the purpose of my study, drug-resistant samples were run on separate gels. To
enhance accuracy, clusters of identical drug-resistant isolates were subjected to further
genotyping. The Pvull digested DNA was sequentially hybridised with ECL labelled
IS6110-5' and 32p labelled ORr probe". The membrane was stripped after each
hybridisation process with a neutralising reagent (0.2 M TRIS, 0.1% SDS and 0.1%
SSC) to remove all present probe. In addition, 6 ug of DNA was also digested by Hinjl
and hybridised with 32p labelled MTB484 (1) probe". The RFLP patterns were
visualised by autoradiography.
26
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3. Mutation detection analysis by dot-blot hybridisation method.
A detailed description of the detection of mutations in drug resistance genes of M
tuberculosis by a dot-blot hybridisation method is attached as an addendum to this
chapter. In short, extracted DNA of drug resistant M tuberculosis isolates was
amplified by PCR technique with specific primers directed at amplifying regions of the
katG, kasA, rpoB, rpsL, rrs and embB genes, directed towards genes which are most
frequently associated with resistance to antituberculous drugs. Efficient amplification
was confirmed by gel electrophoresis. An aliquot of each PCR product was fixed onto a
Hybond-N" membrane. The membranes were then hybridised with radiolabelled wild
type and mutant-specific oligonucleotide probes. Hybridisation results were visualised
by autoradiography.
Definitions
1. Clinical definitions
Drug resistance is defined as a decrease in the in-vitro susceptibility of M
tuberculosis of sufficient degree to be reasonably certain that the strain concerned is
different from a strain that has never been in contact with the drug'. Clinical drug
resistance was determined according to the results of bacteriological testing (indirect
proportion method). Single-drug resistance is defined as a strain resistant to only one
antituberculous drug. Multidrug resistance (MDR) is defined by the WHO as resistance
against at least isoniazid and rifampin I. Multiple-drug resistance is defined as a strain
resistant to more than one antituberculous drug but not the combination of isoniazid and
rifampin.
Acquired drug resistance is defined as resistant bacilli retrieved from a patient who
had previously received one month or more of antituberculosis treatment, as
documented in the tuberculosis registry, in medical records or by the patient's account'.
Primary drug resistance is defined as the presence of drug-resistant strains of M
tuberculosis in a patient who denies having had anti-tuberculosis treatment for more
than one month and has no evidence of such a treatment in the tuberculosis registry or
medical records I.
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2. Molecular epidemiology definitions
A cluster of drug resistant isolates was defined as a group of two or more drug-
resistant isolates originating from different patients, with RFLP fingerprint patterns
identical with respect to both the number and molecular size of all bands 12 on all probes
used (186J 10-3', 186110-5', ORr and MTB484 (I». A drug-resistant strain was
classified as unique if the RFLP pattern was unique (i.e. did not match with any other
drug resistant isolate) with respect to both the number and molecular size of all bands
among all drug-resistant strains retrieved from the communities. To calculate the extent
of transmission of drug-resistant isolates, the formula n - 1 was used, assuming that a
typical cluster of n persons comprises one index case29. Tbe first patient in a cluster
presenting with drug-resistant TB was assumed to be the index case.
RESULTS
Strain diversity among patients with drug resistant tuberculosis based on RFLP
analysis with 186110-3' probe
During the 5-year period, 70 patients were treated for drug-resistant TB. The 63
(90%) patients of whom at least one M. tuberculosis isolate was available for RFLP
analysis constitute the study population. According to the drug-susceptibility results, the
majority of patients (71%) had MOR-TB, 12 (19%) had single-drug-resistant TB (11
resistant to isoniazid, I resistant to rifampin) and the remaining 6 (10%) patients had
multiple-drug-resistant TB (table I).
According to the internationally recommended RFLP analysis (digestion with the
Pvull restriction enzyme and 186110-3' hybridisation 30), 26 different drug-resistant
strains were retrieved from the 63 patients. The number of 186110 copies per isolate of
M. tuberculosis varied from 2 to 23. Twenty-one strains represented unique strains as
they were retrieved from only one patient with drug-resistant TB (table 1). The
remaining 7 strains represented clustered strains as each of these strains was retrieved
from at least 2 different patients. The size of the outbreaks, caused by each cluster
varied from 2 to 16 patients.
28
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Table 1: Classification of 63 drug-resistant patients by clinical method and
Restriction Fragment Length Polymorphism (RFLP) analysis
All patients MDR-TB Single-drug- Multiple drug-
resistant TB resistant TB
No. (%) No. (%) No. (%)
63 (l00) 45 (71) 12 (19) 6 (10)
No. of patients
RFLP classification
IS6IlO-3'probe
Unique 21(33) 10(22) 9 (75) 2 (33)
Cluster 42 (67) 35 (77) 3 (25) 4 (67)
Transmission * 35 (55) 30 (67) 1 (8) 4 (67)
A1l4 probes
Unique 24 (38) Il (24) Il (92) 2 (33)
Cluster 39 (62) 34 (76) 1 (8) 4 (67)
Transmission * 33 (52) 29 (64) 0(0) 4 (67)
Overall, 42 (67%) patients with drug-resistant TB were infected with an isolate
belonging to one of the 7 clusters of drug-resistant isolates (table 1). Four clusters
included only MDR- TB patients; one cluster included only single-drug-resistant TB
patients. The 2 other clusters consisted of a mix between either MDR- TB and multiple
drug-resistant TB, or single-drug-resistant TB and multiple drug-resistant TB. The
diversity of RFLP patterns of M tuberculosis strains among patients with MDR- TB is
presented in figure 1. This figure shows that the majority of the MDR-TB patients
(35/45 or 77%) were infected with a M tuberculosis strain belonging to a cluster. The
same is true for patients with multiple drug-resistant TB (67%) (table 1). In contrast,
75% of patients with single-drug-resistant TB were infected with a unique M
tuberculosis strain (table 1). According the n-l formula'", 55% of all drug-resistant TB
patients, 67% of MOR-TB and multiple-drug-resistant TB patients but only 8% of the
single-drug-resistant TB patients were classified as infected with a drug-resistant strain
due to transmission of the strain from an infectious drug-resistant TB case (table 1).
29
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Figure 1 Diversity of Restriction Fragment Length Polymorphism patterns of Mycobacterium
tuberculosis strains among patients with multidrug-resistant tuberculosis. Lanes R are control
strains (MTS 14323)30; lanes Cl to CS represent clustered M. tuberculosis strains (CI=cluster I
etc.); lanes U I to U8 represent unique M. tuberculosis strains. Two of the 10 unique strains are
not represented.
30
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These results demonstrate a relatively low rate of IS6110 strain diversity among
drug-resistant isolates (28 different strain among 63 patients) retrieved from a
community where TB is endemic. The lowest degree of strain diversity was observed
among patients with MDR- TB (15 strains/45 patients) while strains infecting patients
with single-drug-resistant TB showed a high degree of genomic polymorphism (11
strainsl12 patients).
Use of multiple genetic markers in the differentiation of drug-resistant M.
tuberculosis strains.
To improve the accuracy of strain typing, clusters of identical (with IS6110-3'
probe) strains were subjected to further analysis with additional probes: (lS6110-5',
DRr, MTB484(1». One of the 11 strains with 5 IS6110-3' elements and both strains
with 3 IS6110-3' elements, initially classified as clustered were now found to be unique
(figure 2). This reduced the rate of transmission among drug-resistant TB patients, from
55 to 52% (table 1). For MOR-TB, the rate of transmission was reduced from 67 to
64%. When multiple RFLP probes were used, there was not a single case of
transmission among single-drug-resistant TB cases.
Correlation between conventional and molecular epidemiological data.
A medical anthropologist could conduct interviews with 38 of the 42 patients
infected with a drug resistant isolate that belonged to a (lS6110) cluster. Three of
patients (7%) could not be interviewed as they had died. One patient could not be
interviewed, as he was lost to follow-up after moving away from the study area.
Epidemiologic connections among patients infected with an identical strain were
identified for 26 of the 38 patients (68%), ranging from 50 to 75 of epidemiological
connections among patients within each cluster. The most frequent places of contact
were either house of residence or social drinking places.
The use of RFLP analysis with multiple probes marginally improved the correlation
between conventional and molecular epidemiologic data: the percentage of social links
that could be identified among patients infected with clustered isolates increased from
68% (26/38 patients) to 74% (26/35patients).
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Figure 2. Restriction Fragment Length Polymorphism analysis with four probes (IS61 10-3',
IS61 10-5', ORr and MTB484(1» of two clusters with low IS-6110-3' copy numbers.
A. Cluster of Il isolates (3 represented) with 5 IS6110-3' elements. Arrows indicate where one
isolate has a different RFLP pattern with the IS611 0-5' and DR probe.
B. Cluster of 2 isolates with 3 IS6110-3' elements. Arrow indicates where the isolates have a
different RFLP pattern with the MTB484( I) probe
-
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Diagnosis of unsuspected cases of drug-resistant TB by the application of DNA
fmgerprinting
Cluster analysis was applied to the complete RFLP
database (consisting of more then 2000 isolates of
approximately 900 patients with drug sensitive or drug
resistant TB included in the prospective epidemiology study
of TB) in order to identify strains classified as 'drug-
sensitive' or 'drug resistance not tested', with RFLP patterns
identical to those of drug-resistant strains. One or more
matching isolate could be identified for 16 of the 24 unique
and 2 of the 6 clusters of drug-resistant isolates. One of
these clusters was studied in detail. Four isolates had an
RFLP pattern that matched the IS6110-3' pattern of the
cluster of drug-resistant isolates with 5 IS6110-3' elements
(fig3). Further RFLP analysis of these 4 isolates showed
that the position of the top band on MTB484(1)
hybridisation differed for two of those 4 strains (lane 4 and
5 of fig 3). Mutation detection analysis identified the same
mutations in katG315, rpoB513 and rpsL43 in the drug
resistant isolate (lane 1, fig 3) and in the two genetically
identical strains (lane 2 and 3, fig 3) but no mutations in the
genetically different isolates (lane 4 and 5, fig 3).
Phenotypic drug resistance was never detected in these
isolates, as the infecting isolates were never tested for drug
resistance. Epidemiological investigation by contact tracing
demonstrated that one of the patients had been in close
contact with a patient belonging to the outbreak as
originally defined. This patient had been 'cured' (lost to
follow-up one year after diagnosis of TB) with standard
treatment. The other patient could not be interviewed as she
had died after interruption of treatment.
Fig.3 Restriction fragment
length polymorphism
pattern by MTB484(1)
probe of strains with 5
IS6110-3' copies. First lane
is a drug resistant strain;
lanes 2 to 5 are 'drug
sensitive' or 'resistance not
tested strains'. Arrow
indicates the difference in
RFLP pattern of isolates in
lane 4 and 5
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DISCUSSION
We used RFLP analysis and traditional epidemiologic methods to investigate the
disease dynamics of drug-resistant TB in an area characterised by a high TB incidence.
Our results show, by contrast to the high degree of strain diversity found by population-
based studies in low incidence areas", a relatively low degree of genomic
polymorphism among drug-resistant M. tuberculosis strains. The lowest degree of strain
diversity was found among MOR-TB patients. This can probably be explained by the
prolonged infectiousness of MOR-TB patients facilitating transmission of MOR-TB
strains.
The retrieval of drug-resistant isolates from patients not diagnosed as cases of drug-
resistant TB indicates a shortcoming of the current NTP strategy. Guidelines state that
drug resistance should only be tested for in patients with a history of previous TB
treatment and in patients with current treatment failure. Diagnosis of patients with
primary drug-resistant TB (no history ofTB treatment) will be delayed substantially. A
first and essential step to improve the yield of case finding of drug-resistant TB could be
a more thorough contact tracing procedure for cases with drug-resistant TB.
Several studies have combined molecular and conventional epidemiologic data and
found that there is never a 100 % correlation, especially outside small outbreak
situations 29,31.32.The explanation for this is threefold. First, a detailed interview and
record review might not be sensitive enough to identify all potential epidemiologic
connections"·31.33. Second, patients infected with identical strains are not always
epidemiological connected. The predictive value of RFLP clustering will be higher in
crowded, urban populations where TB is still endemic then in scarcely populated rural
areas with a low TB incidence'". In areas with a high TB incidence, there may be
multiple index cases with identical strains at the same time. In areas with a low TB
incidence, identical RFLP pattern may not point to recent transmission but to contact in
the past. Third, not all strains with an identical IS6110 pattern are necessarily part of
one cluster, especially when a strain contains only a few IS6110 copies. In one study,
the proportion of patients infected with identical strains and identified epidemiological
connections increased with the number of IS6110 copies from 14% for clusters with less
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than 5 IS6110 copies to 60% for clusters with more than 12 copies'", In that study, the
overall percentage of patients in clusters with an epidemiologic connection increased
from 34 to 42% when RFLP by multiple probes was analysed. In our study, the
proportion of patients infected with identical strains and identified epidemiological
connections increased from 68 to 74% by the use of multiple-probe RFLP analysis. It is
now generally accepted that the RFLP method based on a single probe (lS6110) is not
accurate enough to distinguish all strains, in particular strains with a low number of
IS6110 copies30,34-36. Accurate interpretation of strain identification by RFLP analysis
therefore requires knowledge on the demographic characteristics of the population, a
combination of clinical and molecular data and the use of multiple probes. Only then
will molecular epidemiology improve our understanding of disease dynamics and aid to
the formulation of more efficient disease control strategies.
In this study, RFLP analysis could refine the knowledge on drug-resistant TB in an
area with a high TB incidence. First, RFLP analysis showed that the current control
strategy is insufficient in case finding of drug-resistant TB cases because cases of
primary drug resistance are missed. Second, chains of transmission could be identified
among patients without known social links, indicating the possibility of transmission of
drug-resistant strains by casual or unidentified contact. Third, the limited strain diversity
among drug-resistant strains, especially among MDR strains, implies substantial
transmission of drug-resistant strains in an endemic area. The focus of the TB control
strategy in an area endemic for TB should therefore not only focus on the extremely
important prevention of acquisition of drug resistance but also limit transmission of
drug-resistant strains by improved case finding and accurate treatment of cases of drug-
resistant TB.
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Detection of mutations in drug resistance genes of Mycobacterium
tuberculosis by a dot-blot hybridization strategy
Setting: Mycobacterium tuberculosis isolates from patients in
communities endemic for tuberculosis in South Africa. Objective: To
develop a reliable peR-based dot-blot hybridization strategy to detect
mutations conferring drug resistance. Design: Different loci in six genes
associated with drug resistance to isoniazid, rifampin, streptomycin and
ethambutol were selected to develop the PCR-based dot-blot
hybridization strategy. Results: Primers and probes to detect mutations
at codons 315, 463 (katG) 269 (kasA) 531, 526 (rpoB) 43 (rpsL) 513 (rrs)
and 306 (embB) were designed and used to develop a peR-based dot-
blot hybridization strategy. The dot-blot hybridization strategy with
wild-type probes can efficiently be used to detect drug resistant
mutations since these do not hybridize to mutant loci. Stripped blots
and mutant probes can be used to identify the precise mutation. The
embB gene (ethambutol resistance) was used to show how the dot-blot
strategy can assist with the prediction of drug resistance more
accurately. The method is rapid, reproducible, not technically
demanding and samples can be done in batches. Additional loei can
easily be incorporated. Conclusions: A PCR-based dot-blot
hybridization strategy is described which can accurately identify drug
resistant strains and the method is useful to patients at risk and in areas
endemic for tuberculosis.
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INTRODUCTION
Tuberculosis remains one of the world's most senous afflictions, leading to 3
million deaths per annum. This epidemic is further complicated by the emergence of
drug resistant strains of M. tuberculosis, which pose a threat to tuberculosis control
programmes and often result in high-level mortality 1,2. Traditional susceptibility testing
depends on a positive culture for diagnosis and subcultures for susceptibility testing.
Usually a minimum of 3 - 6 weeks is required for a positive culture diagnosis and at
least a further 3 weeks for susceptibility testing on solid media using conventional
techniques, or 15 days when radiometric methods with the BACTEC system are used 3-
6. Susceptibility testing is not only time-consuming, but there are significant technical
problems in the standardization of these tests, such as difficulties to establish an
appropriate inoculum size, the stability of the compounds in different culture media and
the reliability of results when testing the drugs 7,8. Rapid diagnosis of drug resistance
may help to stop chains of transmission of multi drug resistant tuberculosis, which is a
threat in many societies.
The molecular basis of drug resistence to all the front-line drugs is due to mutations
in specific genes of M tuberculosis. To date, approximately 12 genes are known to be
linked to resistance 9. Molecular results indicated that the genome of M tuberculosis,
including mutations in the drug resistant genes, is stable in follow-up samples from
multi drug resistant (MDR) patients 7. This favours the use of molecular techniques to
predict drug resistance by mutational analysis. Many PCR-based strategies have been
used to detect mutations in genes of interest, which include DNA sequencing 7,9,
dideoxy-Fingerprinting lO, heteroduplex analysis Il , RFLP 7,12, SSCP 7,13 and the use of
probes 14,15. Each system has inherent problems: for example, not all mutations result in
the gain or loss of a restriction enzyme site, therefore limiting the use of RFLP as a
general method to screen for (drug resistant) mutations. Other screening procedures
which depend on DNA mobility shifts (eg. PCR-SSCP) are often used, but are
technically demanding and mutations are not always detected by these procedures. PCR
amplification followed by DNA sequencing is possibly the most widely used technique
for the identification of mutations, but is not readily available in routine laboratories.
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Furthermore, in countries most severely affected by tuberculosis there IS often a
shortage of expertise and funding for sequencing.
It is for these reasons that additional techniques for the efficient detection of drug
resistant mutations are needed. Ideally, a simple technique which can detect any known
or newly described mutation and which fullfills the criteria of accuracy, speed an
simplicity is required. In the present study, a dot-blot strategy is described which can be
used to analyse any of the drug resistant mutations. The results show that hybridization
with wild-type probes can be used to efficiently screen for all mutations, conferring
drug resistance.
MATERIALS AND METHODS
Clinical isolates
The clinical isolates included in this study originate from patients with culture-
tested susceptible and drug resistant tuberculosis. Patients were from two communities
of Cape Town, South Africa, with a tuberculosis notification rate of over 1000/100 000
p.a.16. Antibiotic susceptibility testing was done as described previously 7. The reference
strain HJ7R v, together with susceptible isolates and molecularly well-characterized
clinical isolates of M. tuberculosis 7 were used as controls.
peR amplification
Primers to amplify regions of the katG, kasA, rpoB, rpsL, rrs and embB genes were
designed (Table 1). Five microlitres (300ng) of genomic DNA were used as template for
amplification in a 100 JlI reaction mixture consisting of Magnesium Chloride, 2.25 mM;
dNTP's (dATP, dGTP, dCTP and TIP) [Boehringer Mannheim], 200 JlM each; 5'
primer and 3' primer, 0.2JlM each and 1.5 U of Taq Polymerase (Promega). Reaction
mixtures were then heated in a thermal cycler (Techne Gene E) as follows: 93°C for 3
min followed by 35 cycles at 93°C for) min, annealing at Tm for 1 min and an
extension step at noc for 2 min. Final extension was done at 72°C for lOmin. The
annealing temperature tor each primer set was calculated as follows: Tm = 4(G+C) +
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2(A+T) and the optimal annealing temperature is given In Table 1. Efficient
amplification was confirmed by gel electrophoresis on !2% polyacrylamide mini-gels
(Biorad, Protean II). Care was taken to prevent false results due to amplicon
contamination 18.
Table 1: Primers for PCR amplification
Primer Sequence Tm Fragment Reference
katG gene
RTB59 GCTGGTGATCGCGTCCTTAC
RTB36 TCGGGGTCGTTGACCTCCCA 66°C 804 bp Ref.17
kasA gene
kasA 51 ATTGAGTCGGAGAACCCCGA
kasA 31 CCTTCCATATCGGTCCGACT 56°C 1389bp Current
rpoB gene
TR8 TGCACGTCGCGGACCTCCA
TR9 TCGCCGCGATCAAGGAGT 58°C 157bp Ref.7
rpsL gene
STR52 GTCAAGACCGCGGCTCTGAA
STR34 TTCTTGACACCCTGCGTATC 60°C 272 BP Ref.7
rrs gene
STR 53 TCACCATCGACGAAGCTCCG
STR31 CTAGACGCGTCCTGTGCATG 64°C 570 bp Ref.7
embB gene
emb 151 CGGCATGCGCCGGCTGATTC
emb 131 TCCACAGACTGGCGTCGCTG 65°C 260bp Current
Dot-blot Hybridization
Wild-type and mutant-specific oligonucleotides to screen for the presence or
absence of specific mutations in six of the genes associated with resistance to
antituberculosis drugs, were designed according to published sequences (X6808!, katG;
RV2245, kasA; L059!0, rpoB; L080!!, rpsL; X529!7, rrs and U68480, embB).
Oligonucleotide sequences are given in Table 2. Oligonucleotides were 5' end-labelled
by phosphorylation with [y_32P]_ATP(Amersham) as described previously (l9) or 3'
end-labelled with digoxigenin by terminal transferase (Boehringer) according to the
specifications of the manufacturer.
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Table 2: Probes for dot-blot hybridization
Probe Sequence
katG3JS wt
katG31S mu
katG31S dmu
katG463 mu
katG463 wt
kasA 269wt
rpoBS31 wt
rpoBS31 mu
rpoBS26 wt
rpsL43 wt
rrsS12/3 wt
cmbB306 wt
GATCACCAGCGGCATCGAGG
GATCACCACCGGCATCGAGG
GCGATCACCACAGGCATCGA
AGCCAGATCCTGGCATCGGG
AGCCAGATCCGGGCATCGGG
GGTGCCGGTATCACCTCGGA
AGCGCCGACTGTCGGCGCTG
AGCGCCGACTGTTGGCGCTG
GGGTTGACCCACAAGCGC
ACCACTCCGAAGAAGCCGAA
ACGTGCCAGCAGCCGCG
CCTGGGCATGGCCCGAGTCG
An aliquot of each PCR product was adjusted to 0.4 N NaOH, 25mM EDTA in 100
ill, heat-denatured at 95°C for 10 min and applied under vacuum to a Hybond-N" nylon
filter (Amersham) in a dot-blot apparatus (Biorad). The DNA was fixed onto the
membrane by baking at 80°C for 1 hour. For radioisotopic detection, each filter was
hybridised in 5xSSPE and finally washed in 1.5xSSPE for 10 min at 74°C as described
previously (19). Autoradiography was done at room temperature for 2-3 hours. Non-
radioactive hybridization was done in 5xSSPE solution and the final wash and detection
was done with anti-DIG alkaline phosphatase according to the specifications of the
manufacturer (Boehringer). Although it is important to confirm DNA amplification by
gel electrophoresis, the results indicate that small differences in efficiency of
amplifcation do not have a significant effect on the outcome of the hybridization results.
To reprobe, the membranes were stripped by incubation at 46°C for 30 min in 25 ml 0.4
M NaOH with constant shaking. The NaOH was neutralized by a further 15 min of
incubation at 42°C in 25 ml of neutralizing solution containing 0.2M Tris-HCL (pH
7.5), 0.1% SDS, 0.1 x SSC (20xSSC = 175.3g NaCL, 88.2g C6HsNa)07.2H20 dissolved
in H20 to a final volume of 1 litre, pH 7.0). Although radioactive and non-radioactive
detection procedures gave similar results, the radioactive procedure was favoured to
empirically evaluate stringent hybridization washes during the developmental phase of
this strategy. The following experimental flow is recommended: PCR amplification,
confirmation of amplification by gel electrophoresis; label of probe for region of
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interest; dot-blot hybridization; overexposure of first time autoradiography to ensure
that samples were sufficiently blotted; final autoradiography.
Sequence analysis
Direct sequencing of amplified peR products was done with an ABI PRISM
(model 377, Perkin Elmer).
RESULTS
A dot-blot hybridization strategy was developed to test the hypothesis that mutant
and wild-type allele specific probes can detect drug resistant conferring mutations in M
tuberculosis. Results for codon 315 in the katG gene and codon 531 in the rpoB gene
are given in Figures 1 and 2 respectively. Firstly, a 804 bp region of the katG gene
containing the codon 315 mutation associated with isoniazid (INH) resistance, was peR
amplified from MDR and drug susceptible clinical isolates. Autoradiography after
hybridization correctly identified the control samples on the blot and demonstrated
katG315 mutant alleles for 16 of the clinical isolates. To test the accuracy of the
technique, one of the INH resistant clinical isolates (sample A3) was subjected to
sequence analysis which then confirmed the presence of a G-e mutation at codon 315.
Secondly, the example in Figure 2 for codon 513 of the rpoB gene (RMP resistance)
does not only confirm the accuracy of the technique, but also show how efficiently
allele specific wild type probes can detect drug resistant conferring mutations. Good
discrimination was obtained for control samples and confirms that the wild-type probe
hybridizes specifically to the amplified region of susceptible isolates, while no
hybridization was detected after hybridization to amplified regions containing
mutations. Gel electrophoresis and the combined strategy with wild-type and mutant
probes also showed that the absence of a signal was not due to poor amplification. The
codon 531 mutation (e-T) in clinical isolate B6 was confirmed by sequence analysis.
Both wild-type and mutant probes clearly indicated which of the other clinical samples
loaded onto the filter have a mutation at codon 531.
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Figure 1. A 804 bp region of the kalG gene was amplified with primers RTB59 and RTB36 from drug
resistant and drug susceptible isolates. The dot-blot hybridization strategy with radiolabelled probe
katG3l5 mu was subsequently used to screen for mutations at codon 315. The M. tuberculosis reference
strain H37Rv was included as a negative control (09) and amplified genomic DNA from two previously
well-defined isolates (ref 7) were included as additional controls. Good discrimination was obtained for
samples 07 (known G-C mutant for kalG3 IS) and 08 (known wild-type sequence at codon 315).
2 3 4 5 6 7 8 9A
A ••• • • • •
B • • ••
B 2 3 4 5 6 7 8 9
A • •
B • • • • •
figure 2. Dot-blot hybridization of codon 531 in the rpoB gene. DNA (n = 18) from drug resistant and
susceptible isolates of Msuberculosis were amplified with primers TR 8 and TR 9 and hybridized in a
dot-blot fomlat with radiolabelled probes rpoB53 I wt (filter A) and rpoB53 I mu (filter B; same filter as
A, but were stripped and reprobed with rpoB53 I nm). Good discrimination was obtained for samples B7
and B8 which are a known mutant (C-T) and wild-type for codon 531 respectively, as characterized
previously (Ref 7). Amplified DNA from the control H37Tv was loaded in B9.
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Isolate Drug pattern
Table 3: Genotype and phenotype resistance data
Mutations
Similar results were obtained for codons 463 (katG gene), 269, (kasA gene), 526,
(rpoB gene), 43, (rpsL gene), 306 (embB gene) and position 513 (rrs gene). Comparison
of genotype and phenotype results in Table 3 are examples of results obtained from
clinical isolates with the described dot-blot hybridization strategy.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
INH, RMP, SM,
INH,RMPSM
INH
INH, RMP, SM,
INH
RMP
INH,RMP
INH, RMP, SM,
INH,RMP, SM
INH
INH,RMP, SM
S
S
S
katG315, katG463, rpoB531, rrs513,
katG315, rpoB531, rpsIA3
katG315
katG315, katG463, rpoB531, rrs513,
kasA269
rpoB531
katG315, lpoB531
katG315, katG463, rpoB531, rrs513,
katG315, rpoB531, lpsIA3
katG315
katG315, rpoB526, rpsIA3
INH = isoniazid, RMP = rifampin, SM = streptomycin, EMB = ethambutol,S = susceptible
However, drug resistance testing in M tuberculosis is difficult and can sometimes
give inconsistent results 7. Table 4 shows how mutational analysis, using the wild-type
probe strategy, can assist with the correct diagnosis of EMB resistance in follow-up
MDR clinical isolates. A wild-type probe for codon 306 (embB306 wt) was designed
and used to analyze follow-up samples from a patient diagnosed with EMB resistant
tuberculosis. None of the samples hybridised to the wild-type probe and therefore
predicts codon 306 mutations 20 for samples VI21-VI23. A mutation (ATG~ATA)
was subsequently confirmed for all the samples by sequence analysis (Table 4).
However, only one of these were phenotypically classified as EMB resistant. This
strongly suggests that samples Vl22 and Vl23 were misdiagnosed by the routine
(culture) diagnostic laboratory. Subsequent re-testing by culture-confirmed initial
misdiagnosis.
Sample Drug pattern
Table 4: Mutational analysis of ethambutol resistance
Sequence
V121
Vl22
Vl23
INH, RMP, SM, EMB
INH, RMP, SM, KM, TH
INH, RMP, SM, KM, TH
Probe*
+
+
+
ATG~ATA
ATG~ATA
ATG~ATA
INH, Isoniazid; RMP, Rifampin; SM, Streptomycin; EMB, Ethambutol;
Probe*: positive in this column indicates presence of a mutation at codon 306 of the embB gene.
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DISCUSSION
Mutations 10 clinical isolates of M. tuberculosis have been the focus of many
investigations in order to determine their association with drug resistance and more
recently as markers to study the evolution of drug resistance in this organism 21.
However, the complexity of molecular techniques used to study these mutations make
them unsuitable as routine diagnostic tools throughout the world. This study has shown
how a dot-blot hybridization strategy with wild-type probes can be used efficiently to
detect mutations (in multiple isolates) at different loci in six genes associated with INH,
RMP, SM, and EMB resistance. Although the current study focussed on selected
regions in some of the most important target genes, the flexibility of the dot-blot
strategy ensures that additional loci can easily be incorporated into the screening
strategy as described (e.g. recently described kasA gene, 22).
The dot-blot procedure described may be specifically useful in countries with a
high incidence of tuberculosis and where procedures such as automated DNA
sequencing are not readily available. As the predictive value of any test is dependent on
prevalence, a mutational screening strategy should initially focus on the mutations most
frequently diagnosed in the geographic area studied. Codons 315, 463 (katG), 531, 526,
516 (rpoS), 43 (rpsL), 491,513 (rrs) and 306 (embS) are frequently altered in clinical
isolates from other studies and these were the initial focus for isolates originating from
the Cape Town communities. Results in Table 3 are examples of drug resistant strains
from the local communities where the described dot-blot strategy was used. This forms
part of an ongoing study where mutational and DNA fingerprint analysis forms the basis
of a molecular approach to understand the dynamics of drug resistant tuberculosis in a
high incidence community. Molecular studies are needed to determine the most
important mutations associated with drug resistance in different geographical regions,
since it is known that drug resistant mutations may vary with the geographical origin of
the samples 23. The wild-type probe strategy is unable to provide a precise
understanding of the different mutations occurring at a specific codon, however, it is
known that >99% of mutations within these loci confer resistance and therefore the
absence of a hybridization signal has been interpreted to directly reflect drug resistance.
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These results are confirmed by phenotyping. The application of specific mutant probes
can be applied to identify or confirm the nature of this mutational event, although it may
be argued that it would not be possible to identify cases where both the resistant and
sensitive bacilli are present in the host. This may also be true for all other molecular
based methods. The dot-blot hybridization strategy with mutant probes can detect drug
resistant alleles when they represent 1-2% of the overall population (results not shown).
However, a review of the literature indicates that mixed infections in active tuberculosis
cases are rare. Telenti et al., reported a mixed population of susceptible and resistant
strains in lout of 42 RMP resistant isolates 24. Furthermore, while spontaneous resistant
isolates clearly arise, the rate is low «10-5) and is usually confined to mono-resistance,
which is effectively dealt with under compliant conditions with the multiple drug
regimen. Thus, under normal conditions, a resistance level of 1-2% may not be seen. In
cases of transmission of drug resistant isolates, the resistant alleles will be 100%. In
those cases when resistance is acquired, one may assume that a 100% sensitive
population will become superceded by a resistant mutant and that at a certain stage of
disease, the resistant population will be <2% of the total. However, these cases are
relatively rare and furthermore, detection will be problematical at certain stages only. In
practice, there will usually be other indicators of problems to come, for example, non-
compliance. When possible, these individuals will be managed appropriately.
The screening strategy is adaptable and lends itself to the easy inclusion of any
other previously untested or newly discovered loci. This methodology demonstrates
how the wild-type probe hybridization strategy can effectively be used to detect the
presence of mutations in genes conferring drug resistance in clinical isolates of M
tuberculosis. The method is reproducible, not technically demanding and it takes about
two normal working days to obtain results from the start of amplification (done in
batches of 30-40 samples) to the final autoradiography step of the dot-blot hybridization
(done in batches of up to 150 samples, including controls). This technique could be
adapted to amplify and detect drug resistant mutations directly from sputum samples or
microscopy stained slides. The high daily output possible with this strategy would
enable the focus of drug resistance control strategies to include all smear-positive
samples.
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Drug susceptibility testing is usually performed in order to provide information for
the treatment of individual patients. In addition, resistance surveillance gives a good
measure of the efficacy of regional Control programmes. Apart from time, the other
limiting factor associated with susceptibility testing is the technical complexity 7.8,
leading to problems such as intermittent resistance patterns, which have been reported
previously 7 and in this study. An alternative means of testing would be particularly
useful for EMB and pyrazinamide (PZA), since susceptibility testing to these drugs
remains suboptimally standardized because of the poor stability of the agent in growth
medium and discrepancies encountered when performing the analysis in solid versus
liquid medium 25. Misdiagnosis of drug resistance by traditional culture methods can be
a problem at times as indicated for EMB resistance in this study. The same may be true
for other drugs, specifically in high incidence areas with a high throughput of samples.
Mutational analysis such as described in this study may help to investigate the extend of
the problem. Furthermore, molecular epidemiological studies based on the dot-blot
method could determine the frequency of specific mutations in a geographical area and
monitor the spread of a cluster of drug resistant strains within a community or
institution.
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Background: Traditionally, patients with drug-resistant
Classification of drug-resistant tuberculosis in an epidemic area
tuberculosis are classified as having acquired drug-resistant or primary
drug-resistant disease on the basis of a history of previous tuberculosis
treatment. Only cases of primary drug resistance are assumed to be due
to transmission of drug-resistant strains. Methods: This descriptive
study of 63 patients with drug-resistant tuberculosis assessed the
relative contribution of transmission of drug-resistant strains in a high
incidence community of Cape Town, South Africa, by restriction
fragment length polymorphism (RFLP). The RFLP results were
compared with the results obtained by traditional classification
methods. Findings: According to RFLP definitions, 52% (33 cases) of
drug-resistant tuberculosis was caused by transmission of a drug-
resistant strain. The proportion of cases due to transmission was
higher for multidrug-resistant (64%; 29 cases) than for single-drug-
resistant (no cases) tuberculosis. By the clinical classification, only 18
(29%) patients were classified as having primary drug-resistant
tuberculosis (implying transmission). The clinical classification was
thus misleading in 25 patients. Interpretation: The term acquired drug-
resistance includes patients infected with strains that truly acquired
drug resistance during treatment and patients who were initially
infected with or reinfeered with a drug-resistant strain. This definition
could lead to misinterpretation of surveillance studies, incorrect
evaluation of tuberculosis programmes and delayed diagnosis and
treatment of patients with multidrug-resistant disease. The clinical term
acquired drug resistance should therefore be replaced with the term
"drug resistance in previously treated cases", which includes cases with
drug resistance due to true acquisition as well as that due to
transmitted drug-resistant strains.
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INTRODUCTION
A 1994-97 survey by the WHO and International Union Against Tuberculosis and
Lung Disease (IUATLD) found that multidrug-resistant tuberculosis has become
established worldwide.' In 1995, the WHO estimated that 50 million people were
infected with drug-resistant strains of Mycobacterium tuberculosis.2 In Sub-Saharan
Africa, 200 000 cases of multi drug-resistant tuberculosis can be expected by the year
2000.3
Drug-resistant tuberculosis is a man-made problem." Poor management, including
the prescription of incorrect regimens and non-compliance with treatment, can lead to
the selection of M tuberculosis with mutations conferring resistance to antituberculosis
drugs. Resistant strains can then be transmitted from an infectious patient to another
person. We need to know the relative contribution of acquisition and transmission in
different settings so that tuberculosis control strategies can be evaluated and new
strategies for the control of multidrug-resistant tuberculosis can be developed.
Traditionally, patients with drug-resistant tuberculosis are classified as having
acquired or primary drug resistance on the basis of a history of previous treatment.
WHO criteria define acquired drug resistance as the isolation of a drug resistant M.
tuberculosis from a patient who has been treated for tuberculosis for 1 month or longer.Ï
and primary drug resistance as the isolation of a drug-resistant strain from a patient
without a history of previous treatment. In surveys, primary resistance has been
consistently less common than the acquired resistance." In the recent WHO/IUATLD
survey in 35 countries,' the median prevalence of primary resistance to any
antituberculosis drug was 9'9% (range 2 - 41%) and that of acquired resistance was 36%
(range 5 - 100%).
Analysis of restriction fragment length polymorphism (RFLP) is useful in the study
of the epidemiology of tuberculosis, because different strains of M. tuberculosis can be
reliably distinguished. Patients infected with M. tuberculosis strains that have the same
RFLP pattern are classified as part of a chain of recent transmission, whereas strains
with a unique RFLP pattern are assumed to represent reactivation of a latent infection.i'"
RFLP analysis has been extensively used to document the disease dynamics of
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multidrug-resistant tuberculosis in institutions such as hospitals and prisons."! I Most of
the cases involved in nosocomial outbreaks were the result of transmitted infection.'?
RFLP analysis has been seldom used to investig~te multidrug-resistant tuberculosis in
community settings. A study in Scotland found that M. tuberculosis strains isolated
from patients with multidrug-resistant tuberculosis were genetically diverse and
unrelated to each other, suggesting acquisition of drug resistance as the predominant
mechanism.V No data are available on the characteristics of multidrug-resistant
tuberculosis in less developed countries, where the burden of tuberculosis and drug-
resistant disease is the largest.
The aim of this study was to find out by RFLP analysis the contribution of
transmission of drug-resistant strains within a community with a high incidence of
tuberculosis. The results were compared with those obtained by traditional classification
method based on tuberculosis treatment history.
METHODS
Participants
The patients were identified between April I, 1992; and March 31,1997. All lived
and were treated in two neighbouring communities of Cape Town, South Afiica. This
area (2·5 km2) has a population of roughly 34000 people living in poor socio-economic
conditions. The annual incidence of new (never previously treated) patients with
bacteriologically positive tuberculosis in the area is 225/ 100 000, 13 and the annual
notification rate of bacteriologically positive patients (new and retreatment cases) is
363/100 000. A survey of drug-resistant tuberculosis in the Western Cape province
conducted in 1992-93 found a rate of 8·6% acquired and 3·2% initial drug resistance.l"
The reported prevalence of HIV infection in the region ranged from 0·25% in 1992 to
3.0% in 1996 (data from the National HIV surveys on women attending antenatal
clinics, conducted by the Department of Health and Population Development, South
Africa).
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Procedures and definitions
Information on age, sex, medical history, HIV status, previous :tuberculosis
treatment, sputum microscopy and cultures and susceptibility testing was obtained by
review of medical files and compliance charts.
In patients who had not previously received antituberculous drugs, the bacterial
resistance was classified as primary. In patients with a record of previous treatment for
1 month or longer, the bacterial resistance was as classified acquired. Multidrug-
resistant tuberculosis was defined as resistance to at least isoniazid and rifampin.
Multiple-drug resistance was defined as resistance to more than one first-line
antituberculous drug but not the combination of isoniazid and rifampin. Single-drug
resistant tuberculosis was defined as resistance to only one antituberculous agent.
Sputum samples were sent to the routine laboratory for microscopy and culture.
Drug-susceptibility testing was done by the indirect proportion method on Lëwenstein-
Jensen medium containing critical concentrations of 02 mg/L isoniazid, 30 mg/L
rifampin, 2 mg/L ethambutol, 5 mg/L streptomycin and 20 mg/L ethionamide.
Kanamycin and thiacetazone resistance was tested on Middlebrook 7H 10 agar
containing critical concentrations of 5 and 2 mg/L, respectively. Resistance was defined
as 1% or more bacterial growth in comparison with a control according to international
criteria. We did not test for resistance to pyrazinamide. As an internal control, a
susceptible H37Rv strain as well as a Mycobacterium avium strain resistant to all drugs
were included in every batch of drug-resistance testing. Furthermore, external quality
control is done every 6 months.
A prospective study aimed at genotyping (RFLP analysis) all positive M.
tuberculosis cultures from patients in these communities was started in 1992.15,16 This
study has had a recovery rate of about 80% of positive cultures 13 and resulted in an
RFLP database consisting of 1272 isolates from 571 patients. The Dice coefficient and
UPGMA clustering formula were used to analyse the results of the IS6110-3'
(complementary to the IS6110 domain between nucleotides 631 and 875) RFLP data to
identify possible clusters of transmission. To improve accuracy, clusters of identical
drug-resistant isolates were subjected to further genotyping: genomic DNA digested
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with PvuII was sequentially hybridized with Enhanced-chemiluminescence-labelled
IS6//0-5' probe (complementary to the 5' IS61/0 domain between nucJeotides 77 and
462) and phosphorus-32-labelled oRr probe.l ' In addition, the DNA was digested by
HiI!fl and hybridised with 32P-labelled MTB484(1) probe.18 RFLP patterns were
visualised by autoradiography.
The extent of accumulated laboratory error for the complete RFLP database was
calculated for serial isolates collected during the first two months of treatment, as the
number of isolates with results that did not match the result of subsequent isolates
divided by the total number of serial isolates analysed. The extent of accumulated
laboratory error was 3"4 % (17 discordant results/ 499 serial isolates);'?
A cluster was defined as a group of two or more drug-resistant isolates originating
from different patients for which RFLP fingerprint patterns were identical in terms of
both the number and molecular size of all bands! with all four probes. M. tuberculosis
strains with an RFLP banding pattern that did not match the RFLP pattern of any other
drug-resistant isolate (in terms of number and molecular size of all bands) were
cJassi fied as non-clustered or unique. To calculate the extent of transmission of drug-
resistant isolates, we used the formula n - 1 for each cluster, with the assumption that a
typical cluster of n individuals includes one index case," The first patient in a cluster
presenting with drug-resistant tuberculosis was taken to be the index case.
RESULTS
Clinical data
During the 5-year period, 70 patients were treated for drug-resistant tuberculosis. In
63 patients (90%), at least one M. tuberculosis isolate was available for RFLP analysis,
and these patients formed the study population.
All patients had pulmonary tuberculosis. 84% were smear positive. 33 (52%)
patients were female. The mean age at diagnosis of drug-resistant tuberculosis was 33
years (range II to 55 years). 54 (86%) patients were tested for HIVand all were
seronegative. In one patient, an undifferentiated carcinoma of the lung was diagnosed 5
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months after the diagnosis of isoniazid resistance. No patient was found to have diabetes
or end-stage renal disease, and none was given or immunosuppressive therapy. Only
one patient had been admitted to hospital for tuberculosis treatment before the diagnosis
of drug-resistant tuberculosis.
Clinical classification
According to the drug-susceptibility results of the entire treatment episode, most of
the patients (45 [71%]) had multidrug-resistant tuberculosis (table 1). In 12 (19%) cases,
the isolate was resistant to a single drug (11 isoniazid, one rifampin). The remaining six
(10%) had multiple-drug resistance; because this number was small, comparisons are
restricted to the other categories.
By the clinical definitions of drug resistance, 45 patients were classified as having
acquired drug resistance and 18 as having primary drug resistance (tablet) because of a
history of prior treatment with antituberculous medications (table 1). The majority of
both multi drug-resistant and single-drug-resistant cases had acquired resistance.
Table 1. Classification of 63 patients with drug-resistant tuberculosis by clinical
method and by RFLP analysis
All patients Multidrug Single-drug Multiple-drug
(n=63) resistant* resistant resistant
(n=45) (n=12) (n=6)
Clinical classification
Acquired 45 (71%) 32 (71%) 8 (67%) 5 (83%)
Primary 18 (29%) 13 (29%) 4 (33%) 1 (17%)
RFLP classification
Unique 24 (38%) 11 (24%) 11(92%) 2 (33%)
Cluster 39 (62%) 34 (76%) 1 (8%) 4 (67%)
Transmission 0 33 (52%) 29 (64%) 0 4 (67%)
*Resistance against isoniazid and rifampin
°n-l
Molecular classification
In 24 (38%) patients the M. tuberculosis strain had a unique RFLP pattern; 39
(62%) were infected with an isolate belonging to one of six clusters of drug-resistant
isolates (table 1). 34(76%) of the patients with multidrug-resistant tuberculosis were
infected with a strain belonging to a cluster. By contrast, Il of the 12 patients with
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single-drug-resistant disease were infected with a unique strain (Table I).Transmission
of a drug-resistant sp-ain was calculated to have occurred in 52% of the whole group,
64% of the multidrug-resistant group but none of the single-drug-resistant group.
Comparison of clinical and RFLP classification
According to the clinical classification, 45 of the patients had acquired drug-
resistant tuberculosis. On RFLP classi fication, only 17 of these 45 patients had a unique
strain and 28 were infected with a strain belonging to a cluster of drug-resistant isolates.
The majority (25 out of 45 [56%]) of cases therefore had drug-resistant tuberculosis
caused by transmission of an already drug-resistant strain as calculated by the formula
suggested by Small and colleagues," Of the 32 patients with acquired multidrug-
resistant tuberculosis, 21 (66%) were classified as having transmitted drug-resistant
tuberculosis on the basis of the RFLP definitions. Only nine of these 32 patients were
infected with a unique strain. The history of previous antituberculous treatment was thus
associated with the presence of drug resistance in only 28% of multidrug resistant cases.
Table 2. Comparison of the clinical and RFLP classification
All patients Multidrug resistant Single-drug resistant
Acquired Primary Acquired Primary Acquired Primary
(n=45) (n=18) (n=32) (n=13) (n=8) (n=4)
RFLP classification
Unique 17 (38%) 7 (44%) 9 (28%) 2 (15%) 7 (88%) (100%)
Cluster 28 (62%) 11(56%) 23(72%) 11(85%) 1(12%) 0
Transmission 0 25 (56%) 8 (44%) 21(66%) 8 (62%) 0 0
DISCUSSION
In the community studied, we recorded a higher proportion of cases of acquired
resistant tuberculosis than primary resistant tuberculosis cases (29%) by clinical
definitions. We confirmed this finding in multidrug-resistant tuberculosis and in cases
of single-drug-resistance. This finding accords with results of surveillance studies in the
region 15 and worldwide.':"
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By contrast, the use of RFLP analysis in the same population showed that a high
proportion of transmission of drug resistant strains in this area were transmitted from
another person infected with a drug-resistant strain.. The history of previous tuberculosis
treatment was misleading in the majority of patients, because the history implied
acquisition of drug resistance whereas what had really happened was transmission
resulting in infection with or reinfection with a drug-resistant strain. The contribution of
transmission differed substantially between the multi drug (nearly two-thirds of cases)
and single-drug resistant (no cases) categories. The low rate of transmission of singly
resistant strains probably reflects the fact that patients with these strains, in contrast to
those infected with multidrug-resistant strains, are not infectious for long periods of
time because a standard treatment regimen will provide drugs to which the bacterium is
sensitive. Transmission was thus an important mechanism in the creation of multi drug-
resistant tuberculosis in this community, and acquisition was the predominant
mechanism for single-drug-resistant tuberculosis. These findings contrast with the
generally accepted idea that multidrug-resistant tuberculosis occurs only exceptionally
in new cases but mainly in chronic cases, as a consequence of sequential selection of
drug-resistant mutant M tuberculosis organisms." Furthermore, primary drug resistance
is believed to be less severe because it is common in single-drug-resistant cases and rare
in multidrug-resistant cases.4 RFLP analysis indicates the opposite. Of the patients
classified as having transmitted drug resistance, none had single-drug-resistant
tuberculosis, 12 % had multiple drug resistance, and 88 % had multidrug-resistant
tuberculosis. Thus, transmitted drug resistance can be severe, because it is common in
multi drug-resistant tuberculosis.
The importance of transmission of drug-resistant mycobacteria in this study may
have been overestimated for two reasons. First, clustering can be the consequence of
laboratory contamination. We believe that this explanation is unlikely because the
accumulated laboratory error rate for the complete RFLP database is 3A %, and more
than one RFLP result was available in 28 of the 39 patients with cluster infections.
Second, in theory, M. tuberculosis could be transmitted as a drug-susceptible organism,
and patients could acquire drug resistance independently. However, in this case, drug-
sensitive isolates with similar RFLP patterns to drug-resistant isolates should be found.
We found matching drug-sensitive isolates for only 9% of isolates classified as
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transmitted drug-resistant strains by RFLP. Furthermore, in all the clusters (except one
cluster of four isolates), the resistance pattern of the isolates within a cluster was
similar.
We believe, instead, that the importance of transmission in this study may have
been underestimated. First, because the study was confined to a specific period, patients
could have been infected by an infectious case before the start of the study. Second,
index cases could have been missed because retrieval of drug-resistant strains in the
community was 90 % (63/70 patients). Third, patients spent time in other communities
where they could have been infected and transmitted infection to others.
The classification of patients as primary or acquired is used as an indicator of the
efficiency of national tuberculosis programmes and in the adjustment and development
of these programmes. The rate of primary drug resistance is interpreted as an
epidemiological indicator for long-term surveillance of the quality of tuberculosis
treatment in the community. The rate of acquired drug resistance reflects the efficacy of
management of individual patients.l" The evaluation of the South African national
tuberculosis programme on the basis of the rates of multidrug-resistant tuberculosis in
the community would give different results depending on the classification method
used. By the traditional clinical classification, the predominance of acquired multidrug-
resistant tuberculosis indicates poor management of individual patients before of drug-
resistant tuberculosis is diagnosed. By contrast, with the RFLP classification, the
predominance of transmitted multidrug-resistant tuberculosis cases points to a problem
of continuing transmission of multidrug-resistant tuberculosis within the community. To
reduce the rate of transmission of multidrug-resistant tuberculosis in an epidemic area,
greater awareness of this problem is essential. Effective treatment of infectious cases
and the use of rapid diagnostic tests might be helpful.
In the study population described, the clinical classification was not a valid
representation of the mechanisms leading to drug resistance. The study showed that the
category acquired drug resistance includes patients in whom M. tuberculosis truly
acquired drug resistance during treatment as well as patients initially infected with or
reinfected with a drug-resistant strain. I We therefore suggest that the current
terminology should be replaced by the terms "drug resistance in previously treated
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cases" and "drug resistance in new cases". To improve our understanding of the disease
dynamics of drug-resistant tuberculosis, further studies should investigate stratification
of cases classified as drug resistance in previously treated cases into transmitted and
truly acquired drug-resistant tuberculosis in areas with a high and low rates of
tuberculosis. Furthermore, the effect of HIV coinfection on the disease dynamics of
drug-resistant tuberculosis within communities needs to be investigated. Design and
interpretation of surveillance studies in epidemic areas should take into account that the
traditional clinical classification based on a history of previous treatment may result in
misleading interpretations and the underestimation of transmission. This inaccuracy
may in tum lead to inappropriate and ineffective clinical management. If, as shown in
this study, most cases of multi drug-resistant tuberculosis occur in clusters and are due to
transmission, the prevention of transmission by early detection and appropriate
treatment needs urgent attention.
ACKNOWLEDGEMENTS
We are indebted to the technical, secretarial and nursing staff of the TB research team, University of
Stellenbosch and to I. Toms, Head Health Services City of Tygerberg. The Collen Research Foundation,
Leuven, Belgium and Glaxo Wellcome Action TB Programme financially supported this study.
REFERENCES
1. Pabloz Mendez A, Laszlo A, Bustreo F, et al. Anti-tuberculosis drug resistance in the world. The
WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance 1994-1997.
WHOITB/97.229.
2. World Health Organization. WHO Report on the Tuberculosis Epidemic. Geneva; WHO, 1997.
3. Carpels G, Fissette K, Limbana V et al. Drug resistant tuberculosis in Sub-Saharan Africa: an
estimation of incidence and cost for the year 2000. Tubercle Lung Dis 1995; 76:480-486.
4. Crofton J, Chaulet P, Mahler D. Guidelines for the management of drug resistant tuberculosis.
WHO/TB/96.2l (RevII) p8.
5. WHO/IUATLD Global Working Group on Antituberculosis Drug Resistance Surveillance.
Guidelines for surveillance of drug resistance in tuberculosis. WHO Geneva / IUATLD Paris. Int J
Tuberc Lung Dis 1998; 2:72-89.
Stellenbosch University http://scholar.sun.ac.za
6. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: Review of the world-wide
situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997; 24(Suppl
1):SI21-30.
7. SmalJ PM, Hopewell PC, Singh SP, et al. The epidemiololgy of tuberculosis in San Francisco: a
population based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-
09.
8. Alland 0, Kalkut GE, Moss AR. et al. Transmission of tuberculosis in New York City: an analysis by
DNA fingerprinting and conventional epidemiological methods, N Engl J Med 1994; 330: 1710-1716.
9. Coronado VG, Beck-Sague CM, Hutton MD, et al. Transmission of multidrug-resistant
Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an
urban hospital: epidemiological and restriction fragment length polymorphism analysis. J Infect Dis
1993; 168: 1052-5.
lO. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant
tuberculosis. Epidemiology and clinical outcome. JAMA 1996; 276: 1229-35.
Il. Valway SE, Richards SB, Kovacovich J, et al. Outbreak of multidrug-resistant tuberculosis in a New
York State Prison, 1991. Am J Epidemiol 1994; 140: 113-22.
12. Fang Z, Doig C, Rayner A, et al. Molecular evidence for heterogeneity of me multiple-drug-resistant
Mycobacterium tuberculosis population in Scotland (1990 to 1997). J Clin Microbiol1999; 37:998-
1003.
13. Van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent
tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-1179.
14. Weyer K, Groenewald P, Zwarenstein M, Lombard CJ. Tuberculosis drug resistance in me Western
Cape. S Afr Med J 1995; 85:499-504.
15. Van Embdcn IDA, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium
tuberculosis by DNA fingerprinting: Recommendations for a standardized methodology. J Clin
Microbiol 1993; 31 :406-9.
16. Warren R, Richardson M, Van Der Spuy G, et al. DNA fingerprinting and molecular epidemiology
of tuberculosis: use and interpretation in an epidemic setting. Electrophoresis 1999; 20: 1807-12.
17. Hermans PWM, van Soolingen 0, de Haas PEW et al. Insertion element IS987 from Mycobacterium
bovis BCG is located in a hot-spot integration region for insertion elements in Mycobacterium
tuberculosis complex strains. Infec Immun 1991; 59:2695-705.
18. Warren R, Richardson M, Sampson S, et al. Genetyping of Mycobacterium tuberculosis with
additional markers enhances accuracy in epidemiological studies. J Clin Microbiol 1996; 34:2219-24.
19. Chaulct P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: why and
how? Tuberc Lung Dis 1995; 76:487-492.
64
Stellenbosch University http://scholar.sun.ac.za
65
CHAPTERS
Exogenous Reinfection as a Cause of Recurrent
Tuberculosis after Curative Treatment
ANNELIES VAN RIE12,ROBIN WARREN3,MADELENE RICHARDSON3,
THOMAS C. VICTOR3, ROBERT P. GlEI, DONALD A. ENARSON4, NULDA
BEYERSI,PAUL D. VAN HELDEN3
Department of Pediatrics and Child Health I 2, MRC Center for Molecular and Cellular Biology and
Department of Medical Biochemistry, University of Stellenbosch, South Africa", Department of
Pediatrics, Catholic University Leuven, Belgium' and the International Union Against Tuberculosis and
Lung Disease, France4
New England Journal of Medicine 1999; 341 :1174-1179
Printed by copyright permission. Copyright © 1999 Massachusetts Medical Society.
All rights reserved.
Stellenbosch University http://scholar.sun.ac.za
Exogenous Reinfection as a Cause of Recurrent Tuberculosis
after Curative Treatment
Background. For decades it has been assumed that postprimary
tuberculosis is usuaUy caused by reactivation of endogenous infection
rather than by a new, exogenous infection. Methods. We performed
DNA fingerprinting with restriction-fragment-length polymorphism
analysis on pairs of isolates of Mycobacterium tuberculosis from 16
compliant patients who had a relapse of pulmonary tuberculosis
curative treatment of postprimary tuberculosis. The patients lived in
areas of South Africa where tuberculosis is endemic. Medical records
were reviewed for clinical data. Results. For 12 of the 16 patients, the
restriction fragment-length polymorphism banding patterns for the
isolates obtained after the relapse were different from those for the
isolates from the initial tuberculosis disease. This finding indicates that
reinfection was the cause of the recurrence of tuberculosis after
curative treatment. Two patients had reinfections with a multidrug-
resistant strain. All 15 patients who were tested for the human
immunodeficiency virus were seronegative. Conclusions. Exogenous
reinfection appears to be a major cause of postprimary tuberculosis
after a previous cure in an area with a high incidence of this disease.
This finding emphasizes the importance of achieving cures and of
preventing anyone with infectious tuberculosis from exposing others to
the disease.
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INTRODUCTION
Postprimary tuberculosis, which occurs many years after a primary infection,' may
develop as the result of reactivation of the exogenous, primary infection or as a result of
a recent exogenous infection. Models developed by Sutherland and colleagues I and
more recently Vynnycky and Fine2, based on estimates of the annual risk of infection
and the incidence of tuberculosis, have suggested that the relative contribution of
exogenous reinfection increases in parallel with the incidence of the disease. However,
data for use in evaluating these statistical models have been difficult to obtain. In only a
few patients has there been reasonable proof of reinfection by a different organism after
known previous infection.
Before the introduction of antituberculous medication, there was little recognition
of the distinction between endogenous reactivation and exogenous reinfection in
patients who had multiple episodes, since untreated established tuberculous lesions may
be alternately active and dormant.' Effective treatment regimens made possible the
sterilization of pulmonary lesions, but it was accepted that subsequent episodes of
tuberculosis were almost invariably caused by endogenous reactivation4. The complete
sterilization of a lesion became possible with improved treatment regimens, especially
with the introduction of rifampin, a drug with a potent sterilizing effect. With short-
course combination therapy consisting of isoniazid, rifampin and pyrazinamide, the
relapse rate dropped from 21 percent to 1 to 2 percenr'". In this era of effective
treatment regimens, the notion that multiple episodes of tuberculosis in one patient are
almost always caused by endogenous reactivation may be questioned. It is now possible
to characterise the genotype of Mycobacterium tuberculosis by DNA fingerprinting,
which can show whether a new episode of the disease is caused by infection with the
same strain that caused a previous episode by a different strain.
In this study we used DNA fingerprinting to determine the relative frequency of
endogenous reactivation and exogenous reinfection in patients with multiple episodes of
postprimary tuberculosis. We aimed to determine the importance of this distinction in
terms of the definition of cure, the efficacy of current treatment regimens, and the
control of tuberculosis.
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MATERIALS AND METHODS
All patients described in this report were treated in two neighbouring suburban
communities of metropolitan Cape Town, South Africa. These communities have a
geographic area of 2.42 k:m2 and a population of 34,294 people of whom 99.7 percent
are of the mixed race. The number of reported cases of tuberculosis per year in these
two is very high (1000 cases per 100,000 population per year)8. The birth rate is 29.3 per
1000 population and the infant mortality rate is 38 per 1000 live births. In general,
people live in poor socio-economic conditions, although most live in houses with
running water and electricity. Two primary care clinics and an adjacent tertiary hospital
serve the area.
Before 1996, when all the elements of the World Health Organisation (WHO)
strategy of directly observed short-course treatment (DOTS) were implemented, all
patients were treated at one of the primary care clinics by directly observed therapy with
three drugs (patients needing treatment for a first episode [new patients]) or four drugs
(patients needing treatment for a subsequent episode [returning patients]). Until 1996,
there was no systematic surveillance for treatment failure, although for most patients a
sputum sample was examined (directly and by culture) between the fourth and sixth
months. With its implementation in 1996, the WHO DOTS strategy required an accurate
recording of cases in clinic registers, the administration of directly observed therapy
(four drugs for new patients and five drugs for returning patients), and surveillance for
treatment outcome, including treatment failure. Except for multidrug-resistant
infections, there was no surveillance for relapse.
Patients
Patients included in this study have had at least two episodes of postprimary
pulmonary tuberculosis within the study period (between September 1992 and May
1998), with the cultures of the last two most recent successive episodes (referred to as
first and second episode) available for restriction-fragment-length polymorphism
(RFLP) analysis and with cure as the outcome of the first episode. Extensive clinical
histories of the included patients were obtained and included data on age, sex, medical
history, status with regard to infection with the human immunodeficiency virus (HIV),
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findings on chest radiography, the results of sputum staining and cultures, drug
sensitivities, treatment, and outcome. According to WHO criteria, cure was defined as
the completion of a course of six to eight months -of directly observed combination
therapy (with isoniazid, rifampin, and pyrazinamide in a single tablet), compliance
(attendance for the course of therapy, with at least 80 percent of prescribed doses taken),
and sputum culture positive for M tuberculosis at diagnosis and at least one negative
sputum culture at the end of treatment. All patients who needed treatment for a
subsequent episode but who did not meet the criteria for previous cure were excluded
from the study.
M.tuberculosis Isolates
Sputum samples were stained and cultured at the laboratory that routinely served
the clinics. Drug-susceptibility testing was performed by the indirect-proportion method
in accordance with guidelines of the South African National Tuberculosis Program. In
September 1992, in the Cape Town communities described above, we initiated a
prospective study in which all cultures positive for M tuberculosis from patients
residing in these communities were genotyped by RFLP and a data base of the results
was established. To evaluate the representatives of the patients included in the RFLP
data base, they were compared with patients who had positive cultures in the district
tuberculosis register from January 1996 through May 1998 with regard to the clinical
classification. The percentage of cultures obtained for RFLP analysis was calculated for
both new and returning patients. These data were also used to calculate the annual
number of cases of culture-positive pulmonary tuberculosis per 100,000 population.
Isolates of M tuberculosis were genotyped by RFLP according to an internationally
standardized method," and the results were analyzed with Gel Compar software (version
4.0 Applied Maths BVBA, Kortrijk, Belgium). For the RFLP data base, the extent of
accumulated laboratory error was calculated by comparing successive DNA fingerprints
for serial isolates collected during the first two months of treatment, according to the
following formula: laboratory error rate equals the number of isolates with DNA
fingerprints that failed to match the DNA fingerprints of the subsequent isolate, divided
by the total number of serial isolates analyzed. To exclude the possibility of mixed
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infection, DNA was isolated from the entire culture, and all RFLP patterns were
carefully analyzed to identify any background bands reflecting different strains.
Analysis of the complete RFLP data base identified only five isolates with background
bands. The isolates were excluded from further analysis.
The isolates included in this study were analyzed as follows. Genomic DNA was
digested with PvuII or Hinfl, electrophoretically fractionated, and transferred to Hybond
N+ membranes (Amersham, Buckinhamshire, United Kingdom). The PvuII digests were
hydridized with an IS6110 3' probe (complementary to the IS6110 domain between
nucleotides 631 and 875) that has been labelled by enhanced chemiluminescence. The
Hinfl digests were hybridized with a 32P-labeled MTB484(1) probe.'" The respective
RFLP patterns were visualized by autoradiography. The IS6110 3' DNA fingerprints
from each patient's isolated were compared with those in the complete RFLP data base
(with data gathered from September 1992 through May 1998) by means of the
clustering formula known as the "unweighted pair-group method using arithmetic
averages" and the Dice coefficient to determine whether the isolates belonged to a
cluster (suggesting infection by recent transmission) or were unique (suggesting
reactivation of a latent infection) within the communities studied.
A patients whose isolates of M. tuberculosis from the first and second episodes of
postprimary tuberculosis were identical on RFLP analysis with each DNA probe was
considered to have tuberculosis due to reactivation of endogenous infection. A patient
whose isolates from the first and second episodes of postprimary tuberculosis were
different was considered to have tuberculosis due to a new, exogenous infection.
RESULTS
The rate of reported cases of culture-positive pulmonary tuberculosis from January
1996 through May 1998 was estimated to be very high (225 cases per 100,000 per year
for all true incidence cases) (Table I).
During the study period (September 1992 through May 1998), DNA from cultures
of M. tuberculosis was available for al least one RFLP analysis for 698 patients. For the
period from January 1996 (when reliable information became available for case
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notification as a result of the implementation of the DOTS strategy) through May 1998,
the average rate of recovery of cultures of M. tuberculosis for RFLP analysis was
estimated to be 82 percent (83 percent for new patients, 67 percent for patients needing
retreatment after cure and 84 percent for other patients needing retreatment) (Table 1).
Table 1: Distribution of patients with tuberculosis for whom cultures were
available for analysis, according to source of information *.
Patients RFLP data Base District Rate of culture Incidence of
Register recovery for Culture-
RFLPt positiveCases
September 1992 January 1996 January 1996
through through through
May 1998 May 1998 May 1998
No. of patients percent no.!IOO,OOO/yrt
Total 770§ 279 339 82
New patients 461 179 210 85 225
Patients requiring 48~ 16 24 67 26
retreatrnent after
previous cure
Others requiring 261 88 101 84
retreatment
* RFLP denotes restriction-fragment-length polymorphism, and ND not determined.
t The rate of recovery of M tuberculosis for RFLP analysis was estimated as the number of
patients with results in the RFLP data base from January 1996 through May 1998 divided by
the number of patients with episodes in the register for the same period.
These rates were calculated only for new patients and patients needing retreatment after cure,
since other patients needing retreatment do not represent true incidence rates.
§ This value includes 698 individual cases plus 72 samples from 55 patients from whom DNA
was available for two or more treated episodes.
This value includes patients from whom an RFLP analysis was available for an episode
requiring treatment after a previous cure. For 16 of these cases, the RFLP result of the first
episode was also available, and these patients thus constituted the study population.
DNA from at least one episode was available for RFLP analysis for 48 patients
considered to have tuberculosis requiring retreatment after cure. However, in only 16 of
these 48 patients were the results of the RFLP analysis for two episodes available, and
these 16 patients thus met the requirements for inclusion in the study: two episodes of
postprimary pulmonary tuberculosis within the study period and cure as the outcome of
the first of those two episodes.
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The median age of these 16 patients was 35 years; 9 were women and 7 were men
(Table 2). The median interval between cure and subsequent diagnosis (isolation of a
subsequent culture-positive specimen) was 25.5 months. Fifteen patients (94 percent)
were tested for HIV infection, and all 15 tested negative. None of the patients had a
medical history of diabetes, end-stage renal disease, or cancer or had been treated with
immunosuppressive drugs. Chest radiographs revealed evidence of cavitary disease in
I 1 patients during the first episode of tuberculosis and in 12 during the second episode
of tuberculosis.
Table 2: Epidemiologic and clinical characteristics of 16 patients with postprimary
pulmonary tuberculosis after previous cure. *
Patient Age (yr) Interval Negative smear, Exogenous
110. /sex Between Single positive reinfection
episodes] culture
Previous subsequent
episode episode
I 25/F 28 yes no Yes
2 291M 26 yes no yes
3 34/F 38 yes no yes
4 421M 32 no no yes
5 361M 19 yes no No
(reactivation)
6 40/M 8 no no yes
7 47/F 7 no yes yes
8 50/M 21 no no yes
9 45/M 12 no yes yes
10 30/F 35 no no yes
II 39/F 31 no no No
(reactivation)
12 30/F 52 yes no yes
13 28/F 35 yes no yes
14 54/M 25 no no yes
15 24/F 13 no no No
(reactivation)
16t 33/F II no no No
(reactivation)
• for patients one through 14,RFLP patterns are shown in figure I For patients 13 and 14, the
subsequent episode was diagnosed as multidrug-resistant tuberculosis, for patients 15 and 16,
the subsequent episode was diagnosed as tuberculosis resistant only to isoniazid.
t lIis interval is the time between the cure of the previous episode and the diagnosis of the
subsequent episode.
t patient not tested for HIV
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For 12 of the 16 patients, the RFLP patterns of the strains of M tuberculosis
responsible for the disease differed between the two episodes, indicating exogenous
reinfection (Table 2 and Fig. I). For the other four patients the RFLP patterns of the M
tuberculosis strains were identical for the two episodes, indicating endogenous
reactivation. Of the 16 patients, 4 had drug-resistant tuberculosis during the second
episode (Table 2), which in 2 patients was caused by exogenous reactivation with a
rnultidrug-resistant strain and in the other 2 patients (both resistant to only isoniazid)
was caused by endogenous reactivation. In one of the latter two patients, drug-
susceptibility testing performed during the first episode identified a fully drug-sensitive
organism. However, during an episode before the two described in this study, resistance
to isoniazid had been diagnosed. During the episode after cure, drug resistance was
proved in only one of five cultures obtained, indicating that the resistance to isoniazid
was borderline. In the other patient, no drug-susceptibility testing was performed on the
isolate from the first episode.
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Figure 1. RFLP patterns of 14 pairs of M. tuberculosis isolates obtained from patients with
recurrence of tuberculosis after cure. Lane I to 14 correspond to patient I to 14 respectively,
lanes R are control strains (MTB 14323)
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Because exogenous reinfection most likely results from close contact with an adult
who has active infection, isolates from the 12 patients with reinfection were studied in
relation to the complete RFLP data base for the two communities (covering September
1992 through May 1998 and including 698 patients). It was found that II of the 12
isolates obtained during the second episode of tuberculosis from patients who had
exogenous reinfection belonged to a cluster of strains present in the communities; for
the remaining isolate no matching strain was identified in the data base.
Of the four patients with tuberculosis due to reactivation, two were older than the
median age and two younger. The interval from cure to reactivation was longer than the
median interval in one patient and less than the median in the other three. All four
patients were infected with a strain that belonged to a cluster circulating in the
community during their respective disease-free intervals.
DISCUSSION
Using DNA fingerprinting, we found evidence that exogenous reinfection can have
a dominant role in the pathogenesis of postprimary tuberculosis in adults in an area with
a high incidence of the disease.I.2.11To our knowledge, there have been only two other
reports ofRFLP analysis of isolates from patients with repeated episodes of tuberculosis
who were living in a high-incidence area.12,13These studies suggested that under
conditions of endemic disease, the rate of endogenous reactivation far exceeds the rate
of exogenous reinfection. However, these reports do not include a definition of cure or
detailed information on the patients' drug regimens, compliance, or immune status.
Furthermore, 15 patients (34 percent)12 and 40 patients (49 percenu'? were excluded
because only a single culture was positive and the possibility of laboratory
contamination was raised. If they had not been excluded, 90 percent of these patients
would have been classified as having disease due to exogenous reinfection. Their
exclusion might therefore have biased the results toward the importance of exogenous
reacti vation.
In our study, the rate of recovery of cultures of M. tuberculosis for RFLP analysis
was lower for patients needing retreatment after cure than for other patients. The reason
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for this difference is not clear; it was not the result of any deliberate policy. The results
of the study must, however, be viewed with caution because of the possibility of some
unintentional bias. Nevertheless, there is no reason to suppose that strains from cases
due to reinfection would be preferentially recovered as compared with those from cases
due to reactivation, a condition necessary for such bias.
In our study, we did not exclude patients with only a single positive culture, for the
following reasons. It has been shown that tuberculosis lesions can yield an isolated
positive culture.14 There was no evidence of false positive culture: all the patients
received a diagnosis of active tuberculosis for both episodes on the basis of positive
sputum-test results, the findings on chest radiographs, and the clinical history. The
complete RFLP data base was analyzed to assess the extent of laboratory contamination,
and the rate of accumulated error was found to be only 3,4 percent (17 discordant results
among 499 serial isolates). On the basis of this error rate, it is possible that results for 1
isolate (3.4 percent of 32 isolates) may have been erroneous. Therefore, we believe it is
unlikely that the classification of disease as due to exogenous reinfection reflects
extensive laboratory error, such as error due to cross-contamination or mixed infection
at the first episode. This argument is further supported by the observation that in 11 of
the 12 cases of exogenous reinfection, the strain responsible for reinfection was
identified as one of a cluster of strains present in the communities. Only one isolate was
retrieved from a patient with reinfection for whom there was no matching isolate in the
entire data base. This patient appears to have been reinfected outside the communities or
by an undetected source within the communities.
All four patients who were found to have disease due to reactivation were infected
with individual strains that belonged to a cluster circulating within the communities
during these patients' respective disease-free intervals. The molecular definition of
exogenous reinfection used in this study excludes the possibility of exogenous
reinfection with the same strain. Therefore, it is possible that some of the patients
considered to have reactivation actually had new, exogenous infection with the same
strain. Our results may thus underestimate the extent of exogenous reinfection.
It has generally been believed that reinfection is more difficult to confirm than
primary infection, because of the immune response to M. tuberculosis antigens that
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develops after primary infection. There are no empirical data on the changes in the level
of immunity over time, but it is assumed that in immunocompetent persons, reinfection
is rare during the first two to five years after a first infection.i In our study, cases of
reactivation tended to occur soon after the previous episode was cured, but many of the
cases due to reinfection also occurred early after a previous cure. It has been shown in
persons infected with HIV that reinfection can occur not only years after a previous
infection (or episode of disease) but even during treatment for active tuberculosis.l ' In
our study, in which all the patients tested for HIV infection were negative, reinfection
occurred as little as seven and eight months after a previous cure. These results suggest
that in immunocompetent persons living in an area where tuberculosis is endemic,
reinfection and progression to active disease may occur at any time after treatment has
been discontinued.
In patients previously treated and cured, a subsequent episode would be expected to
represent endogenous reactivation. We found that exogenous reinfection has a
predominant role in this population of patients, who have multiple episodes of active
tuberculosis. In areas with a high incidence of tuberculosis, exogenous reinfection might
also be a cause of the first episode of postprimary tuberculosis, since the immunity that
develops after primary infection followed by a period of latency cannot be expected to
confer more protection against exogenous reinfection than the immunity that develops
after an episode of active disease.
The controversy with regard to endogenous as opposed to exogenous pathogenesis
of tuberculosis is of importance In the planning of clinical trials and national
tuberculosis-control programs. If, 111 areas with a high incidence of the disease
postprirnary episodes of pulmonary tuberculosis after previous cure result
predominantly from exogenous reinfection, as indicated by our results, the effectiveness
of a drug regimen cannot be evaluated on the basis of the relapse rate without the
additional information provided by RFLP analysis of bacterial isolates. In the evaluation
of national tuberculosis-control programs for areas in which the disease is endemic,
RFLP analysis can prove the effectiveness of the currently used treatment regimens.
"Cure" in a patient who later has another episode of tuberculosis is not necessarily an
incorrect concept. The more likely possibility is that he or she has a new infection after
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the cure. The emphasis should thus be placed on achieving cure in patients and on
prompt case detection to prevent re-exposure to sources of active tuberculosis.
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Exogenous Reinfection In Tuberculosis
Tuberculosis, like all infectious diseases, involves exposure to a pathogen resulting
in an asymptomatic period of incubation or latency that may progress to active disease.
Unlike most other infectious diseases, tuberculosis involves a delay between infection
and disease that is extremely variable, ranging from a few weeks to a lifetime.
Therefore, the development of active tuberculosis in someone known to have been
previously infected raises the question whether this represents a recrudescence of the
initially infecting organism (endogenous reactivation) or a new strain of Mycobacterium
tuberculosis (exogenous reinfection).
For decades, this question has been central to a debate in which the intensity of the
sentiments seems to be inversely proportional to the quality of the supporting data.
Publications dating to the 1920s reflect highly divergent views, from the assertion that
reinfection "for all practical purposes ... can be ignored" 1 to the contention that "the adult
type of tuberculosis is, with few exceptions, the result of exogenous reinfection." 1
Currently, most medical textbooks refer to the unitary concept of pathogenesis, which
states that the majority of cases of tuberculosis are a consequence of endogenous
reactivation.i Yet there is persistent evidence that exogenous reinfection may also be an
important contributor to the total tuberculosis burden.'
This question is of more than academic interest. If exogenous reinfection is
common, the use of antituberculosis chemoprophylaxis in people who have recently
been exposed to infectious tuberculosis may be prudent, regardless of whether they have
evidence of prior infection. It would be dangerous to assume that elderly patients with
tuberculosis have disease caused by infection they acquired before the widespread
emergence of drug-resistant organisms. If exogenous reinfection, which is clinically
indistinguishable from relapse, is common, then new regimens that effectively eliminate
infection or treat disease will be unfairly judged in clinical trials. If natural infection
does not confer protective immunity, the development of improved vaccines against
tuberculosis will be especially challenging and the need for better understanding of host
defenses against tuberculosis particularly critical. Perhaps most important, the
achievable rate of decline in tuberculosis worldwide would be much faster if most cases
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are due to recently acquired infection rather than to continual reactivation throughout
the lifetime of the more than 1.5 billion persons already infected.
In elegant animal models, the presence of acquired jmmunity makes it more~ .
difficult to establish a new infection." However, these types of data cannot tell us
whether exogenous reinfection occurs under natural conditions in humans. Rapid
advances in immunology and techniques such as the use of genetically altered animals
now hold the promise of elucidating the biology of antituberculosis immunity --
information that is crucial for the development of improved vaccines.
There is anecdotal evidence that exogenous reinfection does occur in humans. For
example, during an outbreak in a homeless shelter, there were four cases of exogenous
reinfection in persons with previously documented tuberculosis infection or disease.'
More recently, fingerprinting techniques for analysis of bacterial DNA have proved that
reinfection can occur in both immunocompromised and apparently immunocompetent
persons.Y However, such anecdotal evidence cannot be used to answer the more
important question about the relative contribution of exogenous reinfection within
populations. More important, we have not been able to quantify the prevalence of
reinfection in high-risk, resource-poor communities -- where the majority of cases are
found today.
A report by van Rie et al. in this issue of the Journal provides the most dramatic
data to date on the extent to which tuberculosis is attributable to reinfection.s The
authors used DNA fingerprinting to examine isolates of M tuberculosis obtained over a
period of almost six years from 698 patients from a metropolitan area in South Africa
that has one of the highest rates of tuberculosis in the world. They identified 16 patients
with recurrent tuberculosis after curative therapy for whom complete data were
available. Fifteen of these patients were known to be seronegative for the human
immunodeficiency virus. After comparing the DNA fingerprints of bacilli isolated
during the initial episode with those of bacilli isolated during the subsequent episode,
the authors concluded that 12 patients had been exogenously reinfected with a different
strain. This finding suggests that 75 percent (95 percent confidence interval, 50 to 94
percent) of the cases of postprimary disease were attributable to exogenous reinfection.
This study is a model of the way in which population-based research, when integrated
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with detailed information about patients and coordinated with a tuberculosis-control
program, can provide basic insights and have important public health implications.
Some of the most important challenges in this type of research are to eliminate both
sampling bias and the risk of cross-contamination in the laboratory. Although van Rie et
al.8 could identify no bias in their selection process, their analysis included only 16 of
the 698 patients with a culture available for analysis during the study period and their
results must therefore be interpreted cautiously. For example, if infections are
transmitted at disproportionate rates in various health care settings, patients with
exogenous reinfection may be overrepresented in an analysis that includes only patients
known to have regularly attended clinics to receive observed therapy. The low overall
rate of contamination (3.4 percent) in the study by van Rie et al. strongly supports their
contention that laboratory error did not contribute to their results.
This study provides an important clue to resolving this age-old debate, but it is not
the final word. The relative contributions of reinfection and reactivation are likely to
depend on the epidemiologic context." In populations at high risk for infection, people
may have an appreciable chance of repeated infection, and thus reinfection may be a
major contributor to the overall rate of tuberculosis in adults. However, in populations
with a low risk of infection, such as those in developed countries, the likelihood of
reexposure, let alone successful reinfection, is small, and thus most cases of postprimary
disease in adults probably result from reactivation.
The realization that exogenous reinfection may account for much of the
tuberculosis in a given region has implications for control of the disease. It is widely
acknowledged that the most important recent advance in tuberculosis control has been
the implementation of the strategy of directly observed short-course treatment (DOTS).
Although the DOTS strategy is frequently assumed to consist simply of direct
observation of treatment, it actually contains the essential elements for national control
of tuberculosis. The program includes governmental commitment, the use of sputum
smears for diagnosis, careful tracking of each patient, and measures to ensure an
uninterrupted drug supply.l" When successfully implemented, the DOTS strategy
dramatically improves patient outcomes. By reducing the transmission of disease, this
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approach should also decrease reinfection and thus will be the essential first step toward
controlling tuberculosis in areas of high prevalence.
Much of the success and appeal of the DOTS strategy IS attributable to the
simplicity and broad applicability of its principles. However, a hallmark of the
epidemiology of tuberculosis is its variability among populations, which may be
reflected as differences in the proportions of disease caused by reinfection. Attempts to
go beyond the DOTS strategy will require a more open-minded approach. Given the
persistent toll of tuberculosis, the formulation of an array of specific interventions
tailored to the diverse settings in which patients suffer will be one of the major public
health challenges of the coming millennium.
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Correct and rapid diagnosis is essential in the management of
multidrug-resistant tuberculosis (MDR- TB). This population based
study of 61 patients with drug-resistant tuberculosis evaluated the
frequency of mutations and compared the performance of a genotypic
(mutation analysis by dot blot hybridisation) to a phenotypic (indirect
proportion method) drug-resistance test. Three selected codons
(rpoB531, rpoB526 and katG315) allowed identification of 90 % of
MDR- TB cases. Ninety percent of rifampin, streptomycin and
ethambutol resistance and 75% of isoniazid resistance was detected by
screening for 6 codons: rpoB531, rpoB526, rrs513, rpsL43, embB306
and katG31. The performance (repeatability, sensitivity and specificity)
of the genotypic method was superior to the routine phenotypic test
with tbe exception of sensitivity for isoniazid resistance. A
commercialised molecular genetic test for a limited number of target
loci might be a good alternative for a drug-resistance screening test in
the context of an MDR DOTS-plus strategy
Comparison of phenotypic and genotypic drug-resistance testing of
mycobacterium tuberculosis in a middle income country
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INTRODUCTION
The emergence of drug-resistant strains of Mycobacterium tuberculosis, especially
muItidrug-resistant (MDR) strains, defined as resistant to at least isoniazid (INH) and
rifampin (RIF) I, poses a threat to the success of tuberculosis control programs. As a
consequence of the increase in multidrug resistant tuberculosis (MDR-TB) and the
relatively restricted number of therapeutic agents, there has been a renewed effort
during the last decade to define the molecular basis of drug resistance in M
tuberculosis. Resistance to drugs is due to particular genomic mutations in specific
genes of M. tuberculosii. To date 9 genes are known to be linked to resistance to the
first line antituberculous drugs: katG, inhA, aphC, kasA for INH resistance; rpoB for
RIF resistance; rpsL and rrs for streptomycin(SM); embB for ethambutol (EMB)and
pncA for pyrazinamide (PZA) resistance. Multiple drug-resistance is the consequence of
an accumulation of mutations:".
Under the current WHO guidelines for TB control in low and middle-income
countries', diagnosis of new TB patients is based on examination of sputum smears by
microscopy for the presence of acid-fast organisms. Cases of primary drug-resistant TB
will thus be missed with consequent prolonged infectivity and further spread of drug-
resistant tuberculosis. A new strategy, "DOTS plus,,6,7,which reinstalls M tuberculosis
culture and sensitivity testing at diagnosis, has been introduced in a few pilot projects.
However, when drug-susceptibility testing is culture-based, detection will still take 2 to
9 weeks". The molecular basis of drug resistance in M tuberculosis makes it possible to
create new, rapid diagnostic tests. Rapid detection of drug resistance could not only
optimise the treatment and improve the outcome of patients with drug-resistant TB, but
is especially important in the prevention of transmission of drug-resistant TB. When the
first study on detection of mutations in clinical isolates was published, it was hoped that
early detection of resistance in M tuberculosis would soon be routine clinical practice",
Seven years later, mutation detection analysis is still not part of clinical practice. To be
cost-effective in resource-poor countries where most MDR-TB patients reside, it will be
crucial that molecular genetic tests fulfil the criteria of accuracy, speed and simplicity.
The evaluation of the frequency distribution of various mutations in clinical isolates
Stellenbosch University http://scholar.sun.ac.za
originating from different geographical regions will be essential for the selection of a
limited number of target mutations which enable the detection of the majority of drug
resistance/'".
This study investigates the frequency of gene mutations in clinical isolates of M.
tuberculosis originating from two communities of Metropolitan Cape Town (South
Africa) with a high incidence ofTB and documented outbreaks of MOR-TB within the
studied communities II. This site, a high TB incidence area of a middle income country,
provides the possibility of evaluating the clinical usefulness of a genotypic method
compared to the culture-based phenotypic drug susceptibility test under routine
conditions.
MATERIALS AND METHODS
Setting
The patients described in this paper were identified as active eases of drug resistant
tuberculosis (on the basis of culture based drug susceptibility tests) between 1 April
1992 and 31 March 1997. All patients resided in two neighbouring communities of
metropolitan Cape Town (Western Cape Province, South Africa), a 2.4 km2 area with a
population of approximately 34,000 people living in poor socio-economic conditions.
The rate of new bacteriologically confirmed cases in these communities is
225/1 00.000/yearI2. A survey of drug-resistant tuberculosis in the Western Cape
province conducted in 1992-1993 found a rate of 8.6% acquired and 3.2% initial drug
resistance in the West Cape region'<. The reported prevalence of HIV infection in the
region ranged from 0.25% in 1992 to 3 % in 1996 (data from the National HIV surveys
on women attending antenatal clinics, conducted by the Department of Health and
Population Development, South Africa).
All patients were treated by direct observation at the loeal primary health care
clinics, 62% also received inpatient care. Compliance during treatment was defined as
the intake of > 80% of prescribed dosages before interruption or completion of
treatment,
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Laboratory procedures
Sputum samples were sent for microscopy and culture to the routine ·laboratory,
which is the provincial reference laboratory for drug susceptibility testing. Phenotypic
drug susceptibility testing was performed by the economic version of the indirect
proportion method'" on Lêwenstein-Jensen medium containing critical concentrations
of 0.2 ug/ml isoniazid, 30 ug/ml rifampin, 2 ug/ml ethambutol, Sug/ml streptomycin
and 20J.lg/ml ethionamide. Resistance was defined as I% or more bacterial growth in
comparison with a control using international criteria.
Genotypic drug resistance testing was performed by mutation analysis according to
a recently described PCR based dot-blot method'", The probes and primers used in this
study were directed towards mutations most frequently described in the literature. All
samples were tested for mutations at the following loci: katG 315, kasA269, inhA -10
and -34, rpoB 531,526 and 516, rpsL 43 and 88, rrs 513, 491 and embB. The reference
strain H37Rv, 10 fully susceptible isolates and isolates characterised by gene
sequencing as mutant (resistant) or wild type (susceptible) for specific gene loci were
used as negative and positive controls. In cases where resistance could not be explained
by the identification of mutations in the above gene codons, samples were also tested
for additional codons (katG 275, 409; kasA 66, 312, 413; inhA-15, rpoB 533, 513 and
rrs 904). Direct sequencing of selected PCR products was performed with the
Sequenase peR Product sequencing kit (United States Biochemical, Cleveland, USA)
according to the manufacturers' instructions.
M. tuberculosis isolates were also genotyped by RFLP analysis'", A cluster was
defined as a group of two or more isolates originating from different patients whose
RFLP fingerprint patterns were identical with respect to both the number and molecular
size of all bands 17.
For each patient, the first and last available isolates were defined as the first and last
isolate for which DNA was available for mutation detection and RFLP analysis. The
results of the first available isolates were used to evaluate the frequency of mutations
and thereby compare the clinical usefulness of phenotypic and genotypic methods. The
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result of the last available isolate was used to determine the acquisition of additional
mutations during treatment.
A discrepancy between the phenotypic and genotypic drug-resistance test of the
first available isolate was defined as a false positive result of the genotypic method if
the isolate was predicted to be resistant by mutation analysis but phenotypically drug
susceptible. A false negative result of the genotypic method was defined as a
phenotypically resistant isolate in which no mutations conferring resistance were
detected.
In cases of discrepancies, the infecting M. tuberculosis isolate was retested by
phenotypic and genotypic method if no follow-up isolate was available. Retesting by
phenotypic method was performed using a different method (BACTEC) at a different
laboratory (Department of Biochemistry, University of Stellenbosch). In cases of
discrepancies where at least one follow-up isolate was available, the result of the
follow-up isolate(s) was used to re-evaluate the discrepancy of the first isolate.
After investigation of all discrepancies, the "corrected pattern" for each of the first
available isolates was determined using a method similar to the method used by Telenti
et al.". This "corrected pattern" was used as the "gold standard" to evaluate and
compare the intrinsic characteristics such as the sensitivity and specificity of both
phenotypic and genotypic drug-resistance testing.
Results of drug-susceptibility tests of consecutive isolates of individual patients
were used to determine the repeatability of both phenotypic and genotypic tests by
calculating the Kappa coefficientl9. Pairs of isolates retrieved from either a single
clinical episode or from different clinical episodes but caused by the same M.
tuberculosis strain as determined by RFLP analysis were included in this analysis. Pairs
of isolates where the first isolate was drug susceptible and the following isolate drug
resistant were discarded for this analysis as this might not represent a lack of intra-
subject variation but acquisition of resistance during treatment.
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RESULTS
Patient Characteristics:
Between April 1992 and March 1997, 70 patients were identified with isolates
phenotypically resistant to one or more antituberculous drugs. In 61 of these, a
minimum of one culture was available for molecular genetic analysis. These 61 patients
constitute the study population. All patients had pulmonary tuberculosis and 84% were
smear positive. Half of the patients were female (31 or 51%). The mean age at diagnosis
of drug-resistant tuberculosis was 33 years (range 11 to 55 years). Fifty-two patients
(85%) were tested for HIVand all were seronegative. Thirty-five patients (57%) were
compliant during their MDR-TB treatment.
Phenotypic resistance pattern of first available M. tuberculosis isolates
The resistance pattern was determined by phenotypic drug susceptibility tests (table
1 and 2). In 34 (56%) patients, the first isolate available for this study was the isolate on
which the diagnosis of drug resistance was based. In 2 patients (case 41 and 42),
resistance was detected by mutation analysis on an isolate predating the isolate on
which the diagnosis of drug resistance was made by phenotypic method. Resistance was
detected in 57 (93%) cases for INH, in 34 (56%) cases for RIF, in 25 (41%) cases for
SM and in 11 (18%) for EMB. Thirty-two (52%) cases were diagnosed as multidrug-
resistant TB.
Additional resistance acquired during treatment was diagnosed as in 40% (n= 25) of
the patients (table 1). The additional resistance acquired was for INH (n=2), EMB
(n=8), RIF (n=IO) and SM (n=I4).
RFLP data
Six clusters of drug-resistant strains and 23 unique strains were identified. Clusters
1 (19 IS6110 insertion elements with a pattern resembling "strain W,,20) and cluster 2 (5
IS6110 insertion elements) represent the predominant type of drug-resistant strains in
these communities.
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Table 1: RFLP classification, phenotypic, genotypic and corrected drug-resistance
pattern in 61 patients
r.li~nl R~l,P FIRST AVAILABLE.ISOLATE Inl~rv.1 LAST ISOLATE P.I.i~DI
p."~rn lO 1.,1 compIianI
Ph~nolypic mut.tion an.lysis Correct uol.I~ Addldonal Additional
resuI.ncc pallem (days) resistance MuI.tiolU
bonluid rir.mp!n Strepto- ('th.mutol
myein
I cluster I H.R knlGJH rpo8HI rrs513 embBJ06 H.R.S.E J23 S.E yes
2 cluster I H.R.E knlG) I) rpo853 I rn)IJ ~mbB306 H.R.S.E 176 S yes
3 cluster I H. R. S.~. knlG31S rpoBS3/ rrs5/3 embRJfM Ii. R. S. E 399 no
4 cluster I II. S knIG3/) rpoBH/ rrs5/] embBJ06 H. R.S. E NA R.E yes
S eluSler I H.R.S.E knlG3/5 rpoRH/ rrs5/3 rmbR3(}6 H.R.S.E NA yes
6 cluster I II. R.S. E knlG31S rpoR53/ rrs5/3· emb8J06 H. R.S. E 302 no
7 cluster I II. R.S. E knlG315 rpo8HI rrs5/3 embBJ(}6 II. R. S. E 175 no
8 cluster I II. R. S. E knIG)/5 rpoR5)/ rrs51J o"bR)06 H.R.S.E 77 no
9 clusler I H.H.S k1llG)15 rpoOHI rrs5/3 emb830ó H. R.S. E 346 E yes
10 cluster I H. R knlG315 rpo/JHI rrs513 cmbB3IJó H.R.S.E NA S yes
" cluster I H. R.S. E kll/G315 rpoR531 rrs513 embR306 H.R.S.E 277 yes12 cluster I II. R. S knlGJI5 rpoOS) I rrs513 emb8)(}6 II. R. S. E NA E yes
IJ cluster I H. R.S. E kn1G)15 rpoRS31 rn5/3 enab8306 H. R. S. E NA yes
14 cluster I II.R knlGJH rpoB5) I rrs51J embR3fM H. R.S. E 269 S.E no
IS cluster I H. R.S. E knlG315 rpoBHI rrs51) ~ntb8J(/6 H.R.S.F. NA no
16 cluster 2 H knIGJ/Sd rpo8H/· rpsVI3 H. R.S 363 R.S yes
17 cluster 2 H. R. S knlG31Sd rpoR5JI rpsL4J H. R.S NA yes
18 cluster 2 H. R.S kn,GJ/jd rpo853 I rpsL43 H. R. S 394 no
19 cluster 2 H. R.S AnIGJHd rpo8HI rpsL43 H. R. S 215 yes
20 unique H.S knlGJHd rpoRHIo· rpsU3 H. R. S 1026 R no
21 cluster 2 H. R.S /(II/GJI5d rpo05JI 'psL43 H. R.S NA yes
22 cluster 2 H.R.S /(Il/GJ/Jd rpoOS) I ,psL43 H. R.S 660 E no
lJ cluster 2 H. S ~nlGJ15d rpo115),1< rpsL43 H. S 201 no
24 cluster 2 H. R.S knlGJ/5d 'poRHI rpsUJ H. R.S NA yes
25 cluster 2 H. R. S knlG)IJd rpoR5) I 'psL4J H. R.S NA yes
26 cluster 2 H.R knlG315d rpllRS)I ,psL43 H. R.S 444 S no
27 cluster 3 H.R kmG315 'poR53I H.R NA yes
28 cluster 3 H.R klllG31S 'po053 I H.R 1450 S yes
29 elusler) H.R MIG315 rpoR53 I H.R 14 yes
30 cluster 4 H . none 124 R rpo8526· no
31 cluster 4 II H 493 yes
32 cluster 4 II.R ,poD53 I rpsL43 H. R.S NA no
33 cluster 4 R rpollJ) I R IIR8 H /tlflA-IO no
34 clcsrer 5 Ii. R. S kOIGJH rpoDHI rpsL43 emb8JOÓ· II. RS. E NA yes
35 dUSle.S II.R knlG315 rpoR5!6 rpsVI3 Ii. R.S NA S yes
36 cluster 5 II. R.S MIGJJ5 rpoR51ó rpsL4J II. R.S 103 no
37 etester 6 Ii knlv)IJ II NA yes
38 cluster 6 II kn1GJ/5 rrs491 H.S 332 S yes
39 unoque II . rpoJl5111d· Ii 7$ yes
40 unique H II NA no
41 unique none AnIGl/Jd rpoRJ) I H.R 21$4 H.H.S no
42 unoque none rpolIS)I· R NA R no
43 UU!<luC ~I ktrtGJIS II NA yes
44 unique H. R.E emb83()(, II.R.E 92 S 'l'oB516 no
4!' unique R 1,,"A-15· ,poH5J1 R NA yes
46 unique II.S knle315 Ii.S 253 E yes
47 unsque " none 268 rpo05'" no48 uurque II " (,I) R.S ,poRHI no49 unique II II NA no
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Table 1: continued
Patient RFLP FIRST AVAILABLE ISOLATE Interval LAST ISOLA TE Patient
pattern to compliant
last
isolate
Phenotypic mutation analysis Correct Additional Additional
resistance pattern resIstance Mutations
iso niazid rifampin Strepto- ethambutol
myein
SO unique H.R.E rpoB516' embB306 H.R.E 683 S inhA-34 no
SI unique H H NA yes
52 unique H.S kil IG315 . H.S 131 R rpoB526 yes
53 unique H H NA yes
54 unique H rpoB53I H.R 307 R rrs49 I no
SS unique H rrs49 I H 669 yes
56 unique H kasA269' H NA no
57 unique H.R rrs49 I none NA
58 unique H H NA yes
59 unique H kil IG315 rpoB526 rpsL43 embB306 H.R.S.E 1056 S.E.R yes
60 unique H kil IG315 H NA yes
61 unique H.S kill G315d rrs513 • H.S NA no
Legend:
Definition of abbreviations: Hand INH = isoniazid, R and RIF = rifampin, S and SM = streptomycin, E and
EM B = ethambutol.
katG315=AGC to ACC mutation, katG315d=AGC to ACA mutation, katG315d*=katG315 + inhA-IO
mutation
* indicates that the presence or absence of a specific mutation has been confirmed by gene sequencing.
Table 2: Number (%) of resistant first isolates as determined by different methods
isoni azid rifampin streptomycin ethambutol isoniazid +
rifampin
Phenotypic test 57 (93) 34 (56) 25 (41) 11 (18) 32 (52)
Genotypic test 43 (70) 41 (62) 35 (57) 19 (31) 34 (56)
Corrected 55 (90) 40 (66) 35 (57) 19 (31) 37 (61)
Genotypic analysis of first available M. tuberculosis isolates (table 1 and 2).
Mutations in genes conferring resistance to INH were detected in 43 (70%) cases.
The most frequent mutation associated with INH resistance was codon 315 in the katG
gene (41/43, 95%). One isolate (2%) had a mutation in inhA-10 and one isolate had a
kasA269 mutation. A katG315 mutation was present in 1 of 4 (25%) isolates classified
as phenotypically susceptible to INH. No mutations could be detected in 16 of 57 (28%)
isolates phenotypically resistant to INH.
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Mutations in genes conferring resistance to RIF were identified in 41 (62%) cases.
Codon' 531 of the rpoB gene (34/41, 83%) was the most frequent mutation associated
with RIF resistance. Other mutations detected were rpoB526 (3/41, 7%), rpoB516 (2/41,
5%), IpoB533 (1/41,2%) and rpoB518 (1/41, 2%). Nine of the 41 (22%) isolates with
rpoB mutations were phenotypically classified as susceptible to RIF. No rpoB mutations
could be detected in 2 of34 (6%) isolates phenotypically classified as RIF resistant.
A total of 34 of the 61 isolates (56%) demonstrated mutations of both katG and
rpoB genes. Seven of these isolates were phenotypically not classified as multidrug
resistant. Mutations conferring resistance to both isoniazid and rifampin were absent in
4 of 32 (12%) isolates phenotypically classified as multidrug-resistant.
Mutations in genes conferring resistance to SM were detected in 35 (57%) cases.
The most frequent mutations conferring resistance to SM were found at position 513 of
the rrs gene (16/35, 46%) and codon 43 of the rpsL gene (16/35, 46%). Three isolates
(8%) had a mutation in at position 491 of the rrs gene. Mutations were present in 12 of
the 36 (33%) isolates phenotypically classified as susceptible to SM. Gene mutations
could not be detected in 2 of25 (8%) phenotypically SM-resistant isolates.
Codon 306 in the embB gene was the only codon screened for EMS resistance. A
mutation was detected in 19 (31%) cases. Mutations were present in 8 of 50 (16%)
isolates phenotypically susceptible to EMS. EmbB306 mutations were detected in all Il
isolates phenotypically resistant to EMB.
Except for one drug susceptible control isolate with a rrs 491 mutation, none of the
other 9 susceptible isolates or the H37Rv control strain had mutations in the screened
genes.
Investigation of discrepancies between phenotypic and genotypic tests of the first
available M. tuberculosis isolates
Twenty discrepancies (INH n= 16, SM n=2, RIF n=2) represented potential false
negative results of mutation analysis, according to the definition outlined in the methods
section. Retesting by genotypic method confirmed prior results in all cases. Ten of these
cases were confirmed resistant according to the result of a phenotypic test of follow-up
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isolates (INH n=7, SM n=2, RIF n= 1). Upon retesting of the remaining 10 isolates by
phenotypic method, 4 isolates were confirmed resistant to INH. Two isolates could not
be retested as they had lost viability. For further analysis, the original phenotypical
result of these 2 isolates was considered correct. Four isolates were found to be drug
susceptible on retesting by phenotypic method (INH n=3, RIF n=l). In conclusion, after
investigation of 20 discrepancies, 16 cases of false negative results of mutation analysis
remained. False negative results occurred predominantly in cases oflNH resistance.
There were 31 (SM n=12, RIF n=9, EMB n=8, INH n=2) potential false positive
results of mutation analysis, according to the definition proposed in the methods
section). The presence of a mutation was confirmed in follow-up isolates (n=21) or
upon retesting of the first isolate (n= 10). Phenotypic resistance was detected on the next
available follow-up isolate in 23 cases. The genotypic classification of the first isolate as
resistant was considered correct in the cases (n=23) where the mutation present in the
first isolate conferred for the resistance phenotypically detected in the follow-up isolate.
Five cases were classified as drug suceptible because follow-up isolates remained drug
susceptible. The three remaining cases were phenotypically retested. Case 10 was found
to be resistant to EMB. Case 32 was found to be resistant to 2 and 4 ug of SM but
susceptible to 8 ug of SM. Case 34 was found to be resistant to 2.5 ug of EMB but
susceptible to 5 and 10 ug of EMB.
In conclusion, after investigation of the 31 discrepancies, 5 cases of false positive
results of mutation analysis remained. False positive results occurred in cases with rare
mutations such as rpoB533, rpoB518d, rrs491 and inhA-15.
Additional resistance acquired during treatment
Additional resistance acquired during treatment (as determined by phenotypic
method) was present in 25 cases (40%) (Table 1). Of these patients, 46% (n=12) were
non-compliant during treatment. The mutation conferring the "additional acquired"
resistance was already present in the first available isolate in 9 of 14 cases (64%) of
additional resistance to SM, 7 of 11 cases (64%) of additional resistance to RIF, 6 of 8
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cases (75%) of additional resistance against EMS and in 3 of 4 cases (75%) of
additional resistance to INH.
lri 35 patients, a follow up isolate was available for genotypic analysis (Table 1).
The time between the first and last isolate was on average 485 days (range 14-2145)
days. First and last available isolate possessed the same RFLP pattern in all cases. An
additional mutation was detected in 8 of the 35 (23%) cases. Seven of these 8 cases
(88%) with an additional mutation on follow-up were non-compliant.
Performance of phenotypic and genotypic test
After correction for errors in phenotype assessment and mutation analysis, the
resistance pattern of each isolate was re-c1assified (Table 1 and 2).
Isolates were correctly classified as MDR in 90 % of cases by genotypic method
and in 84% of cases by phenotypic method. Phenotypic resistance was detected in 98%,
83%, 71% and 58% of all isolates resistant to respectively INH, RIF, SM and EMS
according to the correct classification. The diagnosis of resistance of the first isolate by
phenotypic method was thus missed in 2% (n=l ) of cases resistant to £NH, 17% (n=7)
of cases resistant to RIF, 29% (n=10) of cases resistant to SM and 42% (n=8) of cases
resistant to EMS. Genotypic resistance was detected in 76%, 98%, 94% and 100% of all
isolates resistant to respectively £NH, RIF, SM and EMS according to the correct
classification. Detection of resistance was thus missed in 24% (n= 13) of cases resistant
to INH, 2 % (n=l) of cases resistant to RIF and 6% (n=2) of cases resistant to SM. The
lowest yield of mutation detection (31%) was for isolates mono-resistant to INH.
Repeatability, sensitivity and specificity of each method were evaluated for each
drug using the corrected classification as the "gold standard" (Table 3). Genotypic
analysis had a repeatability of 100 % (Kappa 1.0) for all drugs tested (no discrepancies
between 151 follow-up isolates of 35 individual patients). Repeatability of the
phenotypic method was evaluated in 246 follow-up isolates of 54 patients and found to
be fair for INH and EMS (Kappa 0.43 and 0.49) and good for RIF and SM (Kappa 0.68
and 0.6). Except for INH, sensitivity (ability to detect true drug resistance) was lower
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for phenotypic test while the specificity (ability to detect true drug susceptibility) was
lower for the genotypic tests.
Table 3: Repeatability and validity of phenotypic and genotypic drug resistance
testing
isoniazid rifampin streptomycin ethambutol
p G P G P G P G
Repeatability 0.43 0.68 0.6 0.49
(Kappa coefficient)
Sensitivity (%) 98 76 83 98 71 94 58 100
Specificity (%) 50* 83* 95 91 100 92 100 100
P: phenotypic test (economic variation of the indirect proportion method)
G: genotypic test (mutation analysis)
* Results cannot be interpreted correctly because of the high prevalence (90%) of INH resistance in
the study population
DISCUSSION
This population-based study investigated 61 patients diagnosed with drug-resistant
TB by conventional drug susceptibility methods. The analysis of the results focussed on
the first available isolate of each patient, as this is the most important isolate for patient
management. We did not correct for the number of strains involved in an outbreak
because the detection of resistance is important for clinical management, independent of
the classification of an isolate as clustered or unique. In contrast to most studies, where
phenotypic tests are performed in a high-quality national, supranational or research
laboratory, the phenotypic tests for this study were performed in a routine provincial
laboratory to approximate everyday reality of M tuberculosis drug-resistance testing in
a middle-income country. As done previously by Telenti et ailS, we did not use the
phenotypic test as the gold standard but the "corrected" version of resistance patterns
obtained by investigation of discrepancies between phenotypic and genotypic tests. In
this way, the performance of both phenotypic and genotypic test could be evaluated and
compared.
In this study, genotypic tests for only 3 selected codons (rpoB531, rpoB526 and
katG315) allowed correct identification of90 % of all MDR-TB cases from the studied
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communities. Furthermore, more then 90% of resistance to RIF, SM and EMB and 75%
of resistance to INH could be detected by screening for only 6 gene codons: rpoB531,
rpoB526, rrs513, rpsL43, embB306 and katG315. Except for position rrs513, this array
of loci is reported in the literature as the most frequently mutated loci2.lo.21-24.The only
category with a low yield of mutation analysis (31%) was for isolates mono-resistant to
INH. The genotypic method was superior to the phenotypic method in the correct
identification of resistance to R1F, streptomycin and EMS while the phenotypic method
was superior in the correct identification of INH resistance.
An important question in the evaluation of a new diagnostic test is the advantages
and disadvantages as compared to the existing tests. Sensitivity, specificity and
repeatability are important elements in this comparison, besides complexity, labour
intensiveness, and turnaround time for results and cost. The repeatability was excellent
for the genotypic tests while fair to good for the phenotypic tests. Under such
conditions, phenotypic tests will be evaluated as relatively unreliable by the health
professional and repeated several times to ensure correct clinical management while one
can rely on a single positive molecular genetic test. This reduces the total time to
diagnosis of molecular genetic test even further as compared to phenotypic tests. In this
study, resistance would have been detected by molecular genetic tests on an isolate prior
to the phenotypic test in 2% of INH-resistant cases, 17% of Rlf-resistant cases, 29% of
SM-resistant cases and 42% of EMS-resistant cases.
The poorer performance of phenotypic tests could serve as an explanation for the
discrepancy between the acquisition of phenotypical resistance during therapy (25
cases) compared to the acquisition of an additional mutation (8 cases). This speculation
is supported by the fact that 88% of patients acquiring an additional mutation while on
treatment were non-compliant compared to only 46% of non-compliance among
patients who phenotypically acquired additional resistance.
The specificity of both methods was high for RlF, SM and EMS. The specificity
tor INH-resistance could not be interpreted because of the extremely high prevalence
(90%) of INH-resistance in the population studied. The sensitivity (detection of true
drug resistance) of the molecular genetic test was superior to the phenotypic test for
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detection of resistance to RIF, SM and EMB while the sensitivity of the phenotypic test
was superior for detection of INH resistance.
There remain, however, major limitations to the molecular genetic detection of drug
resistance'. (i) Molecular genetic tests only detect the mutations that are screened for
while phenotypic test detects resistance independent of the underlying mechanism. (ii)
Not all mutations conferring resistance to antituberculous drugs are known. This is
especially a problem in the detection of INH resistance and explains the low sensitivity
of the genotypic method for INH-resistance testing. (iii) Only a few mutations
conferring resistance to second-line drugs are known. (iv) The causal relationship
between the presence of a mutation and the occurrence of resistance has been shown for
some mutations, for example codon 315 in the katG gene", but a causal relationship has
not been reported for all mutations currently believed to confer resistance. In our study,
false positive results were obtained with rpoB533, rpoB518, rrs419 and inhA-15,
mutations that are infrequently described. It is possible that these are silent mutations.
Analysis of the rrs491 mutation at our laboratory showed that the rrs491 mutation was
also detected in several pansusceptible isolates. The mutation responsible for a low-
grade resistance to EMB in case 34 was explained by a rare embB306 mutation (ATG to
GTG). Further research should therefore be directed at establishing causal relationships
between specific mutations and drug resistance.
The high sensitivity in combination with rapid diagnosis and high reliability of
genotypic drug-resistance testing are important as it will allow correct patient
management within days of TB diagnosis. The detection of 90 % of cases of MDR- TB
by screening only 3 codons (rpoB531, rpoB526 and katG315), the correct identification
of more then 90% of resistance to RIF, SM and EMB by screening 5 gene loci
(rpoB531, rpoB526, rrs513, rpsL43, embB306) and correct identification of 75 % of
isoniazid resistance by screening for 1 locus (katG315) is promising for the
development of a cost-effective commercial screening test. Although molecular genetic
testing cannot as yet (and probably will never) fully replace the traditional phenotypic
susceptibility tests, a commercialized molecular genetic test for a limited number of
target codons might be a good alternative for a drug-resistance screening test in the
context of a MDR DOTS-plus strategy.
Stellenbosch University http://scholar.sun.ac.za
ACKNOWLEDGEMENTS
The authors would like to thank the, Harry Crossly Foundation, the IAEA (project SAF6/003) and the
D. Collen Research Foundation for financial assistance.
REFERENCES
I. Pablos-Mendez P, Laszlo A, Bustreo F, Binkin N, Cohn DL, Lambregts-van Weezenbeek CSB, Kim
SJ, Chaulet P, Nunn P, Raviglione M. Anti-tuberculosis Drug Resistance in the World. Geneva:
World Health Organization. WHOrrB/97.229. 1997, p 36.
2. Ramasway S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in
Mycobacterium tuberculosis: 1998 update. Tub Lung Dis (1998) 79:3-29.
3. Morris S. Bai GH, Suffys P, Portillo-Gomez L, Fairehok M, Rouse D. Molecular mechanisms of
multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995;
171:954-960.
4. Heym B. Honore N, Truffot Pernot C. et al. Implications of multidrug resistance for the future of
short course chemotherapy of tuberculosis: a molecular study. Lancet 1994:344:293-298.
5. Maher 0, Chaulet P, Spinaci S, Harries A. Treatment of Tuberculosis: Guidelines for National
Programmes, 2nd ed. Geneva: World Health Organization. WHOITB/9.220. 1997, pp 77.
6. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected
problem at the tum of the century. Int J Tuberc Lung Dis 1999; 3:564-581.
7. Farmer P, Kim JY. Community based approaches to the control of multidrug resistant tuberculosis:
introducing "DOTS-plus". BM] 1998; 317:671-674.
8. Telenti A, Imboden P, Marchesi P, Lowrie 0, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T.
Detection of rifampicin mutations in Mycobacterium tuberculosis. Lancet 1993,341 :647-650.
9. Dobner P, Bretzel G, Rusch-Gerdes S, Feldmann K, Rifai M, Lëscher T, Rinder H: Geographic
variation of the predictive values of genomic mutations associated with streptomycin resistance in
Mycobacterium tuberculosis. (1997) 11: 123-126.
10. Pozzi G, Meloni M, lona E, Orru G, Thoresen OF, Ricci ML, Oggioni MR, Fattorini L, Orefici G.
rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J Clin
Microbiol. 1999; 37:1197-1199.
II. Van Rie A, Warren RM. Beyers N, Gie RP, Classen CN. Richardson M, Sampson SL, van Heiden
PD. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain among
non institutionalized, human immunodefieciency virus-seronegative patients. J Infect Dis 1999;
180:1174-1179.
100
Stellenbosch University http://scholar.sun.ac.za
101
12. Van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, Beyers N, van Helden PD.
Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med
1999;341:1174-1179.
13. Weyer K, Groenewald P, Zwarenstein M, Lombard CJ. Tuberculosis drug resistance in the Western
Cape. S Afr Med J 1995; 85:499-504.
14. Kleeberg HH, Blacklock Z, Boulahbal HL, Davis HL et al. A simple method of testing drug
susceptibility of Mycobacterium tuberculosis: a report of an international collaborative study. Bull Int
Union Tuberc 1985; 60:147-150.
15. Victor TC, Jordaan AM, Van Rie A, van Der Spuy GD, Richardson M, van Helden PO, Warren R.
Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot
hybridization strategy. Tub Lung Dis 1999; 79:343-348.
16. Van Embden JD, Cave MD, Crawford IT, Eisenach KO, Gicquel B, Hermans P, McAdam R,
Shinnick TM. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting:
Recommendations for a standardized methodology. JC/in Microbiol1993; 31 :406-9.
17. Alland 0, Kalkut GE, Moss AR, Mc Adam RA, Hahn JA, Bosworth W, Drucker E, Bioom BR.
Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and
conventional epidemiologic methods. N Engl J Med 1994; 330: 1710-1716.
18. Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B, Takiff HE, Cole ST. Genotypic
assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at
reference laboratory level. J Clin Microbiol. 1997; 35:719-723.
19. Fleiss JL. In: Statistical methods for rates and proportions, 2nd edition. New York: Wiley, 1981.
20. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant
tuberculosis. Epidemiology and clinical outcome. JAMA 1996; 276: 1229-35.
21. Williams DL, Waguespack C, Eisenach K, Crawford IT, Portaels F, Salfinger M, Nolan CM, Abe C,
Sticht-Groh V, Gillis T. Characterization of rifampin resistance in pathogenic mycobacteria.
Antimierob Agents Chemother. 1994; 38:2380-2386.
22. Martilla HJ, Soini H, Eerola E, Vyshnevskaya E, Vyshnevskiy B, Otten TF, Vasilyef AV, Viljanen
MK. A ser315Thr substitution in KatG is predominant in geneticaly heterogeneous multidrug-
resistant Mycobacterium tuberculosis isolates originating from the St Petersburg area in Russia.
Antimierob Agents Chemother. 1998; 42:2443-2445.
23. Nachamkin I, Kang C, Weinstein MP. Detection of resistance to isoniazid, rifampin, and
streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods. Clin Infect
Dis 1997; 24:894-900.
24. Kapur V, Li LL, Jordanescu S, Hamrick MR, Wanger A, Kreiswirth BN, Musser JM.
Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA
polymerase f3 subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City
and Texas. J Clin Microbiol. 1994; 32:1095-1098.
Stellenbosch University http://scholar.sun.ac.za
25. Cockerill FR. Genetic methods for assessing antimicrobial resistance. Antimierob Agents
Chernother, 1999;43:199-212.
26. Wengenack NL, Ubi JR, St Arnand AL, Tomlinson Al, Benson LM, Naylor S, Klin BC, Cockerill III
FR, Rusnak F. Recombinant Mycobacterium tuberculosis KatG (S315n is a competent catalase-
peroxidase with reduced activity toward Isoniazid. 1 Infect Dis 1997; 176:722-727
102
_j
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 7
Transmission of a multidrug-resistant
Mycobacterium tuberculosis strain resembling
"Strain W" among non-institutional, HIV
seronegative patients
ANNELIES VAN RIEI2, ROBIN M. WARREN3, NULDA BEYERSI, ROBERT P.
GlEI, COLLETTE N. CLASSEN4, MADELEINE RICHARDSON3, SAMANTHA. L.
SAMPSON3, THOMAS C. VICTOR3, PAUL D. VAN HELDEN3
Department of Paediatrics & Child Hea/th; University of Stellenbosch, South
Africa I, Department of Paediatrics, Catholic University Leuven, Belgium', Department
of Medical Biochemistry, University of Stellenbosch', Department of Anthropology and
Sociology, University of Western Cape, South Africa4
Journal oflnfectious Diseases 1999; 180:1608-1615.
Printed by copyright permission
103
Stellenbosch University http://scholar.sun.ac.za
Since 1990, several outbreaks of multidrug-resistant tuberculosis
(MOR-TB) have been described among institutionalised patients
infected with human immunodeficiency virus (HIV). We describe a
community MDR- TB outbreak among HIV-seronegative patients in
Cape Town, South Africa. Isolates were characterised by restriction
length polymorphism (RFLP) analysis and dot-blot hybridisation
analysis of mutations conferring resistance for isoniazid, rifampin,
streptomycin and ethambutol. The outbreak involved 16 patients of
which twelve could be linked epidemiologically. All isolates were
identical on RFLP analysis. In 2 patients, RFLP analysis showed
exogenous reinfection during or after treatment for drug susceptible
tuberculosis. Mutation analysis confirmed the genotypic identity of the
isolates. The infecting strain was genotypically related to strain W,
which was responsible for the majority of MOR-TB outbreaks in New
York City. Transmission of MOR-TB is thus not limited to HIV
seropositive patients in an institutional setting but occurs within a
community.
Transmission of a Multidrug-Resistant Mycobacterium Tuberculosis
Strain Resembling "Strain W" Among Non-Institutional, HIV
Seronegative Patients
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INTRODUCTION
Clinical drug resistance in tuberculosis can be classified as acquired resistance,
when drug-resistant mutants are selected as a result of ineffective treatment, or as
primary resistance, when a patient is infected with a resistant strain. Mutations in the
genome of Mycobacterium tuberculosis that can confer resistance to antituberculous
drugs occur spontaneously, with an estimated frequency of 3.5 x 10-6 for isoniazid and
3.1 x 10-8 for rifampin. Because the chromosomal loci responsible for resistance to
various drugs are not linked, the risk of a double spontaneous mutation is extremely
small: 9 x 10-14 for both isoniazid and rifampin'. Multidrug-resistant tuberculosis
(MDR- TB), defined by the World Health Organization (WHO) as resistance to, at least,
isoniazid and rifampin, will thus occur mainly in circumstances where sequential drug
resistance follows sustained treatment failure.
Reports of nosocomial outbreaks of MDR-TB in institutions such as hospitals'?
and prisons" in the United States, Europe and developing countries' have focused
attention on MDR- TB as a major health issue. More than 80 % of these patients were
seropositive for the human immunodeficiency virus (HIV). Infection and a few cases of
active MOR-TB in health care workers following exposure to patients with MDR-TB9-11
and limited spread of a nosocomial outbreak into a cornmunity'f'':' have also been
reported. But even in these settings, most patients with active MDR- TB were
immunocompromised.
Restriction fragment length polymorphism (RFLP) analysis of M. tuberculosis
strains was used to study the disease dynamics of most MDR-TB outbreaks.3,4,6-8,1O,12,13
This technique not only confirmed transmission between patients with suspected
epidemiological connection but also suggested transmission between patients not
suspected to have epidemiologic links.
The most extensive MOR-TB outbreak reported to date consists of 267 cases
infected with an isolate of M tuberculosis with an RFLP pattern identical or closely
related to strain W . Eighty-six percent of these patients were HIV positive. Seventy
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percent of these patients could be epidemiologically linked, and the locations of
transmission were a hospital (96 %), correctional system (2%) and community (3%).14
An opportunity for these outbreaks seemed to be created by the cohabitation of
infectious MOR-TB patients with highly susceptible immunocompromised patients, in
settings with inadequate infection control procedures. HIV is postulated as the major
factor that amplified, accelerated and characterized MOR-TB outbreaks. I
This report documents the genotypic characterization and spread of a "strain W-
like" multidrug-resistant M. tuberculosis strain in an urban South African community
among noninstitutionalized, HIV -seronegative individuals and challenges the view that
MOR-TB outbreaks only occur in very specific population groups.
MATERIALS AND METHODS
The patients described in this paper were given their diagnose between 1993 and
1997 and resided in 2 neighboring communities of metropolitan Cape Town, South
Africa. This 2.5-km2 area has a population of -34000 people, a reported TB notification
rate> 1000/100,000/yearI5, and -150 M. tuberculosis culture-positive patients/year.
Although the socio-economic living conditions are poor, there is no homelessness and
no evidence of intravenous drug use. During the study period, there was a low
prevalence of HIV infection in the Western Cape Province (ranging from 0.25% in
199216to 3 % in 199617).
Sputum samples were collected at the pnmary health care clinics of the 2
communities studied and were sent to the routine laboratory for staining and culture.
Drug susceptibility testing was done by the indirect proportion method on LOwenstein-
Jensen medium containing critical concentrations of 0.2 ug/rnl, isoniazid, 30 ug/rnl,
rifampin, 2 ug/ml, ethambutol, Sug/ml, streptomycin and 20!lg/mL ethionamide.
Kanamycin and thiacetazone were tested on Middlebrook 7H 10 agar containing critical
concentrations ot: respectively,S and 2 ug/ml.. Resistance was defined as I% bacterial
growth in comparison with a control by use of international criteria. Cultures resistant to
isoniazid or rifampin were subsequently tested for resistance to other antituberculous
drugs. Resistance to pyrazinamide was not tested.
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Since late 1992, as part of a prospective study, positive cultures for M. tuberculosis
from patients residing in these communities were genotyped by RFLP analysis (lS6J 10)
according to the standardized method" and analyzed using Gel Compar 4.0 software
(Applied Maths BVBA, Kortrijk, Belgium). This study has had a recovery rate of ~70%
of positive cultures and resulted in an RFLP database consisting of 650 patients. Cluster
analysis (using the Dice coefficient and an unweighted pair group method [UPGMA]
clustering formulaj'" was applied to identify possible clusters of transmission. Since late
1992, 107 clusters of drug-sensitive isolates (average cluster size, 4.7; range, 2-47) and
6 clusters of drug-resistant isolates (cluster size ranging from 2 to 16) have been
identified. These data were then combined with a standardized set of clinical data (date
of birth, sex, history of previous TB treatment and drug sensitivity).
A cluster of identical isolates (19 IS6110 insertion elements) was subjected to
further genotyping as follows: genomic DNA was restricted with Pvull and Hinfl,
electrophoretically fractionated and transferred to Hybond-N (Amersham, UK). The
Pvull digests were sequentially hybridized with enhanced chemoluminescence-Iabeled
IS6110-3' probe (complementary to the IS6110 domain between nucleotides 631 and
875), IS6110-5' probe (complementary to the 5' IS6110 domain between nucleotides 77
and 462), 32P-Iabelled DRr probe and ISL540 (GenBank accession number U60566).
The HinjI digests were hybridized with 32P-Iabelled MTB484(1) probe/". The respective
RFLP patterns were visualized by autoradiography.
This cluster of isolates was analyzed for the following mutations: katG315
conferring isoniazid resistance and the silent mutation katG463; rpoB526 and rpoB531
conferring rifampin resistance; rpsL43, rpsL88, rrs513 and rrs491 conferring
streptomycin resistance and embB306 conferring ethambutol resistance. Mutational
analysis was done by polymerase chain reaction amplification of extracted DNA with
specific primers and dot-blot hybridization for the different loci with a radiolabelled
probe specific for each of the mutations 21.
Extensive clinical histories of patients infected with a strain with 19 IS6110
copies were reviewed and detailed data concerning medical history, HIV status,
previous TB treatment, type of TB, chest radiography, sputum staining and cultures,
sensitivity and treatment were collected. Patients were interviewed in detail by a
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medical anthropologist for completion of data regarding place of work, school,
recreation, focussing on drinking places, church attendance and treatment supervisor.
To maintain patients' confidentiality, other patients' names were never mentioned. To
further enhance the elicitation of epidemiologic links, patients were asked for the names
of their social contacts in certain streets .
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Figure 1.Autoradiograph of RFLP patterns (IS6}) 0 3') of Mycobacterium tuberculosis isolated
from case patients.
Lane R, MTB 14323 (reference strain)"; Lanes 1·16, patients infected with M. tuberculosis strain U;
Lane 17, patient infected with a M. tuberculosis strain closely related to strain U.
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RESULTS
From the strains collected between January 1993 and March 1997,21 patients were
identified with isolates resistant to at least 4 front-line drugs (isoniazid, rifampin,
streptomycin, ethambutol). In 16 of these patients, genotype identity of the infecting M
tuberculosis strain was shown by standardized IS6110 typing (fig 1). These isolates had
19 copies ofIS6110 and were arbitrarily called strain U. For 12 patients, > 1 isolate with
a U-strain pattern on RFLP analysis was available. All 4 remaining patients had clinical
evidence of active TB and multiple positive cultures with similar resistance patterns.
There was thus no evidence of laboratory cross-contaminatiorr". One additional patient
was infected with a M tuberculosis strain closely related to strain U (similarity index of
79% [IS6110-3'] by use of the Dice coefficient and UPGMA clustering formula; figure
1). The other 4 patients with isolates resistant to the 4 front-line drugs, were infected
with an isolate characterized by 5, 7, 10 and 12 copies, respectively, of IS6110. During
the entire prospective study period (late 1992-mid 1998) no samples with strain U were
recovered from 585 patients with drug-sensitive tuberculosis.
All 16 patients infected with strain U had pulmonary MDR- TB, 94% had smear-
positive TB and 80% had cavities on chest radiograph at the time of diagnosis. Nine
patients were female, 7 were male. The average age at diagnosis of MDR-TB was 28
years (range, 11-50; figure 2). All 16 patients were seronegative for HIVand none had a
malignancy or received steroid therapy, which could lead to immunosuppression. None
of the patients had been hospitalized for TB treatment or other respiratory diseases prior
to the diagnosis ofMDR-TB. All patients were treated at the primary health care clinics
of the 2 communities; 13 patients also recieved treatment as inpatients for a median
duration of 107 days at a hospital that specialized in TB treatment. All but 1 patient
were treated with 4 drugs to which the organism was susceptible (i.e., appropriate
treatment). On average, the median time between diagnosis and initiation of appropriate
treatment was 94 days (range, 0-555 days). Ten of the 16 patients were compliant
(>80% of prescribed dosages). Only 13 patients achieved bacterial conversion. The
median time patients were sputum positive was 238 days (range, 35-1102 days).
Patients who achieved bacterial conversion were treated for a median duration of 380
days (range, 121-63 7 days) after conversion.
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1· m housemate of 'index case'
2 m brother of patient 1
3 m friend of sister of patient 1
4· f of patient 5 and 6
5· m of patient 4 and 6
6 f of patient 4 and 5
7 m interview (died) .
8· f of patient 1
9 f daughter of patient 8
10· m of patient 1. 2 and 8
11· f cousin of patient 4, 5 and 6
12· f no interview (moved)
13 f no epidemiological link
14· no epidemiological link
15· cousin of 'index case'
16 friend of 8
• initial isolate available for mutation analysis
_ resistance detected by conventional susceptibility testing on initial isolate
illllI1 additional resistance detected by mutation analysis only on initial isolate
1;'#::.01 additional resistance detected by conventional susceptibility testing on follow-up
isolate
~ additional resistance only detected by mutation analysis only on fOIlOW'UPIsolate
Figure 2 Patient characteristics and resistance pattern of strain U M. tuberculosis isolates.
m = male; f= female; DR-TB = drug resistant tuberculosis, !NH = isoniazid; RIF = rifampin;
SM = streptomycin; EMB = ethambutol; TRIA = thiacetazone; ETH = ethionamide
RFLP analysis by use of the IS6110-3' probe (figure 1) and IS6110-5' probe
(data not shown) showed that all 16 samples representing the infecting strain of each
patient had an identical pattern of 19 IS elements. In addition to IS61 10,2 additional M.
tuberculosis subtyping probes, ORr and MTB484( I), confirmed that the genotypes were
identical for all 16 isolates (data not shown). Comparison of the IS6110-3' and IS6110-
5' RFLP analysis of strain W22 and strain U suggested that strain U may be genetically
related to strain W (figure 3). The similarity index calculated by using the Dice
coefficient and UPGMA clustering formula was 81.1% (IS6110-3') and 78.9% (IS6110-
5'). To test further for similarity, a genomic sequence (ISL540.3) present in H37Rv and
most clinical isolates but absent in all strain U isolates, was hybridized against DNA of
strain W (961-0874). No hybridization was detected suggesting a common ancestry
(data not shown).
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DNA from the initial isolate of the MDR- TB
episode was available for mutational analysis in 9 cases.
In all of these isolates, the following mutations could be
demonstrated: katG315, katG463, rpoB531, rrs513 and
embB306, conferring for resistance to, respectively,
isoniazid, rifampin, streptomycin and ethambutol. No
mutations were identified in the rpoB526, rpsL43,
rpsL88 loci or in rrs491 position. In 6 of the 7 patients
from whom no initial isolate was available, analysis of a
follow-up isolate revealed identical mutations (figure 2).
This result confirms the identical genotype of the isolates
as suggested by RFLP analysis. Mutation analysis of the
strain closely related to strain U revealed identical
mutations responsible for resistance to isoniazid and
ethambutol but different mutations for rifampin
(rpoB526) and streptomycin (rpsL43).
Initially, the outbreak propagated rapidly with 8
cases in 1 year. Thereafter, the spread continued at a
slower rate, with 8 new cases over the following 3 years
(figure 4). Figure 4 might suggest a single chain of
transmission; however, conventional contact tracing
refutes this. Of the 14 patients who could be interviewed,
there were only 2 patients who had no apparent
epidemiologic link with any of the other patients. Among
the 12 patients with social links, there was 1 group
consisting of 8 people who were either relatives or
friends and another group of 4 people who were close or
distant family. No relation between these 2 groups could
be found (figure 2);
Figure 3. Southern blot
comparison ofM tuberculosis
hybridized with A, IS6110-3'
(IS6110 nucleotides 631-875)
and B, IS6110-5' (lS6110
nucleotides 77-462). Lane R,
MTB 14323; lane 1, strain W
(961-0874); lane2, strain U
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Social anthropology data suggest that patient 1 was most likely infected by a
close friend, an HIV-seronegative MDR-TB patient resistant to isoniazid, rifampin and
ethambutol who was culture-positive> 1 year prior to his death in May 1993. As this
person lived outside the communities studied, his M. tuberculosis isolates were not
available for RFLP or mutational analysis. Because this person was infectious for such a
prolonged period of time, it is possible that ha was the source case for > I of the 8
related patients. As this study was performed in 2 communities with a high population
density (14,500 people/km'), casual or unrecognized contact is a likely explanation for
the patients with no apparent epidemiologic link. Moreover, all residents attend the
primary health care clinic as a first line for all health problems, which makes the clinic
itself another possible contact place.
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Figure 4 Schematic representation of a multidrug-resistant tuberculosis outbreak, caused by
strain u, in 16 patients residing in a south african community.
Horizontal bars denote duration of treatment for: solid box, multi drug-resistant tuberculosis;
open box, drug susceptible tuberculosis; diagonal shading, culture positive tuberculosis, drug
susceptibility not tested.
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The majority of patients (11116) received antituberculous treatment prior to the
diagnosis of MOR-TB. Four patients received an average of 5 months of treatment
before drug-sensitivity tests were requested. Seven patients received a prior course of
treatment for an episode of TB, predating the MDR-TB episode by an average of 3
years. In 2 cases, DNA was available from a specimen obtained prior to the diagnosis of
MDR- TB. Patient 3 received treatment for culture-proven TB three months before
diagnosis of MOR-TB. These bacilli were sensitive to all drugs and had an RFLP
pattern of 15 IS6110 elements not related to the strain responsible for the MDR-TB
episode (similarity index of 33% as calculated by use of the Dice coefficient and
UPGMA clustering formula). Patient 16 received a full treatment course for drug-
sensitive TB 3 years before diagnosis ofMDR-TB, the isolate was then characterized by
9 IS6110 elements on RFLP analysis, again not related to the strain responsible for the
MOR-TB episode (similarity index of 27% [data not shown]). Both patients were
compliant during the treatment for drug-sensitive TB as judged on the basis of
attendance of directly observed treatment (taking >80% of prescribed dosages).
DISCUSSION
As far as could be ascertained, this is the first report of an MDR-TB outbreak
occurring in a community without the involvement of a single HIV -seropositive or
institutionalized patient and where transmission was proved by modern molecular
biology techniques, such as RFLP and mutation analysis.
In the pre-AIDS era, outbreaks of MOR-TB were occasionally reported.v': 24 Such
outbreaks were characterized by a slow spread over a number of years and a limited
number of patients. Only 1 of these outbreaks reported before 1990 involved cases
resistant to both isoniazid and rifampin, the current WHO definition of MDR-TB25.
Suspected epidemiological links could only be confirmed by phage typing 26.27, a far less
precise technique than RFLP analysis. The rare occurrence of outbreaks of drug-
resistant TB was ascribed to the conviction that drug-resistant M. tuberculosis strains
are less virulent.f However, recent studies demonstrated that drug-resistant strains do
not differ from drug-sensitive strains in their ability to create infection or disease.29•3o
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This report of a cluster of 16 MOR-TB patients confirms that drug-resistant strains of
M. tuberculosis can be transmitted, and not only to the immunocompromised host.
In 1990, the first outbreak of MDR-TB involving lO epidemiologically related,
noninstitutionalized, HIV-seronegative cases was reported by the Centres for Disease
Control and Prevention of the United stares." However, drug resistance was proven in
only 8 of the 10 cases, the initial resistance pattern was the same in only 2 of the cases
and no further analysis (phage typing or genotyping) was performed to establish
whether all cases were part of a chain of transmission caused by I specific strain.
The results of our study indicate that a difference in resistance pattern on
conventional susceptibility testing of the initial isolate does not exclude recent
transmission. The resistance pattern of initial isolates showed resistance to isoniazid,
rifampin, streptomycin and ethambutol in only 6 of the 16 patients. In 3 of these and 6
other patients, the initial isolate was available and mutational analysis showed the
presence of the same 5 mutations conferring resistance to all 4 drugs, even if
conventional methods reported the isolates as susceptible to 1 of those 4 drugs. This
problem, and the fact that susceptibility testing is not routinely performed, are factors
that lead to suboptimal treatment of patients with primary MDR-TB. This can in turn
cause prolonged infectivity and further transmission within the community. Efficient
molecular procedures such as described in this study could therefore be valuable in the
quick diagnosis and prevention of spread ofMDR M. tuberculosis strains.
Our study also indicates that history of previous treatment is another clinical
parameter that by itsel f cannot be the sole factor to reject the possibility of recent
transmission of MDR-TB. It was believed that exogeneous reinfection was rare because
of the possibility of protective immunity acquired after a first infection. A person with
drug-resistant TB and a history of a previous TB episode was therefore classified as
having acquired drug-resistant TB. There have been a few reports of exogenous
reinfection in immunocompromized patientslJ,32,33 and I report of exogenous reinfection
in an immunocompetent patient. 34 Eleven of the 16 immunocompetent patients reported
in our study had a history of previous treatment. In 2 patients, RFLP analysis of both the
drug-sensitive and drug-resistant isolate could be performed. This showed that in both
these patients the 2 TB episodes were caused by two different, unrelated strains, thereby
114 J
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proving exogenous reinfection during treatment (patient 3) or after completion of a
previous treatment episode (patient 16). The presence of 5 identical mutations in genes
conferring resistance to antituberculous drugs (katG315, katG463, rpoB531, rrs513 and
emB306) in all patients also supports transmission rather than acquisition as the
mechanism responsible for drug-resistant TB in these patients.
MDR-TB outbreaks became an established phenomenon as hundreds of cases were
reported world-wide and transmission between cases was proven by molecular
epidemiologic techniques.i" These outbreaks were characterized by rapid spread,
accelerated progression from infection to disease and high mortality rates. The
overwhelming majority of the patients were HIV seropositive and/or institutionalized
(hospitals, prisons). The characteristics of the outbreak described in this report are very
different from the above. This outbreak propagated over a number of years, the
mortality rate was low (12%), patients were HIV seronegative, and transmission
occurred in the community. However, strain W (New York) and the "strain W-like"
strain U (Cape Town) were responsible for >80% of cases resistant to at least 4 drugs,
respectively, in New York City and the 2 Cape Town communities. Because these 2
strains are not identical, as shown by a related but non-identical RFLP pattern and a
difference in the mutation conferring resistance to streptomycin (rpsL43 in strain W and
rrs513 in strain U), strain U cannot be the result of a recent transcontinental spread of
strain W. These 2 genomically-related strains thus independently arose in 2 different
geographic locations and in 2 very different patient groups suggesting that this M
tuberculosis strain family is prone to the development of mutations conferring
resistance.
Based on the finding that >95 % of 267 cases of MDR-TB caused by outbreaks of
the strain W in the United States over a 3-year period were likely to have been
nosocomial infections, it was suggested that transmission of MOR-TB was almost
exclusively confined to institutional settings, with no significant spread beyond the
walls of institutions.l" This would imply that attention can be focused on hospitals
serving at-risk populations as a unique locus of transmission of MOR-TB35. The
outbreak described in this report challenges this idea. A community can be the location
of rapid spread of MOR-TB even if there is a low prevalence of HIVand no
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homelessness or intravenous drug use. A factor that could have contributed to the extent
of this outbreak is the prolonged period of infectiousness in these patients. This study
describes an outbreak in an area with a high incidence of TB, where the priority is the
application of direct observed therapy short course (DOTS) to treat all smear-positive
(drug-sensitive) cases effectively to reduce the infectious pool and prevent the
acquisition of drug resistance. The DOTS program for low-income countries does not
require sensitivity testing on a routine basis and gives no priority to effective
personalized treatment for patients with MOR-TB. This results in delayed diagnosis and
a delay in initiation of effective MDR- TB treatment, leaving patients infectious for a
prolonged period. Transmission of MDR-TB to nonimmunocompromised individuals
creates a reservoir of persons infected with an MOR-TB strain, an infection for which
there is currently no efficient disease-prevention strategy. To prevent an outbreak of
MOR-TB, as well as the creation of a pool of persons infected with MOR-TB strains
within a community, prevention of transmission of multidrug-resistant bacilli should be
targeted by adequate case investigation (including contact investigation), rapid and
correct diagnosis of drug resistance and adequate treatment of patients with MDR- TB.
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CHAPTER8
The use of a Geographic Information
System to study the epidemiology of
drug-resistant tuberculosis
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The use of a geographic information system (GIS) to study the
epidemiology of drug-resistant tuberculosis
Background: A GIS has been shown to be a powerful tool in
epidemiologic and public health studies, especiaUy of infectious
diseases. The aim of this study was to use a GIS in combination with
molecular epidemiological data to study the socio-economic risk factors
for occurrence and transmission of drug-resistant tuberculosis. Setting:
Fifty-nine patients with drug-resistant TB residing in two South
African communities, characterized by a high TB notification rate,
were studied. Results: According to molecular epidemiological analysis,
29 patients were classified as cases of transmitted drug-resistant TB.
Cases infected with an identical drug-resistant Mycobacterium
tuberculosis isolate (cluster) were spatiaUy aggregated within the
community. The geographic distribution of occurrence and
transmission drug-resistant TB was correlated with the geographic
distribution of TB incidence. There was also a correlation between the
occurrence and transmission of drug-resistant TB and poor socio-
economic conditions. Conclusion: Drug-resistant TB and its
transmission occur in geographically distinct areas of poor socio-
economic conditions and high TB incidence.
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INTRODUCTION
The historical roots of epidemiology lie with Hippocrates who, in 400 BC,
introduced the term "epidemeion" as "diseases that visit the community". Modem
epidemiology is the quantitative study of the distribution and determinants of disease in
human populations. John Snow's study in the 1850's of a cholera outbreak in London is
the first good example of an observational study integrating geography into medical
research. By referring to maps of two water-providing companies and to the 1851
census figures, Snow was able to examine the relationship between the number of
cholera deaths and the number of people living in specific areas'. The power of these
observations led to the hypothesis of the water-borne mode of cholera transmission.
Geographic Information Systems (GIS) emerged in the 1980s as an innovative
component in the field of epidemiology and public health. GIS allows a spatial
perspective on disease by analysing associations between location, environment and
disease on international, national and local levee. GIS has been used in the
identification of locations of high disease prevalence (onchocerciasis'), the analysis of
disease transmission (malaria"), the study of environmental risk factors (Lyme disease"),
in disease surveillance (malaria"), the identification of space-time (leukemia'), the
visualisation of temporal patterns of disease spread (AIDS8) and in health policy
planning (drancunculiasis"). These examples indicate that GIS can be used to identify
problems, produce hypotheses and develop strategies for control of infectious diseases.
GIS has been also used in studies of tuberculosis. A study in South Africa
investigated spatial implications of the DOTS strategy and demonstrated an important
impact of community health workers on access to treatment'". Another South African
study, by the TB research group of the University of Stellenbosch, evaluated the
distribution of tuberculosis within one high incidence community ov.er a lO-year period
and demonstrated that cases were unevenly distributed". A study in Baltimore, USA,
combined a GIS with traditional and molecular epidemiology to study the patterns of
tuberculosis transmission. Results demonstrated that recently transmitted TB cases
occurred in geographically distinct areas of low socio-economic status and high drug
abusc'".
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A GIS was used by myself and others in studies on risk factors for childhood
tuberculosis which could show a relation between crowding, poor socio-economic
factors and the incidence ofTB in children 12.13.
In this study, we made use of a the combination of a GIS with molecular
epidemiological data to study the role of socio-economic risk factors in the occurrence
and the transmission of drug-resistant TB in an area characterized by a high TB
incidence.
MATERIALS AND METHODS
Setting
The study area consists of two communities of Cape Town, South Africa with a
total surface area of 2.42 km2 and a population of 34.294 (1991 census). During the
apartheid era in South Africa, this area was created as a residential area for Coloured
people. J n 1991, 99.7% of the residents were of the coloured ethnic group. The
population increased explosively from the I960s to 1980s and stabilised thereafter. It is
an area with characteristics of rapid urbanisation in a developing country. The
population pyramid has a broad base (birth rate of 29.3/1 000 population) and a narrow
top. Housing varies from freestanding brick houses to one-room flats and rickety
backyard shacks. Living conditions have improved over the last years. Sewage,
electricity and running water is now available for all residents. Two primary health care
clinics and an adjacent tertiary hospital serve the area. During the study period, the
national TB program required the notification of all new cases of active TB and
treatment under supervision at the local health authority clinic. The TB case notification
rate in these two suburbs is reported as more than 1000/100 00011• Within the area,
socio-economic conditions are related to the TB notification rates. The area with the
highest case noti fication rate in children aged 0 to 5 years of age (14062/100 OOO/year)
had a high level of crowding (1.5 adults per room), a low mean annual household
income (4450 Rand) and a low level of parental education (6 years of schoolingj'f,
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Geographic information system
Different sets of data were integrated to study the disease dynamics of drug-
resistant TB. The TB notification rate for the adult population was calculated for each
enumerator subdistrict (ESD) by linking the 1991 population census data (most recent
available census data), 1991 notification data and geographically mapped home
addresses of all patients notified as cases of active TB. The 1991 population census data
divide the two suburbs into 39 ESD's with an average population of 900 people
(minimum 627 and maximum 1 267). The notification data provided the name, address,
age and type of TB of each notified case. All duplicate notifications and previously
treated patients were eliminated to avoid inaccuracies. The home addresses of patients
with drug-resistant tuberculosis identified between 1 April 1992 and 31 March 1997
were subsequently geographically mapped using the computer based GIS (ARC-
INFO®). The distribution of adult TB notification rates of the ESD where patients with
drug-resistant TB reside could then be evaluated. The correlation between the frequency
of different types of drug-resistant TB as determined by Restriction Fragment Length
Polymorphism (RFLP) analysis and the adult tuberculosis notification rate in the two
communities was also studied.
The 1991 census report provides for each ESD demographic variables such as age
and sex, social variables such as number of households, education, type of housing and
economic variables such as employment and annual income per capita. From this data,
we calculated one value for each ESD for crowding, economic status and education
level. Crowding was calculated as the average number of adults (> 15 years of age) per
room (sleeping and living rooms). Economic status was calculated as the average annual
household income. Education level was calculated as the percentage of adults (> 15
years of age) who had completed primary school education. The distribution of
crowding, schooling and economic status among patients with drug-resistant
tuberculosis and different subgroups of drug-resistant tuberculosis were then evaluated.
RFLP analysis
Mycobacterium tuberculosis isolates from patients with drug-resistant tuberculosis
were genotyped by Restriction Fragment Length Polymorphism'<. Cluster
Stellenbosch University http://scholar.sun.ac.za
RAVENSMEAD AND UITSIG:
Drug Resistant TB cases
N
A
TB NOTIFICATION RATE IN ADULTS PERESO
• Transmitted
• other
CJLOW
CJ Medium- low
CJ Medium
CJ Medium- hlgt
"High
~O 150 0 ~O 600 !{JO 1,200
Meters---- ~--- -- --
Figure I, Geographic distribution of cases with drug-resistant tuberculosis. Low TB notification
rate represents areas with a TB notification rate < 6001100 OOO/year,High TB notification rate
represents areas wait a TB notification rate> 2000/100 OOO/year.
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analysis was done by using the Dice coefficient and UPGMA clustering formula. To
enhance the accuracy, clusters of identical drug-resistant isolates identified by IS6110-3'
were subjected to further genotyping with secondary probes (IS6110-5', MTB484(1)
and DRr)I6. Isolates were classified as clustered or unique, depending on respectively
the presence or absence of isolates with identical drug-resistant M tuberculosis strains
retrieved from patients in the studied communities. According to the formula suggested
by Small et aI, all clustered cases except for the index case of each cluster were
classified as cases of transmitted TBI7.
Statistics
Analysis was performed using the non-parametric Mann-Whitney U test.
RESULTS
During the study period (1 April 1992 to 31 March 1997), 70 patients were treated
for drug-resistant TB at the primary health care clinics of the two studied communities.
In 63 of them, DNA of the infecting M tuberculosis was available for RFbP analysis.
Of these, 4 patients resided in the study communities but outside the area covered by the
1991 census report of the communities (figure 1). The remaining 59 patients constitute
the cases of drug-resistant TB used for the geographical distribution analysis. The
control group consists of the 1991 population divided into 39 enumerator subdistricts.
According to RFLP analysis, 23 cases were infected with a unique strain while 36
cases were infected with an isolate belonging to one of 6 clusters of drug-resistant M.
tuberculosis strains. Thirty cases were classified as transmitted drug-resistant TB, 29
cases were classified as other drug-resistant TB (23 infected with a unique strain and 6
index cases of a cluster).
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Figure 2, Geographic distribution of patients infected with clustered strains
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Geographic distribution of cases of drug-resistant tuberculosis.
All cases of drug-resistant tuberculosis were geographically mapped (figure 1). At
least one case occurred in 31 of the 39 ESDs. There was a trend of a higher frequency of
drug-resistant TB cases with an increasing TB incidence of the ESD. The number of
drug-resistant TB cases per ESD ranged from 1.12 cases per ESD for ESDs with a
"low" TB notification rate to 2.28 cases per ESD for ESDs with a high TB notification
rate. The distribution of the TB notification rate among the ESDs in which cases
(patients with drug-resistant TB) and controls (population divided into 39 ESDs) resided
was compared (table 1). The average TB notification rate per ESD was higher for the
case group (1339/100 OOO/year)than for the control group (1085/100 OOO/year)but this
was not significant (p = 0.24) (table 1).
Table 1: Average value (and standard deviation) of adult TB notification rate, social
and economic risk factors of ESDs with-drug-resistant TB cases and the population of
the communities
ESDs with Total p value
drug-resistant population
TB cases
TB notification rate 1339 (887) 1085 (764) 0.24
(per 100 000 per year)
Schooling 71.5 (11.7) 76.2 (10.7) 0.042
(% completion of primary schooling)
Crowding 1.45 (0.29) 1.32 (0.3) 0.02
(adults per room)
Economic status 19831 (7435) 0.057
(Annual household income in Rand) 16396 (8017)
Cases of drug-resistant tuberculosis were classified and geographically mapped
according to the RFLP category of the infecting isolate (figure 1). The majority of
transmitted cases were grouped in the southern part of the area, where the TB
notification rate is the highest (figure 1). The average TB notification rate of the ESDs
where cases with transmitted drug-resistant TB reside was 1525/100 OOO/year.This was
substantially higher but not significantly different (p = 0.285) from the average TB
notification rate for the ESDs where other cases of drug-resistant TB reside
(1147/100000/year). (table 2).
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ESDs with ESDs with
Transmitted Other p value
drug-resistant drug-resistant
TB cases TB cases
TB notification rate 1525 (1015) 1147 (689) 0.285
(per 100 000 per year)
Schooling 69.5 (12.7) 73.6 (10.3) 0.22
(% completion of primary schooling)
Crowding 1.50 (0.3) 1.40 (0.27) 0.18
(adults per room)
Economic status 19152 (7439) 0.013
(Annual household income in Rand) 13732 (7757)
All patients infected with a M. tuberculosis bacillus that belonged to a cluster of
drug-resistant isolates were also mapped with a specific code for each cluster (figure 2).
On average, 80 % (range 67 - 100 %) of cases within each cluster resided within 600
meters of each other (figure 2).
Table 2: Average value (and standard deviation) of adult TB notification rate, social
and economic risk factors of ESDs with cases of transmitted and other types of drug-
resistant TB
Socio-economic risk factors for drug-resistant tuberculosis
Socio-economic risk factors for TB, such as crowding, level of schooling and
economic status, were compared between the ESDs in which cases resided and the 39
ESDs in which the population of the two communities resides. The average socio-
economic status was poorer for the ESDs in which the cases reside as compared to the
average socio-economic status of the population (table 1). The difference was
significant for schooling (p =0.042) and crowding (p = 0.02) but not for economic status
(p = 0.057).
Socio-economic risk factors for transmission of drug-resistant tuberculosis
Socio-economic risk factors were evaluated to determine factors influencing the
transmission of drug-resistant TB. The distribution of crowding, schooling and
economic status (annual household income) of the ESDs in which cases of transmitted
drug-resistant TB reside were compared with the ESDs in which other cases of drug-
resistant TB reside. There was a trend towards lower socio-economic conditions in tbe
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group of transmitted drug-resistant TB cases compared with the other cases (table 2).
The average percentage of adults completing primary schooling was 69.5% for ESDs
where cases with transmitted drug-resistant TB reside and 73.6% for the ESDs where
other cases of drug-resistant TB reside. There was only a minor difference in crowding
for both groups: 1.76 and 1.74 adults per room for the transmitted and other group
respectively. The difference in annual household income between the two groups was
striking: 13732 Rand in the transmitted group compared to 19152 Rand in the other
group. This trend of lower socio-economic status among cases with transmitted drug-
resistant TB was significant only for economic status (p = 0.013).
DISCUSSION
Tuberculosis is not uniformly distributed throughout the world, within one country
or between different population groups. Even within one community, there can be vast
differences in disease incidencell. It is necessary to understand trends of disease
frequency, demographic characteristics and geographic distribution of drug-resistant TB
in a defined area, in order to design effective programs for disease control through
measures assuring that acquisition and transmission of drug-resistant TB is stopped. The
goal of the evaluation of the disease dynamics of drug-resistant TB by the use of a GIS
was to determine the risk factors for the occurrence and transmission of drug-resistant
TB.
In this study, we found that 80% of cases within each of the 6 clusters of identical
drug-resistant strains resided within 600 m of another case of the same cluster.
Furthermore, clusters occurred in geographically distinct areas within the community.
This supports the generally accepted assumption that isolates with identical RFLP
fingerprints are epidemiologically linked and belong to a chain of transmission. Drug-
resistant TB cases, especially cases of transmitted drug-resistant TB, were concentrated
in the areas with the highest TB incidences. The occurrence and frequency of
transmission of drug-resistant TB thus correlated with the overall TB incidence. This is
not surprising, as the chance of more cases developing drug resistance will be higher in
areas where there is more TB. Once drug-resistant TB is present in a specific area,
transmission occurs and even more cases of drug-resistant TB will be produced.
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Another finding was the association between drug-resistant TB and lower socio-
economic living conditions such as housing, schooling and income. The observed trend
was more pronounced for the occurrence than for the transmission of drug-resistant TB.
The association between poverty and health is well documented. Specifically for TB,
socio-economic status appears to be closely related to disease rates. Areas with a high
proportion of people who are poorly educated, poorly paid or poorly housed have high
TB rates'". It was surprising that crowding was not associated with transmission of
drug-resistant tuberculosis in our study. This may have been the result of low case
numbers resulting in insufficient statistical power.
Because TB has a long incubation period and only approximately 10% of infected
individuals progress to active disease, tbe disease dynamics are best understood by
looking at the pathogenesis in the two stages of infection and active disease. The
relationship between low socio-economic living conditions and risk of infection is clear,
but little is known about the relationship between socio-economic conditions and risk of
disease among infected individuals. What leads to a high probability of infection may
have little to do with the probability that disease will develop later. This study, based on
DNA fingerprinting results, could only investigate the individuals that progress to
disease but missed all the infected individuals that remain disease-free. This might be
another reason why it is difficult to obtain a significant relation between socio-economic
factors and risk of transmission of drug-resistant TB.
A further problem with the study is a problem common to all ecological studies: the
ecological fallacy. Even if the ESDs are relatively small and demographically rather
homogenous, as in this study (average of 900 people per ESD), not all individuals have
demographic characteristics equal to the mean value of the ESD in which they reside.
Group (ESD) based mean values of demographic factors may thus erroneously have
been assigned to individuals within the group.
Even though this study has intrinsic problems and can therefore not lead to
certainties but only to probabilities and trends, it is the first study we are aware of which
uses a GIS to examine the relationship between socio-economic factors and the
Occurrence and transmission of drug-resistant tuberculosis. We found that both the
Occurrence and transmission of drug-resistant tuberculosis show a trend of increased
130
Stellenbosch University http://scholar.sun.ac.za
131
frequency with lower socio-economic living conditions and with increases in overall TB
incidence. A prospective study, collecting data on individual socio-economic conditions
of cases with drug-resistant TB will be important to confirm or reject the trends
observed by this study.
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Outcome of multidrug-resistant tuberculosis in a South African
community
Multidrug resistant tuberculosis (MDR- TB) is characterized by a low
cure rate and high mortality rate, which can be improved by
appropriate treatment. Data on outcome of MDR- TB in low and
middle-income countries is scarce. We present a population-based study
of 42 MDR-TB patients residing in two South African communities. All
patients tested (95%) were HIV seronegative. Forty-one patients had
cavitary TB and 88% were smear positive. M. tuberculosis was resistant
to a mean of 4.2 drugs. Virtually all (98%) patients received
appropriate treatment with ~ 3 drugs, however after a long delay (2.8
months) after diagnosis. Thirty (71%) patients were hospitalized in a
specialized MDR- TB treatment unit. Patients were followed-up for a
median of 4.2 years after diagnosis. By the end of treatment, 20% of
patients had died, 42% were cured and 38% had defaulted. The overall
rate of bacterial conversion was 74%, 2-year survival rate was 90% and
S-year survival rate 71% (Kaplan-Meier analysis). Bacterial conversion
was significantly associated with survival (p=O.OOOOI).Compliance with
therapy was associated with survival and bacteriological conversion
(p=O.OIl and p= 0.0016). The results suggest that an individualised
approach and the availability of a specialized MDR-TB treatment unit
can improve the outcome of MOR-TB.
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INTRODUCTION
Multidrug-resistant tuberculosis (MOR-TB), defined as resistance to at least
isoniazid and rifampin, is a worldwide problem posing a threat to global TB control.
Previous studies have found that patients with TB resistant to rifampin and especially
patients with MOR-TB are less likely to benefit from treatment than those infected with
drug susceptible organisms'>'. Patients infected with MDR strains are not only difficult
to cure and more costly to treat", but are also more likely to remain sources of infection
for a longer period of time resulting in exposure to other persons and outbreaks of
MOR-TBs.
Investigations of outbreaks of human immunodeficiency virus (HIV)-related MDR-
TB have found a strikingly high case fatality rate3,6,7. The outcome of HIV seronegative
patients with MDR- TB is substantially better when optimal therapy is provided, but still
poor compared to patients with drug susceptible TB8-IO• Most studies on the outcome of
MDR-TB are investigations performed in high-income countries and are hospital
based8-11• Data on the outcome of MDR- TB in middle and low-income countries, where
most MDR-TB patients reside, is scarce 12,13.
We present a population-based study involving two neighbouring communities of a
middle-income country where, during a 5-year period, 42 patients (of whom 40 were
HIV seronegative) received treatment for MDR-TB. Demographic, clinical and
treatment characteristics are presented, long term clinical and bacteriological outcome
are evaluated and factors influencing the outcome are analyzed.
MATERIALS AND METHODS
Setting and study population
The area studied consists of two neighbouring Cape Town Metropolitan
communities (Ravensmead and Uitsig) with a total rsidential surface area of 2.42 km2
and a population of 34,294 of the Coloured ethnic group living in poor socio-economic
conditions. The incidence of new (never previously treated) bacteriologically positive
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cases in the area is 225/100000/yearI4. The notification rate of all bacteriologically
positive cases (new and retreatment cases) in the area is 363/100000/year. A survey of
drug resistant tuberculosis in the Western Cape province conducted in 1992-1993 found
a rate of 8.6% acquired and 3.2% i~itial drug resistance in the West Cape region 15. The
reported prevalence of Hl'V infection in the province ranged from 0.25% in 1992 to 3 %
in 1996 (data from the National HIV surveys on women attending antenatal cl inics,
conducted by the Department of Health and Population Development, South Africa).
All TB patients were treated at a primary health care clinic under direct supervision.
During the time of the study, there were no official National Tuberculosis Program
(NTP) guidelines for the treatment of drug-resistant TB. However, in the Western Cape
Province, centres specialised in MOR-TB treatment have been developed. These centres
provide in-patient treatment as well as treatment advice and follow-up for outpatients
with MOR-TB. Patients in the communities studied had the option to be treated at the
primary health care clinic or to receive inpatient care at a centre specialised in MDR-TB
treatment. The drug regimen prescribed was determined by the susceptibility pattern of
the individual isolates in combination with the availability of drugs. No standardized
regimens for MOR-TB treatment were followed.
Laboratory procedures
Sputum samples were collected at the health care clinics of the communities and
sent to the routine laboratory for microscopy, culture and drug susceptibility testing if
requested by the managing health professional. Drug susceptibility testing was
performed by the economic version of the indirect proportion method 16 on Lowenstein-
Jensen medium containing critical concentrations of 0.2 ug/ml isoniazid, 30 ug/rnl
rifampin, 2 ug/ml ethambutol, 5 ug/ml streptomycin and 20 ug/ml ethionamide.
Kanamycin and thiacetazone resistance was tested on Middlebrook 7H I0 agar
containing critical concentrations of respectively 5 and 2 ug/rnl, Resistance was defined
as I% or more bacterial growth in comparison with a control using international criteria.
initially, cultures were tested for resistance to isoniazid and rifampin. If resistance to
these drugs was detected, cultures were subsequently tested for resistance to the other
antituberculous drugs as mentioned above. Resistance to pyrazinamide was not tested.
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Patient data and definitions
All patients residing in the studied area with a positive culture for Mycobacterium
tuberculosis resistant to at least one antituberculous drug between April 1,1992 and
March 31,1997 were included. Information on age, sex, medical history, HIV status,
previous tuberculosis treatment, results of sputum microscopy and cultures,
susceptibility testing, treatment and survival were obtained by review of medical files
and compliance charts from the clinic and the specialized MDR- TB inpatient units. If a
patient had been transferred during treatment or had moved after completion of
treatment, the nursing staff of the relevant clinic was asked to do a home visit to ensure
survival of the patient and to collect a sputum sample. Cases were followed until May
1999.
The date of diagnosis of MDR- TB was defined as the date of the first clinical
isolate positive for M tuberculosis resistant to at least isoniazid and rifampin.
A drug was considered appropriate for treatment if M. tuberculosis was not proven
to be resistant to this drug in vitro.
Treatment was considered completed if a patient received 12 months of therapy
(with 3 appropriate drugs) after sputum conversion or 18 months of appropriate
treatment. Treatment compliance was determined as the intake of at least 80% of
prescribed dosages as determined by clinic attendance for the course of therapy. A
patient was considered cured if he/she completed therapy and remained culture negative
for at least 6 months after ending therapy. A patient was classified as defaulted if
treatment was interrupted before completion was reached. The outcome was determined
as bacteriological and clinical success. Clinical success was defined as; bacteriological
success was defined as bacteriological conversion. The date of bacterial conversion was
defined as the first date of three consecutive bacteriologically negative isolates.
Data management and statistical analysis
Data was analyzed using Epi-Info 6.1 and STATISTICA software programs.
Analysis focused on factors suspected to be associated with bacterial conversion and
with survival. Candidate independent variables were treated as two-level dichotomous
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factors dividing, if possible, the study population into two equally sized groups by using
the mean or median of the independent variable. Factors investigated were age, sex,
history of prior TB, number of drugs to which the isolate was resistant, and bacterial
conversion. Characteristics of the treatment for MDR- TB were considered, such as:
number of episodes, compliance with therapy, hospitalisation, administration of 3
appropriate drugs within 96 days of MOR-TB diagnosis and for an uninterrupted period
of 14 months, administration of 4 appropriate drugs within 87 days of diagnosis and for
an uninterrupted period of II months and administration of 5 appropriate therapy drugs.
The outcome (dependant) variables were also dichotomous and were either "bacterial
conversion" or "no bacterial conversion" and "survival" or "death". Relative risk ratios
and their corresponding 95% confidence intervals (95% Cl) were computed from 2 x 2
tables of dichotomous independent and dependent variables with the use of the Chi-
square test or Fisher's exact two-tailed test (depending on whether the expected cell
frequency was> or < 5). Survival analysis and identification of prognostic factors for
bacterial conversion and survival were carried out using the Kaplan-Meier method.
Patients were censored at the time follow-up ended, when they refused further follow-
up (n=3) or when they became lost to follow-up (n=O). Patients who died of causes
other than tuberculosis and had no evidence of tuberculosis at death were censored at
their date of death. Determination of statistical significance of median time to bacterial
conversion and median survival time between groups was calculated using the Log-rank
test for bacterial conversion analysis (emphasis on differences occurring early in the
time frame investigated) and the Peto & Peto Wilcoxon test for survival analysis
(emphasis on differences occurring late in the time frame investigated). The results did
not differ between the 2 methods (2 x 2 table and Kaplan-Meier analysis). For clarity of
the text, the authors have chosen to show only the data of the Kaplan Meier analysis as
this analysis gives not just a crude analysis of survival/death and bacterial conversion
yes/no, but also takes a (clinically important) time factor into consideration.
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RESULTS
Demographic and clinical characteristics
Half (52%) of the 42 patients included were female. The mean age was 33 years.
Forty (95%) patients were tested for HIV, all tested negative. One patient refused HIV
testing and is still alive 4.3 years after diagnosis of MOR-TB; the other patient was
never tested and died 7 years after diagnosis of MDR-TB, at the age of 59 years. All
patients had pulmonary tuberculosis and 37 (88%) were sputum smear positive for acid-
fast bacilli. On chest radiograph, 41 (98%) patients had cavitary disease. Of the 42
patients, 30 (71%) had a history of antituberculous treatment prior to the diagnosis of
MDR-TB ('acquired MDR-TB'). The median time period between the initial diagnosis
ofTB and the first diagnosis ofMDR-TB was 60 months (range 5 months to 14 years).
Nineteen (63%) of these patients had received one episode of TB treatment prior to the
diagnosis ofMDR-TB, 5 (17%) had received two episodes ofTB treatment and 6 (20%)
patients had received 3 or more episodes of treatment.
M tuberculosis was resistant in vitro to a mean of 4.1 drugs. Only 3 (7%) patients
had isolates resistant only to isoniazid and rifampin. Fifteen (36%) patients' isolates
were resistant to 3 drugs, 6 (14%) were resistant to 4 drugs, 10 (24%) were resistant to 5
drugs, 7 (17%) were resistant to 6 drugs, 1 (2%) was resistant to 7 drugs and 1 (2%)
patients' isolate was resistant to all 8 drugs tested in vitro. Drug susceptibility patterns
of the 42 MOR-TB isolates are presented in table 1.
Treatment characteristics
One patient received only first-line antituberculous drugs; all other patients
received a combination of first line and second-line drugs. The median time to initiation
of second-line drugs was 90 days (range 0 days to 1.6 years) from the time ofMDR-TB
diagnosis. During treatment for MDR-TB, patients received a median of 4 first-line
drugs (range 2 to 5) and 4 second-line drugs (range 1 to 6) (table 1).
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Isoniazid
Rifampin
Pyrazinamide
Ethambutol
Streptomycin
Ethionamide
Kanamycin
Thiacetazone
Therizidine
Ofloxacin
Clofazimine
Cycloserin
100
100
Not tested
45
79
14
14
48
Not tested
Not tested
Not tested
17
93
57
83
81
50
88
66
73
61
54
20
2
Table 1: Drug susceptibility pattern and drugs used for treatment in 42 MOR-TB
patients
Drug Resistance pattern (%) Drug used in treatment (%)
In most patients, the treatment regimen used changed during their treatment. Forty-
one patients (98%) received at least 3 appropriate drugs, 38 (90%) patients received at
least 4 appropriate drugs and 26 (62%) patients received 5 or more appropriate drugs.
The median time to initiation of 3 appropriate drugs was 2.8 months (range 0 to 12
months). The longest uninterrupted period of treatment with 3 appropriate drugs was a
mean of 14.2 months (range 1 to 39 months). The median time to initiation of 4
appropriate drugs was 3.4 months (range 0 to 19 months). The longest uninterrupted
period of treatment with 4 appropriate drugs was a mean of 12.3 months (range 1 to 34
months). Patients were treated for MOR-TB for a mean duration of20 months (range 4
to 55 months). Patients who achieved bacterial conversion were treated for a median
duration of I year after bacterial conversion (range I to 38 months). Twenty-three
(55%) patients were compliant during treatment, 19 (45%) were non-compliant. Thirty
(71%) patients were hospitalized for a median duration of 3.2 months (range 6 days to
19 months) after a median interval of 2.9 months since MOR-TB diagnosis (range 0 -
31.9 months). In only 3 patients (7%) was lung surgery undertaken.
Outcome characteristics
Patients were followed up for a median duration of 4.2 years after diagnosis of
MOR-TB. The median duration of follow-up in the group of patients who survived was
4.5 years. Of the 40 patients who stopped treatment before May 1999, 8 (20%) had died,
17 (42.5%) were cured and 15 (37.5%) had defaulted. By end of the study (May 1999),
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3 additional patients had died, 23 patients were bacteriologically negative, two patients
remained bacteriologically positive but refused treatment, one patient had relapsed and
restarted treatment, 2 other patients were still on treatment. The remaining 3 patients
refused follow-up in 1999. In only one case was death not related to tuberculosis. The
average time of follow-up after the end of treatment of 29 patients who had finished
treatment by May 1999 and survived, was 2.2 years (range 2.5 months to 5.9 years).
The 5 year survival rate (estimated by Kaplan Meier analysis) was 71 % (SE
8%), the 2 year survival rate was 90% (SE 4%) (figure 1). No patient died within one
year of diagnosis of MDR-TB. The median time interval between diagnosis and death
was 29 months (range 12 to 57 months).
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Figure 1.Kaplan-Meier curves for survival after diagnosis of 42MDR-TB patients residing in
two South African communities.
The cumulative percentage of patients who reached bacterial conversion,
estimated by Kaplan Meier analysis, was 79% (figure 2). The time by which 50% of the
42 patients reached bacterial conversion was 9.4 months. Of the patients who converted,
the median time for bacterial conversion was 7.2 months (range 1 to 33.9 months) after
initiation of treatment and 3.2 months (range 0 to 32.1 months) after initiation of
therapy with at least 3 appropriate drugs. Bacteriological conversion took place up to 34
months after diagnosis. However only 3 more patients converted after 15 months of
treatment.
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Figure 2. Kaplan-Meier life-table analysis indicating time to bacterial conversion after
initiation of treatment in 42 MOR-TB patients.
Five patients became bacteriologically positive again after achieving initial
bacterial conversion. In only one patient, the only one that did receive 3 appropriate
drugs, did this occur after the end of treatment. The other 4 patients became positive
again during their treatment, in two patients most likely due to non-compliance. Three
of these patients reconverted to a bacteriologically negative status: 2 after a change in
therapeutic regimen, one after lung surgery. The other patient remained non-compliant
and bacteriologically positive. The overall rate of bacterial conversion was thus 74%.
Determinants of treatment outcome
Factors investigated for their associations with the outcome of MOR-TB
treatment are listed in table 2. Patients who achieved bacterial conversion early were
more likely to be younger than 30 years (p=0.046), compliant during the MOR-TB
treatment (p-=-O.0016),not have interrupted their treatment (p=0.0002), treated with at
least 4 appropriate drugs for an uninterrupted period extending II months (p=0.05) and
treated with 5 or more appropriate drugs (p=0.029). Hospitalisation did not influence the
outcome. However, among the hospitalized patients, those who were admitted at an
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earlier stage of disease (within 96 days of diagnosis) converted earlier compared to
those admitted after a longer delay (p=O.005).
TABLE 2: Characteristics associated with outcome ofMDR-TB in 42 patients
Risk factor
p value* for median p value* for 5
time to bacterial year survival
conversion
0.046 0.02
0.078 0.36
0.035 0.12
0.42 0.034
0.66 0.001
0.41 0.69
0.0002 0.018
0.0016 0.011
0.75 0.54
0.005 0.41
0.088 0.86
0.06 0.06
0.065 0.11
0.05 0.05
0.029 0.04
0.00001
age (> or < 30 year)
Sex
prior TB treatment (acquired resistance)
TB diagnosis> 60 months before MDR-TB
1 or more episodes of treatment
Isolate resistant to more then 4 drugs
MDR -TB treatment
Without interuption
Compliant with treatment
Hospitalisation for treatment
within 96 d of diagnosis
3 appropriate drugs within 87d
3 appropriate drugs for> 14m
4 appropriate drugs within 104d
4 appropriate drugs for> 11m
5 appropriate drugs
bacterial conversion
* p valuesare calculatedby KaplanMeiersurvivalanalysis
Patients who survived were more likely to be younger (p=O.02), compliant during
treatment for MDR-TB (p=O.Oll), not have interrupted their treatment (p=O.018),
treated with at least 4 appropriate drugs for an uninterrupted period extending 11
months (p=O.05) and treated with 5 or more appropriate drugs (p=O.04). The factor most
strongly associated with survival was the achievement of bacterial conversion
(p=O.OOOOI)(figure 3).
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Figure 3. Kaplan-Meier curves for survival after diagnosis of 42 MOR-TB cases comparing
cases without bacterial conversion (ful1line) to cases where bacterial conversion was successful
(dotted line).
A history of prior antituberculous treatment in itself was not associated with
survival. However, among the patients with a history of TB treatment, patients with
chronic tuberculosis (history of multiple episodes of tuberculosis treatment) responded
less well to chemotherapy (p=0.00 I). A long interval (>60 months) between the first
diagnosis of TB and the diagnosis of MOR-TB (p=0.034) was also associated with
poorer survival.
The number of drugs the isolate was resistant to did not influence bacteriological
or clinical success.
DISCUSSION
The optimal treatment for drug-susceptible TB is well established. Modem
chemotherapy, appropriately prescribed and administered as in the WHO advised DOTS
regimens, can cure over 85% of previously untreated pulmonary tuberculosis cases!".
No data are available from controlled trials regarding the treatment of patients with
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MOR-TB. The current WHO guideline for treatment of MDR-TB cases consists of at
least 3 drugs to which the isolate is sensitive for a period of 18 months after
bacteriological conversion'". In low and middle-income countries, treatment regimens
for MDR- TB are not included in National Tuberculosis Program guidelines.
TABLE 3: Literature review of studies on MOR-TB outcome in HIV negative patients
Author, Study Patient HIV Mean duration % bacterial % death
reference period selection neg. of follow up conversion total/TB-
and location Patients (months) related
analyzed
Goble (11) 73-83 hospital 134* 51 56 34 120
(USA)
Park (9) 83-93 hospital 41 NA NA 24 117
(USA) (range 0-120)
Schaaf (l3) 87-93 population 226* 60 87 48/NA
(RSA) (survivors) (survivors)
Telzak (8) 91-94 hospital 25 20 65 4/4
(USA)
Turret (10) 91-93 hospital 4 NA 100 OIO
(USA) (range 0-34 )
Flament (2) 94 population 43 NA 41 NA/46
(France) (range 24 -36)
Park (12) 96 hospital 63 17 82.5 NAIO
(Korea)
*Patients were not tested for HIV status, however, considering the HIV incidence in the studied area
at the time, one can assume that, at least the majority of these patients, would have been HIV negative.
Several studies have analyzed the outcome of MOR-TB patients2,8-I3. Results
indicate that HIV seropositive cases clearly have a poorer outcome compared to
immunocompetent patients. It is however difficult to compare results of these studies,
even among studies on outcome of MOR-TB in HIV seronegative patients. This is due
to differences in definitions of outcome (bacteriological or clinical success), duration of
follow-up and patient characteristics (table 3). In addition, analysis is carried out in
various ways, rarely using survival analysis and frequently not displaying results of the
whole cohort due to lack of follow-up data on all patients. The figures on 'favourable
outcome' among HIV seronegative patients varied from 41% to 100%2 for
bacteriological conversion and from 52%13 to 100%10,12 for survival. However, the most
optimistic figures are reported by two studies, one with only 4 patients'? and one which
was biased by the exclusion of 41% of patients from the analysis because of surgery
(21 %), loss to follow-up (19%) and adverse drug reactions (1%)12.
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In the present study, where virtually all patients were proven to be HIV
seronegative, 74% of patients achieved bacterial conversion. Not surprisingly,
compliance with treatment was the most important factor influencing bacteriological
success. The 2-year survival was 90% and decreased to a 5-year survival of 71%. This
underlines the necessity of a long-term follow-up of HIV seronegative MOR-TB
patients. As described by Goble et al.!', the most predictive factor for survival was
bacteriological success. Younger age at diagnosis, compliance with treatment and
treatment with 4 or more appropriate drugs for a period extending 11 months were other
factors associated with improved bacteriological success and a greater chance of
survival. Telzak et al.s noted, as we also found, that multiple previous episodes of
treatment were associated with a less advantageous outcome. This may be due to
extensive lung damage.
The lack of association of outcome to the number of drugs to which the isolate was
susceptible is in agreement with some reports8,I0 but in contrast to others2,ll,l2.
As virtually all of our patients received appropriate treatment, we could not analyse
the finding that institution of appropriate treatment is the factor most strongly associated
with a favourable outcome". We did however find that the strength of association with
favourable bacteriological and clinical outcome increased with the number of
appropriate drugs used, reaching significance at the level of 5 appropriate drugs. The
time to initiation of appropriate treatment did influence the outcome. This is clinically
very important, not only on an individual level but also on a community level as
unsuccessfully treated patients can transmit their disease to other persons in the
community and thus constitute a public health problem 19.20.
In the same province (Western Cape, South Africa), a study determining the
outcome of MOR-TB had been previously undertaken':'. The 5-year survival rate was
then determined to be 46%. At the time of that study, patients with MDR-TB were
treated without the benefit of a centralised specialist facility, by directly observed
therapy, in the same primary health care clinic system as patients with drug-susceptible
TB. There were no second line drugs included into the treatment regimen of MOR-TB
patients. This is still the scenario in most low and middle-income countries, but also in
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some high-income countries'. The survival of MDR- TB cases in that study was not
markedly different from that ofTB patients before chemotherapy was available21.
In our series, as in most other series2,8-13, the majority of patients with MDR- TB
had isolates resistant not only to INH and RIF but also to a mean of 2 other first-line
agents. Empirical therapy recommended for patients who are not multidrug resistant
would therefore not include the administration of 3 appropriate drugs, possibly resulting
in monotherapy and may thus aggravate the problem ("amplifier effect")". With the
introduction of a specialist clinic in the study area for the evaluation and management of
patients with MDR-TB, second line drugs became consistently available for MDR-TB
treatment. Subsequently, the 5-year survival of MDR-TB patients in the area has
increased from 46 to 71%.
The results of this study suggest that a more individualised approach to the
management of MDR- TB could be the most important factor contributing to
improvement in the outcome ofMDR-TB patients. Even though virtually all patients in
this study received treatment with 3 appropriate drugs, the median time between
diagnosis and initiation of appropriate therapy was unnecessarily long, and longer than
that reported elsewhere8. The fact that MDR- TB patients included in this study were not
systematically sent to a specialist MDR-TB clinic might be an explanation for the long
delay in initiation of appropriate treatment and the long time to bacterial conversion.
Similarly to the only other population-based study on outcome of MDR-TB2,
hospitalisation alone had no influence on outcome, although hospitalisation early in the
course of the disease may have been beneficial. Attention to these factors might further
improve the outcome ofMDR-TB patients.
The present study indicates that the availability of a specialized centre for the
management of MDR- TB, the only institution through which second line drugs can be
obtained for treatment, can improve the outcome of MDR-TB treatment. The results
therefore support the development of these centralised, specialised MDR- TB treatment
units as part of a rational "DOTS plus" strategy for management of MDR-TB
patients I8,22,23. Even with these improvements, however, further progress is needed in
development of the treatment of such cases. In the meantime, every effort must be made
to avoid the promotion of drug resistance through appropriate treatment of the initial
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drug sensitive TB episode because, in the end, clinically significant drug resistance is
virtually always to result of a failure of medical practice".
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CHAPTER 10
General Conclusion
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General Conclusion
A. Dogmas on tuberculosis and drug-resistant tuberculosis
Tuberculosis is a chronic infectious disease with a complex natural history.
Transmission occurs by droplet infection and its occurrence is directly associated with
the bacillary load in the sputum, cough frequency and environmental factors such as
closeness of contact and duration of exposure. In only 5-15% of cases will active TB
follow infection after an asymptomatic incubation period ranging from weeks to
decades'. Disease in a previously infected individual may be caused by reactivation of
dormant bacilli (endogenous reactivation) or it may be the result of a new challenge
caused by reinfection with a different strain of Mycobacterium tuberculosis (exogenous
reinfection). The proportion of tuberculous disease attributable to endogenous
reactivation and exogenous reinfection has been the subject of a debate for decades'.
Currently, it is generally accepted that the majority of cases ofTB are a consequence of
endogenous reactivatiorr'. However, there is also evidence to support that the relative
contribution of exogenous reinfection increases in parallel with the TB incidence':'.
Tuberculosis is a disease that may have killed more individuals than any other
single pathogen. The enthusiasm was great when the first antituberculous drugs became
available. But this enthusiasm was soon tempered as drug resistance arose after the
introduction of antituberculous drugs. Drug resistance is the result of selection of
spontaneous mutants that occur even prior to contact with antituberculous drugs".
Selection results from treatment errors, such as prescription of inappropriate regimens
and patient non-compliance". Multiple treatment errors lead to sequential acquisition of
drug resistance", Most cases of drug-resistant TB arise in chronic patients and result
from poor treatment programmes.'. Grzysbowski et al. estimated that the outcome of
patients will be chronic in only 3% of patients under a good TB control programme
while 25% of patients will become chronic in a poor TB control programme". Drug-
resistant TB is thus a man-made problem with an incidence that is related to the quality
of the National Tuberculosis control Programme. However, it is also possible that
patients are infected by transmission of a drug-resistant M. tuberculosis strain (primary
drug resistance). Until recently, it was generally believed that this occurs with a
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relatively low frequency, presumably because the metabolic compromises made by the
bacillus to enable drug resistance makes the bacillus modestly less virulent'". Even a
small reduction in pathogenic capacity would make transmission of drug-resistant
disease quite uncommon in the normal host, whose immune system has a 90% chance
of containing the infection for a lifetime. Only in specific population groups, such as
institutionalised patients co-infected with HIVand TB, is it believed that there is a high
risk for outbreaks of drug-resistant TB 10.
B. Re-evaluation of these dogmas
The aim of this study was to re-evaluate these dogmas in an area with one of the
highest reported TB incidences in the world. This was possible through the use of new
techniques such as a computerised geographic information system, and new molecular
genetic techniques such as Restriction Fragment Length Polymorphism (RFLP) and
mutation detection analysis.
RFLP results demonstrated that community outbreaks of drug-resistant TB
occur, even without the involvement of a single immunocompromised (HIV
seropositive) patient. Not only do outbreaks occur within the community, but the
majority of patients with drug-resistant TB were infected with a strain belonging to a
cluster of drug-resistant isolates, indicating transmission from one infectious patient to
another person. The assumption that patients infected with identical strains are
epidemiologically linked and therefore indicate transmission from one person to another
was supported by additional data. First, results of mutation analysis by dot-blot
hybridisation analysis demonstrate that the initial isolate of all patients infected with an
identical drug-resistant M. tuberculosis strain contained the exact same combination of
mutations conferring resistance. This was true for all isolates except for 3 cases infected
with a strain characterised by an exceptionally high genetic stability. This makes the
possibility of transmission of a drug sensitive strain with subsequent acquisition of drug
resistance in individual patients highly unlikely. Second, results from the investigation
of an outbreak of drug-resistant TB by combining molecular and traditional
epidemiologic data showed epidemiologic links among 12 ofthel6 patients involved in
the outbreak. Third, an analysis combining a Geographic Information System (GIS) and
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Figure l. Influence of the presence of DOTS and the absence of DOTS-plus on the outcome of
cases with drug-sensitive and drug-resistant tuberculosis.
Dark (thick) arrows indicate the outcome of the majority of cases. Light (Thin) arrows indicate the
outcome of a minority of patients. SDR- TB stands for single-drug-resistant tuberculosis.
(I) under DOTS regimen, the majority patients with drug-sensitive TB will be cured
(2) in the absence of an effective MDR- TB programme, few patients with MOR-TB will be cured
(3) the majority of MOR-TB patients will remain infectious for prolonged periods of time in the absence
of effective treatment which can lead to transmission ofMDR-TB strains and the creation of clusters.
transmitted
(2)
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molecular epidemiologic data and showed that 80% of cases within each cluster of
drug-resistant TB resided within 600 meter of another case and this in geographically
distinct areas for each cluster.
There was a difference in the relative contribution of transmission among different
types of drug-resistant TB: transmission was the most important mechanism for
multi drug-resistant TB (MDR-TB) while acquisition was the predominant mechanism
for single drug-resistant TB. I would like to hypothesise that these results are the
consequence of the history of TB control strategies in South Africa, representative for
many middle income counties (Fig 1). The key factors leading to this situation are (i) an
area endemic for TB where people are in repeated contact with infectious TB patients
(ii) a suboptimal TB control programme in the past leading to errors in drug prescription
and patient non-compliance, (iii) a current DOTS program leading to high case holding
rates, high cure rates and the protection of front line drugs and (iv) the lack of an
effective MOR-TB programme. Under such conditions, the overwhelming majority of
new patients with drug-sensitive TB will be cured by the DOTS programme and only a
very small percentage will acquire drug resistance. However, a pool of chronic TB
patients with a relatively high percentage of drug resistance, especially to the "older"
TB drugs such as isoniazid and/or streptomycin, will have been inherited from the past.
A DOTS regimen can be effective in the treatment of single-drug-resistant TB, as the
regimen will still provide drugs to which the isolate is sensitive. Most single-drug-
resistant TB patients will thus be cured and only a few of these patients will evolve to
MDR- TB cases by acquisition of additional resistance. Patients with single-drug-
resistant TB will thus not remain infectious for prolonged periods of time and the
transmission rate of single drug-resistant TB will be comparable to that of drug sensitive
TB. Another inheritance from a poor program in the past is a pool ofMDR-TB patients.
In the absence of a specialised MDR- TB programme with access to first and second line
drugs, these patients cannot be effectively treated. Few MDR-TB patients will be cured
and the majority will remain infectious for prolonged periods of time. They can infect
other people leading to cases of primary MOR-TB. Cases of primary drug resistance
will remain undiagnosed for months, as the DOTS programme does not require routine
culture and drug-susceptibility tests at diagnosis. This allows transmission with further
enlargement of the pool of people infected with drug-resistant strains of M tuberculosis.
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Another hypothesis that could explain the difference in therelative importance of
transmission of different types of drug-resistant tuberculosis could be the
transmissability of the organism. Of all Unique single-drug-resistant isolates, the
mutation conferring resistance to isoniazid was detected in only 27% of cases. This is in
sharp contrast to the MOR-TB isolates in which a katG315 mutation was detected in
89% of isolates. It is possible that the mutation(s), as yet unidentified, do not only
confer resistance to isoniazid but also reduce transmissability. This would confirm the
historical studies in which it was shown that isoniazid resistant bacilli were reduced in
virulencell.
Surveillance of drug-resistant TB cases is important for evaluation of TB control
programmes. It has been suggested that classification of patients according to
pathogenic pathway of drug resistance is essential for better insight', The standard
classification of patients into acquired (previously treated patients) and primary
(patients without a history of prior treatment) drug-resistant TB reflects the general
belief that the majority of drug-resistant TB occurs as a consequence of acquisition of
drug resistance in the individual patients due to treatment errors'. When comparing the
classification of patients according to the clinical classification (acquired or primary)
and the RFLP classification (unique or cluster) it was clear that the group of patients
with acquired drug-resistant TB does not only include patients who truly acquired drug
resistance during treatment but also includes patients initially infected with a drug-
resistant strain as well as patients re-infected with a drug-resistant strain. Surveys based
on the standard classification may therefore result in misleading interpretations and
incorrect evaluations of the quality ofTB control programmes.
The group of patients re-infected with a drug-resistant M. tuberculosis strain was a
numerically important group: 25 of the 45 (56%) patients with a prior history of
antituberculous treatment. If re-infection is an important mechanism in the occurrence
of drug-resistant TB after prior treatment, re-infection should also be an important
mechanism in the occurrence of relapse after prior treatment tor drug-sensitive TB. We
evaluated this hypothesis by RFLP analysis of the infecting strains in patients
presenting with active TB after prior cure for drug-sensitive TB. For 12 of the 16
patients, the RFLP pattern for the isolate obtained after relapse was different from the
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RFLP pattern for the isolate from the initial TB episode. These findings indicate the
importance of re-infection as the cause of recurrence of TB after curative treatment for
drug-sensitive TB.
Treatment of drug sensitive TB is highly efficacious, but the treatment options for
drug-resistant TB and especially MDR- TB are limited. A standard DOTS programme
with first-line drugs regimen can not only manage drug sensitive TB but can also
decrease the prevalence of single-drug-resistant TB 12. In Korea, after the introduction of
a good quality TB control programme, the prevalence of !NH resistance dropped from
25% in 1980 to 4.9 % in 199513. Similarly, in Algeria, the prevalence of acquired !NH
resistance decreased from 34% (1975-1980) to 10% (1981-1985)14. The options for
treatment of patients with MDR-TB are (i) standard DOTS regimen as for patients with
drug sensitive TB, (ii) standard regimens including second line antituberculous drugs,
selected on the basis of the most common drug resistance profiles in the
community/country or (iii) individualised drug regimens, adjusted to the drug resistance
profile of the infecting bacillus. Because of the extremely high cost of second line
drugs, the WHO has opted for the use of standard DOTS regimens and discouraged the
use of routine drug resistance testing in the diagnosis of new TB cases in low and
middle income countries. When the WHO launched their new TB control strategy, it
was hoped for that DOTS would also control MOR-TB and that MDR-TB would simply
disappear if DOTS were established worldwide. The experience gained -since the
introduction of DOTS shows that MDR-TB persists1S-18• In Korea, the rate of acquired
MDR-TB increased from 14.5 to 19.8% between 1985 and 199513• In Algeria,
prevalence of acquired MOR-TB increased from 1.7% to 11%14.The implementation of
a DOTS regimen in the prisons in the former Soviet Union will not lead to a reduction
in MDR-TB, seen that the overall success rate was only 27% for patients with
confirmed MDR-TBI9• Outcome data from patients in the Western Cape treated for
MOR-TB by a supervised standard first line drug regimen, indicate that the outcome is
comparable to that obtained in patients before the era of antituberculous drugs: a 5 year
survival rate of 46% of patients'".
Clinical data of the patients with drug-resistant TB were used to study the outcome
of MOR-TB in an area endemic for TB after the introduction of a specialised MDR- TB
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treatment centre in the Western Cape Province. The majority of patients (98%) were
now treated with at least 3 drugs to which the isolate was sensitive. This individualised
approach to the treatment of MOR-TB was not yet optimal: appropriate treatment was
only started after an average delay of 2.8 months and the longest uninterrupted period of
treatment with 3 appropriate drugs was only a mean of 14.2 months instead of the
proposed 18 to 24 months. Despite these shortcomings, the 5-year survival rate of
patients with MOR-TB in the area increased from 46% to 71%. These results suggest
that an individualised approach and the availability of a specialised MDR-TB unit ean,
even in non-industrialised countries, improve the outcome of MOR-TB.
C. Public health implications of the results
Results obtained in this study have enabled the re-evaluation of general beliefs
concerning the disease dynamics of TB and more specifically the disease dynamics of
drug-resistant TB. The ultimate aim is to go one step further and use the new insight to
improve TB control. That this is possible has been shown, for example, by the
population-based molecular epidemiological work performed in San Francisco. Control
measures directed towards reducing transmission of M. tuberculosis in high-risk groups
were implemented on the basis of the finding of a high proportion of clustered cases.
This resulted in a decrease of the rate of clustered cases as well as a decrease of the
annual TB case rate21•
The results of this study indicate that, if exogenous reinfection is common, the use
of antituberculous chemoprophylaxis in people recently exposed to infectious TB might
be prudent regardless of the prior history ofTB infection or disease. With a high degree
of exogenous reinfection one could also expect a greater impact of sound TB control
strategies than when endogenous reactivation is the predominant mechanisrrr'j.
The results of this study might be helpful in answering questions concerning the
format of future DOTS-plus programmes for MOR-TB. In agreement with Portaels et
a118, Iwould like to state that the central elements of a standard DOTS strategy might
need to be modi tied.
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1. Diagnosis based on microscopy or routine drug susceptibility tests?
The DOTS strategy currently employs standardised treatment regimens depending
on the patients' past treatment history. This approach is based on results of trials, which
failed to show a significant difference in outcome among patients with initial drug-
resistant TB whose treatment was or was not adjusted on the basis of initial drug
susceptibility results23-25.However, these studies were performed when resistance to
rifampin was rare. The limited data available on the outcome ofMDR-TB under DOTS
regimen are disappointing'<t''.
The high failure and death rates are not the only problem involved in the
management ofMDR-TB by standard DOTS program. There is evidence that MDR-TB
patients may develop additional resistance to SM, EMB or PZA under standard DOTS
regimens (amplifier effect)15,18,26.Furthermore, MDR-TB patients will remain infectious
and transmit drug-resistant bacilli into their environment. A question to be answered is
whether the cost of treating all future secondary cases infected by MDR-TB patients
exceeds the cost of routine culture and drug-susceptibility tests at diagnosis.
Heifets et al. have argued that the lack of proper laboratory support for TB control
programmes in countries such as South Africa, is often not a pure matter of
affordability, but rather an underestimation of its importance and the consequence of the
implementation of a DOTS strategy requiring that diagnosis is based on acid-fast bacilli
smear examination only'".
If a decision for routine drug susceptibility tests at diagnosis is made, a further
question raised by the work of this study is whether the standard culture-based drug-
susceptibility tests will be the screening test of choice in a DOTS-plus strategy. The
success of prevention of transmission of MDR-TB depends on the time a patient
remains infectious. Phenotypic drug resistance testing is technically very demanding
and requires a minimum of 3 to 6 weeks for a positive culture and a further minimum of
2 to 3 weeks for susceptibility testing". The use of high quality national and
supranational laboratories increases the reliability of results but also increases the
already long turn-around time of laboratory reports. Results of genotypic drug resistance
testing based on mutation analysis can be available within 24 hours after positive
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2. Passive or active case detection?
culture and has even been successful directly on sputum. In this study, the cost of
genotypic testing could be reduced as the evaluation of 3 selected codons (rpoB531,
rpoB526 and katG3l5) allowed identification of 90% of MOR-TB cases. Furthermore,
we have been able to show that, for MOR-TB diagnosis, the performance of genotypic
drug resistance testing was superior to phenotypic drug resistance testing under routine
conditions. Further research should be directed at the possibility of the development of a
commercial kit testing a limited number of mutations conferring resistance.
Following the DOTS guidelines, case detection is passive. Contact tracing IS
considered ineffective, inadequate and therefore not cost-effective. However, the
efficiency of contact tracing can be improved as shown by a study in San Francisco
where investigators were trained to improve communication with specific populations at
risk. The median number of contacts per new case increased and the percentage of cases
with no contacts identified decreased from 25% in 1990 to 3% in 199721•
For this study, epidemiological data on a community outbreak of MOR-TB was
collected by a medical anthropologist and showed that 12 of the 16 patients involved in
the outbreak had social connections with at least one other person also involved in the
outbreak. Only 4 of these patients were detected by contact tracing through the clinic
system. Because of the importance of early diagnosis of MOR-TB, selective active
tracing for patients in contact with MOR-TB cases could be a cost-effective procedure.
3. Treatment with a standardized DOTS-plus regimen or an individually adjusted
DOTS-plus regimen?
Data on the outcome of MDR-TB under standard DOTS regimen show
disappointing rcsultsI3-20. Adjusted MOR-TB programmes have had better success rates,
especially in HIV seronegative patients. Standardised regimens, consisting of a
combination of first and second line drugs selected on the basis of susceptibility profiles
of MOR-TB strains in the community have been successful in Rwanda28. Individualised
regimens, based on the drug susceptibility pattern of the patients' isolate, have been
successful in the USA29.30, Peru31 and KoreaJ2. The majority of MOR-TB patients
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included in this study were treated by individualised treatment regimens: 98, 90 and 62
% of patients received respectively at least 3, 4 and 5 appropriate drugs according to the
results of the drug susceptibility tests. This increased the 5-year survival of MOR-TB
patients in the area from 46% (treatment by standard first line regimen) to 71%
(treatment by individualised MOR regimen).
Future research should be directed at multieentre clinical trials evaluating the
outcome and cost-effectiveness of standardised versus individualised MOR-TB
treatment regimens.
D. Final comment
MOR-TB is clearly a problem confronting a DOTS programme in its success in TB
control. Mathematical modelling suggests that MOR-TB needs to be aggressively
managed to prevent future epidemics':', Data indicating that MOR-TB is not
uncontrollable exist. In response to large nosocomial outbreaks of HIV related MDR-
TB, resources (> 1000 million US$) were provided to re-establish the decayed TB
control programme of New York City. An effective DOTS programme was introduced,
contact tracing was intensified, the use of isoniazid preventative therapy was increased
and individualised treatment of MOR-TB patients was initiated. Subsequently, the
number of cases ofMDR-TB in New York City decreased by 44% from 1992 through
1994. Epidemiological patterns suggest that the decrease resulted from interruption in
the ongoing spread of MOR_TB34.
It has been shown that a sound DOTS programme can stop acquisition of drug
resistance. The work in this study showed that, even in poorer countries, treatment of
MOR-TB patients could be made much more effective by the institution of specialised
MOR-TB care. Because of the relatively high proportion of MOR-TB caused by
transmission, one can expect effective treatment to have an important impact on the
prevalence of MOR-TB, as effective treatment will reduce the high rate of ongoing
transmission of MOR-TB. It should therefore be possible to tum the tide, not only in
rich industrialised countries but also in poorer countries.
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Until recently, treatment of MOR-TB in resource poor countries had been deemed
by many to be too difficult and too costly to even attempt; others declared that MOR-
TB and transmission of MOR-TB was simply not a problemI6.35. It is now clear that
MOR- TB in the developing world has become a problem that can no longer be
ignored31.3s.36.Worldwide, all TB patients, including MOR-TB patients, should have a
right to effective treatment. Otherwise, we will create enormous problems for the future
and will again be faced with a situation in which medical advances cannot be used in the
poorer population most in need. However, it has been shown that a poor TB control
programme can be more harmful than no programme'. The same might be true for a
DOTS-plus programme for MOR-TB. Therefore, excellent operational studies will be
necessary to decide on the optimal format for OaTS-pius programmes. It is in this
context that the WHO established the WHO Working Group on DOTS-plus for MOR-
TB in 1999. International political commitment and financial support will be necessary
for the implementation of a OaTS-pius programme in selected areas with median and
high levels of MOR-TB. But the most crucial element in the decision for
implementation of a DOTS-plus programme, directed at stopping the spread of MOR-
TB, will be the existence of a sound DOTS programme to stop further acquisition of
MOR-TB.
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